who drug informationapps.who.int/medicinedocs/documents/s21316en/s21316en.pdf · who drug...

323

WHO Drug Information Vol. 27, No. 4, 2013

WHO Drug Information

WHO Prequalification of Medicines ProgrammeWHO launches the PQP Collaborative Registration Procedure 323

Quality Assurance of MedicinesReview of the MQAS and preparation of a harmonized assessment tool for procurement agencies 332

Safety and Efficacy IssuesContaminated dextromethorphan 346Falsified artemether and lumefantrine circulating in Cameroon 347Ponatinib: increased reports of serious blood clots 347Intravenous tigecycline: increased risk of death 348Cinacalcet: hypocalcaemia and arrhythmia 348Ofatumumab and rituximab: reactivation of HBV infection 349Hydroxyethyl-starch solutions: only for hypovolaemia 350Artesunate: haemolytic anaemia 350Carbamazepine: HLA-B*1502 genotype testing 350Epoetin alfa: increase in pure red cell aplasia 351Sunitinib malate: cutaneous reactions 351Panitumumab: RAS status before treatment 352Fentanyl patches: colour changes to avoid exposure 352Ornidazole: adverse eye effects 352Statins: risk of acute kidney injury 352Low molecular weight heparin: risk of spinal column bleeding and paralysis 353Pazopanib: hepatotoxicity 353Regadenoson and adenosine: fatal cardiac reactions 354Thiocolchicoside: risk of aneuploidy 354

Regulatory Action and NewsHelsinki Declaration: 2013 revision 355EudraCT: new version launched 355WHO PQP now charging application fees 356EudraGMDP database: improved information-sharing 356Medical device identification system 357Macitentan approved for pulmonary arterial hypertension 357Liposorber Apheresis System® approved for paediatric glomerulosclerosis 358Riociguat approved for pulmonary hypertension 358Vortioxetine approved for major depressive disorder 359Pertuzumab approved as neo-adjuvant breast cancer treatment 359Paclitaxel: expanded use for late-stage pancreatic cancer 359Lipid injectable emulsion approved for parenteral nutrition 360Ibrutinib approved for mantle cell lymphoma 360Eslicarbazepine acetate approved for adult seizures 361Dolutegravir approved for HIV 361Delamanid and para-aminosalicylic acid approved for multidrug-resistant tuberculosis 361Sofosbuvir approved for chronic hepatitis C 362

Recent Publications, Information and EventsWHO Good Governance for Medicines Model Framework 363Transparency of clinical trial data 363Drug-resistant TB treatments: more support needed 3642013 WHO Global Tuberculosis Report 364International Pharmacopoeia: fourth edition 364

Contents

Continued/...

324


International Conference of Drug Regulatory Authorities (ICDRA)

The 16th ICDRA will be hosted by the Brazilian National Health Surveillance Agency (ANVISA)

Rio de Janeiro, Brazil 24 — 29 August 2014

http://www.anvisa.gov.br

Contents (continued)Consultation DocumentsThe International PharmacopoeiaDissolution testing of tablets and capsules 366General monograph on parenteral preparations.Test for bacterial endotoxins (3.4) 369Niclosamide, anhydrous and monohydrate 374Niclosamide tablets 375

Sulfamethoxazole and trimethoprim intravenous infusion 375Medroxyprogesterone acetate 381Fluconazole 387Fluconazole capsules 392Fluconazole injection 395

International Nonproprietary NamesProposed List No. 110 399

325


WHO Prequalification of Medicines Programme

Given current resource constraints affecting pharmaceutical regulation in many regions of the world, international organizations increasingly rely on the rigorous standards of the WHO Prequalification of Medicines Programme (PQP) (1) and stringent regulatory authorities to ensure the quality, safety and efficacy of medicines that they fund or procure.

Although WHO prequalified medicines are evaluated and inspected according to international standards, they still have to be approved for use by national medicines regulatory authorities (MRAs) in the recipient countries.

The repeated assessment and inspection of medicines consumes scarce regulatory resources and extends the time needed to make them available to patients. In order to facilitate and accelerate registra-tion, PQP has designed a procedure which helps to assure MRAs that WHO-prequalified medicines comply with high quality standards as documented in detailed reports of WHO evaluations and inspection results.

The WHO Collaborative Registration Procedure (CRP) (2) received final approval from the Sixty-sixth World Health Assembly in May 2013. Not only does the CRP enable MRAs to accelerate processing of registration applications for prequalified medicines, but it allows them to make use of work already carried out by PQP to strengthen their own regulatory oversight processes in line with international best practices.

The CRP has been published in the WHO Technical Report Series (3) and is open to all WHO Member States. Its principles can also serve as a model for other regulatory collaborative initiatives.

PrinciplesParticipation of stakeholders is voluntary and MRAs wishing to participate agree:

• To respect the principles of the CRP.• To treat proprietary information shared with PQP as confidential.• To take a decision on CRP submissions for registration within 90 days of receiving access to confidential PQP outcomes of assessments and inspections.

The Collaborative Registration Procedure (CRP) for WHO-prequalified products accelerates registration through improved information sharing between the WHO Prequalification of Medicines Programme (PQP) and national medicines regulatory authorities (MRAs).

The CRP aims to leverage the work of PQP during registration of WHO-prequalified medicines. It enables MRAs to utilize outcomes of PQP evaluations and inspections — thereby eliminating duplication of work, speeding up delivery of quality-assured products and making these more widely available. Since 2012, when the pilot phase began, fifteen MRAs in fourteen countries have decided to participate in the CRP and the present article describes experiences and lessons learned during the launch of this activity.

WHO launches the PQP Collaborative Registration Procedure

326

WHO Drug Information Vol. 27, No. 4, 2013WHO Prequalification of Medicines Programme

Each MRA designates one or two focal points to communicate with PQP on a confidential basis. In the event that the CRP is activated for a specific pre-qualified product, focal points will be granted access to PQP’s evaluation and inspection information through a secured Internet server.

Because PQP expertise outcomes shared within the terms of the CRP do not interfere with national decision-making processes, participation by MRAs may only require modification of regulatory procedures exceptionally. PQP has posted a list of participating MRAs on its web site.

The CRP is applicable only to medicines which have been subject to PQP evaluation and inspection and follows three steps.

• Firstly, a WHO prequalification holder wishing to register a prequalified product in a participating country should submit an application for registration to the MRA accompanied by an Expression of Interest (EOI) in which the company confirms that the product is technically the same as that prequalified, that

submitted data correspond to the dossier as approved during pre-qualification and that it authorizes the MRA to communicate with PQP on product-related issues.

In parallel, the company authorizes PQP, in a pre-defined document, to share with the respective MRA the full outcomes of WHO’s assessments and inspections confidentially through the PQP password-protected web site.

• Secondly, the MRA decides whether to apply the CRP to the specific submission — depending on whether it considers its execution to be expedient in the particular case — and informs PQP of its position. In the event that the MRA decides to make use of the CRP, PQP grants the focal point access

to product-related assessment and inspection reports and other relevant documents providing detailed insight into the prequalification decision-making process and outcomes, including approved product specifications and the applicant’s commitments. PQP is also prepared to provide additional explanations and responses to the MRA’s questions. It is dependent on the discretion and resources of each individual MRA to decide whether the PQP outcome is recognized directly, whether it is considered for verification purposes, whether to organize a partial risk-based evaluation, or whether to use the shared data for quality assurance of its own independent assessment.

In any event, participating MRAs should issue a decision on each submission within 90 days of receiving access to confidential PQP outcomes of assessments and inspections.

• Thirdly, in line with the CRP, WHO and the applicant are informed of this decision within 30 days from when it is taken. The MRA is free to deviate from PQP opinion. However, deviations from WHO PQP conclusions should be explained and communicated to PQP. This process enables PQP to publish on its web site a list of those medicines that have been registered in participating countries under the same conditions as prequalified by PQP. For such products, it is possible to collaborate further with respective MRAs in product post-registration and product regulatory maintenance.

In the post-registration phase, stake-holders should work together to minimize differences between the nationally-registered and the WHO-prequalified product. Companies should submit the same variations to PQP and to participating MRAs, and the parties should inform each other of any major decisions regarding the product.

327


Information sharingPQP does not share the full prequalifica-tion dossier with participating MRAs because the same technical data are submitted as part of the national registration process. Only assessment reports, variation reports and inspection reports are shared. Dossier assessment reports are in the form of PQP Quality Overall Summaries (QOS) — annotated with the assessor’s colour-coded remarks, requests for additional informa-tion and the applicant’s responses at each round of evaluation until prequalifi-cation.

Variation assessment reports are similarly annotated reports on changes to a pre-qualified product as per PQP variation guidelines. Inspection reports and signed-off Corrective and Preventive Action plans are shared for each manufacturing site of the finished product, as well as for those active pharmaceutical ingredient (API) manufacturing sites and clinical trial sites that PQP has inspected. PQP only shares data owned by the prequalification holder. Data provided by API manufacturers for the purposes of an active pharmaceutical ingredient master file (APIMF/DMF) procedure are not shared, unless there is a specific agreement with a data owner.

The MRA is free to use information to the extent it considers appropriate, subject to its participation agreement and confidentiality undertaking. Shared information enables the MRA to verify that the national submission conforms to WHO prequalification standards in all respects. In addition, examples of PQP process steps and documents followed in prequalifying each product may be useful for an MRA’s own training activities. Assurance that the regulatory status of the product remains in line with PQP conditions helps MRAs to define risk-based post-marketing surveillance measures that can be carried out in addition to PQP’s re-assessment and re-inspection. Quality control can be

performed according to the same methods and specifications and in co-operation with other countries that have registered the product under the same conditions.

Experience Ten MRAs participated in the pilot phase organized during the second half of 2012. Staff from seven of these MRAs have worked with PQP through rotational fellowships, while others have either participated in joint bi-monthly prequalification assessment sessions or other assessor training events offered by PQP. These regulators are largely familiar with PQP standards and procedures and have welcomed the opportunity to collaborate.

Since May 2013, the CRP is open to all WHO Member States. By October 2013, participation in the CRP had grown to 15 MRAs, including 12 in Africa that jointly cover more than 45% of the population of the WHO African Region. Three MRAs from Eastern Europe and Central Asia participate and others are considering participation.

PQP informs pharmaceutical companies about the CRP avenue for accelerated registration at its stakeholder meetings and training events, and provides information on its web site and in the standard letter sent upon acceptance of each product for prequalification and after prequalification is achieved. Several participating MRAs have also referred applicants to the CRP.

So far, fifteen prequalification holders have been in contact with PQP con-cerning collaborative registration of their medicines, including two prequalified “firsts” — zinc dispersible tablets and artesunate + mefloquine fixed-dose combination tablets. Swift registration of these products in relevant countries will be of particular interest for international procurement. WHO has reached out to


328


additional MRAs in some potential target countries, inviting them to adopt and participate in the CRP.

Registration proceduresBy October 2013, five prequalification holders had submitted a total of 29 EOIs for collaborative registration of 15 WHO-prequalified products (11 ARVs, one reproductive health product, two antimalarial and one second-line anti-TB product) in a total of seven countries. Participating MRAs agreed to apply the procedure in 18 cases. The most common reason for rejection was that already pending applications for registration in the respective country were at an advanced stage of evaluation.

Thirteen registration procedures were successfully completed for ten prequalified products (nine ARVs and one reproductive health product) through registration in six African countries (Ghana 5, Zimbabwe 3, Namibia 2, Kenya 1, Nigeria 1, Uganda 1).

Adherence to timelinesPQP had shared assessment and inspection information for the accepted EOIs within 0 to 42 days after receiving consent from the prequalification holder and confirmation of interest from the MRA (median: 10 days). The longest delays occurred early in the pilot phase while the confidential web site was undergoing upgrading.

MRAs adhered to the 90-day target timeline for eleven of the thirteen completed procedures (median time to registration 59 days). In seven cases the time taken was less than 60 days. More than 62 days were taken only in two cases (111 and 182 days) — one being due to awaiting the constitution of the relevant regulatory body. However, additional time was taken by MRAs to locate pending applications and identify their status, to respond to EOIs, to arrange access to the shared confidential

web site and to provide feedback to PQP and applicants. Considering the above, total time taken from receiving access to confidential PQP outcomes of assessments and inspections to approval of 13 registered products ranged from 19 to 270 days (median: 99 days).

During the pilot phase, a substantial number of cases were initiated for applications which had already been pending for some time in the national registration system. Considering that 12 of the 18 submissions that the MRAs accepted to review under this procedure had been queued in national systems for a year or more, the collaborative procedure has saved time for all parties.

In Zimbabwe — where almost twice as many dossiers were received in 2012 than the registration system is designed to handle — the regulatory focal person states:

«The PQP Collaborative Procedure was a relief for us in Zimbabwe. … From the pilot phase we established that approval within 90 days is do-able. … The procedure allows us to save our meagre resources and focus them on risky products which have not been subjected to rigorous PQP quality assurance.» Head, Evaluations and Registrations Division, Medicines Control Authority of Zimbabwe.

Experience with specific aspects of collaborationProduct and data responsibilityIn cases where the applicant for national registration is different from the holder of WHO prequalification, the latter must authorize the applicant to act on its behalf for the purposes of the CRP. This situation occurs quite commonly where the prequalification holder has delegated marketing of the product to another entity and/or where the MRA requires that the applicant for marketing authorization must be a local entity. PQP will typically be dealing with only one party, namely


329


that which authorizes it to share pre-qualification information with the MRA. It is up to the company to define and manage any delegated responsibilities at additional levels.

Format of national submissionsPrequalification dossiers must be submitted in Common Technical Document (CTD) format. In a survey conducted by PQP in 2011, 15 out of 17 MRAs stated that they accept dossiers in CTD format. In most cases preparation of national submissions will require little additional effort by prequalification holders and technical data can be presented as approved by PQP. Wide use of the CTD format facilitates information-sharing under the CRP as well as promoting regulatory harmonization.

Abridged dossiers may be acceptable for MRAs wishing to reduce workload, given that detailed dossiers are on record at PQP and that technical advice on specific issues can be sought from PQP. Such special arrangements should always be confirmed to the applicant by individual MRAs. In any case, the MRA should make sure that it has sufficient technical information at its disposal to enable effective regulatory control. An example of this arose with a hormonal contraceptive that was submitted for registration in a version containing placebo tablets. The WHO-prequalified version contained tablets only with an active hormone.

Dealing with product differencesSome companies prefer to apply for national registration before being granted prequalified status. To ensure that the PQP product and technical data remain the same as that prequalified, the applicant is required to state any differences in its EOL and to upgrade the national dossier in line with the prequalified one. It can also happen that major variations have been approved for the already prequalified product and the dossier submitted in countries should be updated accordingly.

In practice, applicants have submitted upgrades in varying levels of detail and a range of approaches have been adopted by MRAs to deal with product data differences. For example, an MRA may decide to discuss pending prequalification variations with PQP before approving the products concerned, and request an applicant to re-submit upgraded dossiers

The CRP was initially designed on the understanding that national applications would be submitted after completion of WHO-prequalification. The high number of CRP applications for pending submissions reflects a regulatory backlog in some countries. This will hopefully decline over time, as well as the strategy of making parallel submissions to PQP and national authorities at the same time.

Initial experience with handling of product differences highlights the importance of variation control once a prequalified product is registered in a country. Demonstrating that a product meets the same uniform international standards in different national markets offers a clear competitive advantage to prequalification holders. It is the responsibility of the applicant to ensure that the national registration status of the product reflects PQP adopted variations in line with regulations of the country.

Existing experience with management of post-prequalification and post-registration variations is still limited. Although the CRP provides principles for post-approval product maintenance and communication between PQP and MRAs, it has not been able to define a protocol due to the highly varying practices of MRAs. Effective management of variations in order to harness capacity of all parties is now a priority in further development of the CRP.

Country-specific conditionsPQP prequalifies products as being acceptable, in principle, for procurement by international organizations. However,


330


it is up to each MRA to evaluate the acceptability of a product in context. A recent example of this difficulty was noted when a prequalified artemisinin-based antimalarial combination treatment was registered in countries where it is not currently recommended in the national standard treatment guidelines. The situation was presented to the WHO Global Malaria Programme which proposed a registration strategy. While it is not PQP’s role to advise on the country-specific risks and benefits of using a product, the CRP provides a platform for discussion between the applicant, the MRA and WHO.

Communication of technical issuesBeyond the formal exchange of pre-defined documents (submission of EOIs, response fom the MRA, and communication of outcomes) the CRP also encourages a flow of ad hoc information and communications on technical and administrative issues. Such interaction by telephone and e–mail between PQP and MRA staff is critical to the functioning of the CRP. The confidential PQP web site which hosts the shared prequalification information also offers a functionality for managed discussion forums. However, it was found that the potential of this form of

Manufacturers • Harmonized data for WHO prequalification and national registration.

• Facilitated interaction with MRAs in assessment and inspection.

• Accelerated and more predictable registration.

• Easier post-registration maintenance.

Procurers • Faster start to procurement processes and wider availability of PQ medicines.

• Access to status of a the same nationally registered and prequalified medicine (web site).

MRAs • Availability of WHO assessment and inspection outcomes to support national decisions and consolidate internal capacity.

• Opportunity to learn from PQP assessors and inspectors.

• Demonstration of MRA efficiency.

Confirming status of product to that prequalified. Quality control using harmonized methods and specifications. Easier post-registration maintenance. Easier problem management. Model of work-sharing.

WHO • Prequalified medicines are available faster to patients.

• Feed-back on WHO prequalification outcomes.

Patients • Timely access to assured quality products.

Benefits of the Collaborative Registration Procedure for key stakeholders


331


communication has not been fully utilized. More work probably needs to be focused on enhancing user-friendliness of the IT system and seeking input from regulators.

The growing number of MRAs joining the CRP from different geographical regions also poses the question of language translation for CRP documents.

ConclusionExperience and lessons learned show that a fully functional CRP can accelerate approval time, reduce workload and enhance the capacity and capability of MRAs in the registration process of WHO-prequalified products. Additionally, the CRP improves regulatory collabora-tion among MRAs — especially those interested in setting up worksharing networks at national and regional levels. The CRP provides benefits to all stake-holders while assuring international quality standards of the products in registering countries.

Next stepsAt this stage of development, the CRP has progressed from a pilot to a fully operational phase. It is expected that new participating MRAs and manufacturers will bring additional experience which is relevant for the evolution of practical processes.

Good communication on technical issues, including effective post-approval control, will be crucial in sustaining successful implementation of the CRP. PQP will take every opportunity to meet with stakeholders and create a basis for effective communication. Regular meetings are scheduled with participating


MRAs to cultivate use of the CRP and discuss ways to expand beyond its existing scope. Additional supporting documents are planned to be developed at these events.

Future challenges will include post-approval maintenance of registered medicines, cooperation on registration sample testing (which is still routine for some MRAs), and work-sharing in inspections — for example, ongoing collaboration on inspections with MRAs in the East African Community.

A frequent topic of discussion is how to expedite registration of medicines that have been approved by stringent regulatory authorities. The CRP provides certain helpful approaches that can be explored further.

References

1. World Health Organization. Prequalification Programme: A United Nations Programme managed by WHO. http://apps.who.int/prequal/

2. World Health Organization. Prequalification of Medicines Programme Collaborative Procedure at http://apps.who.int/prequal/info_applicants/collaborative_registration_main.htm

3. World Health Organization. Expert Committee on Specifications for Pharma-ceutical Preparations. Collaborative procedure between the World Health Organization Prequalification of Medicines Programme and nation medicines regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products. Annex 4. Technical Report Series, No. 981 (2013). http://www.who.int/medicines

332


Management Sciences for Health (MSH); International Union Against Tuberculosis and Lung Disease; United Nations Office for Project Services (UNOPS); United States Agency for International Development (USAID); International Committee of the Red Cross (ICRC), and the Committee for Medicinal Products for Human Use (CHMP).

An independent consultant was appointed in December 2011 to work with the group and the first working group meeting the took place on 12 March 2012. The group recognized the growing success of the MQAS and looked for ways to promote its further use. It was suggested to consolidate the MQAS by focusing on quality assurance aspects and communicating a message on the importance of main-taining quality throughout the supply chain. Development of a harmonized assessment tool would facilitate assessments and outcomes could be shared. This would lead to less duplication of inspection — of wholesalers, for example.

The next meeting was planned in Geneva in June 2012 and work on preparation of the assessment tool and revision of the MQAS continued. A meeting was also held with representatives of WHO to discuss the project and ways forward.

A draft assessment tool was launched as a pilot phase project in 2012 and several organizations were requested to comment. These included the Pan American Health Organization

In 2001, the World Health Organization (WHO) began development of the Model Quality Assurance System for Procurement Agencies (MQAS) which sets recommended standards for pro-curement agencies. In October 2005, following a consultative procedure, the MQAS guideline was adopted by the WHO Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP) and published in 2006 (1).

Procurement agencies (PA) implement-ing the MQAS recommendations are routinely subject to assessment by customers — in many cases, using the PA’s own assessment tools to evaluate the potential service supplier. Due to the variety of standards used in assessment, the WHO–Global Fund (2) Joint Stakeholders meeting held in 2011 identified a need to revise the MQAS and develop a harmonized assessment tool that could be utilized by all. The aim was:

• To achieve a better use of resources.

• To coordinate PA assessments.

• To work towards mutual recognition of PA assessment findings.

A working group was created and com-prised representatives of: QUAMED, Institut de Médecine Tropicale, Antwerp, Belgium; Partnership for Supply Chain Management (PFSCM); United Nations Children’s Fund (UNICEF); Médecins Sans Frontières (MSF); International Dispensary Association (IDA); Crown Agents; Global TB Drug Facility (GDF); * Article by Adriaan J. van Zyl, Consultant to The Global Fund to Fight AIDS, TB and Malaria (2). Joelle Daviaud and Sophie Logez, The Global Fund to Fight AIDS, TB and Malaria.

Review of the MQAS and preparation of a harmonizedassessment tool for procurement agencies

Quality Assurance of Medicines

333


(PAHO), Missionpharma, Ecumenical Pharmaceutical Network (EPN), Western Pacific Group and Faith-based organizations. At its meeting in October 2012, the ECSPP was informed of progress and an article on revision of the MQAS and development of the assessment tool was published in the WHO Drug Information (3).

The working group next met in February 2013 where the outcome of the pilot phase was discussed. One organization had used the tool to assess an inter-national PA, another organization had used the tool to assess national centres procuring nationally-approved products (sometimes prior to national agency approval). A further organization had assessed six medium-sized PAs and twenty smaller ones in Africa and Asia. Although the assessment tool initially included values based on risk assess-ment, this was found to be too complex and cumbersome for use during the pilot phase of testing. The assessment tool was reworked and further comments based on actual assessments were used for revision of the MQAS. PAs declared their willness to take part in training aimed at improvement of the tool.

The working group also felt that explanatory notes to supplement the tool would be helpful. In the subsequent months, further revision of the MQAS was undertaken and a new assessment tool in the form of an Aide Memoire was developed. Explanatory notes to support the Aide Memoire and a model inspection report were prepared. A small working group was appointed to revise the product questionnaire.

A final consultation took place in June 2013. Documents discussed included: the MQAS, assessment tool, Aide Memoire, format for an inspection report, interpretation guideline and the self inspection tool. The documents were then edited, circulated to all working group members and the ECSPP secretariat. WHO then published the documents and invited comments globally.

In October 2013, all revised documents with additional comments received were presented to the ECSPP. The documents were adopted and will be published in the forthcoming Expert Committee Report. The MQAS assessment tool Aide Memoire adopted by the ECSPP is set out below and on the following pages.

IntroductionThe Expert Committee on Specifications for Pharmaceutical Preparations of the World Health Organization (WHO) adopted a Model Quality Assurance System for Procurement Agencies (MQAS) during its meeting in 2005. This was subsequently published as Annex 6 of the Technical Report Series, No. 937 in 2006.

The Secretariat of the Global Fund to Fight Aids, Tuberculosis and Malaria (GFATM) coordinated this project with the aim of preparing a harmonized assessment tool based on the WHO docu-ment: Model quality assurance system for procurement agencies (MQAS); WHO guidelines on good storage practices (GSP) and WHO Guidelines on good distribution practices (GDP).

The harmonized assessment tool was developed by a working group consisting of represen-tatives from the following organizations: CHMP, Crown Agents, GDF, ICRC, IDA, MSF, MSH, PFSCM, QUAMED, UNICEF, UNION, UNOPS and USAID.

PurposeThe C assessment tool was developed by the working group with the objective of better using resources through coordination of procurement agency (PA) assessments and working towards mutual recognition of PA assessment findings.

Assessment tool based on the Model Quality Assurance System for Procurement Agencies: Aide Memoire for Inspections


334


ScopeThe assessment tool is based on six MQAS modules:

Module I General requirements for procurement agencies Module II Prequalification Module III Purchasing Module IV Receiving and storage Module V Distribution Module VI Reassessment

The tool covers these topics, as set out in the modules below: quality system and infrastructure of the PA under assessment, how the PA performed prequalification, purchasing of the products, receiving and storage. The last two modules focus on receipt of orders and dispatch of products, followed by the re-evaluation concept.

Harmonized assessment toolThe tool should be used by qualified, experienced persons when assessing PAs (including whole-salers and distributors) for compliance with recommended international standards. It can also be useful for a PA carrying out a self-assessment.

The tool is not a checklist but a document serving to remind inspectors what should be assessed during PA inspections.

Module I: General requirements for procurement agenciesThis Module covers general requirements for procurement agencies including premises, equipment, transport and documentation (such as SOPs, confidentiality, code of conduct and complaint handling). t should be used in all cases of PA assessment. (Modules 2 to 6 may be used depending on the activities performed by the PA.)

Area of operation Note Critical aspects

Premises, Equipment, General Compliance with legislationFurniture, Transport • Licensed to operate (licence) • Sufficient space (offices for There must be a sufficient personnel, products, documents, and functional infra- samples, etc.) structure to enable the PA • Suitable conditions to perform its activities • Necessary furniture • Working office equipment • Stationery and consumables • Telephone and email access • Appropriate transport available

Human resources Personnel • Compliance with national legislation Compliance with legislation (e.g., responsible person) Quality assurance/ • Sufficient number of people prequalification and • Key personnel – quality assurance, purchasing independent of prequalification, purchasing, storage one another (personnel – and distribution and reporting structure) • Quality assurance/ prequalification and purchasing independent of one another • Support staff • Contracted personnel and agreements Training, education and experience


335



Organization Organization chart • Authorized and current • In line with job descriptions Job descriptions • Written job descriptions • Signed and dated

Ethical considerations Conflict of interest • Policy on conflict of interest is observed • Signed declaration of interest. No vested interests

Code of conduct • Written, authorized and implemented Declaration and manage- • Covers conduct of personnel ment of conflict of interest • All personnel to comply with a code of conduct

Confidentiality • Relevant product information kept confidential • Confidentiality agreements exist

Computers Appropriate hardware and software • Sufficient capacity and memory • Access control • Data transfer procedures • Reliable and accurate quality and management of data and information • Data storage (e.g. hard copies) If used, reliable data • Back-up at defined intervals, management (including storage, access, readable access control) • Virus protection programme and firewall • Technical support • Maintenance • Trained personnel

Financial systems • Adequate banking facilities • Signatories of bank accounts appointed • Accounting system in place • National and international financial transactions • Financial transactions performed without delay • Funds available • Regular financial audits are performed.

Documentation Comprehensive documented system • Covers policies, guidelines, norms, standards, manuals, procedures, records and related documents • SOPs for activities


336



Quality manual (QM) • Contains a quality policy • Evidence of QM implementation, QM maintained, reviewed and amended as necessary

Standard operating procedures Activities and responsi- • SOP for writing an SOP followed bilities described in • Written, clear, detailed SOPs for SOPs which are activities implemented and • Controlled, distributed and retrieved followed; Records when required reflecting activities • Available for use • SOPs are reviewed periodically • Quality risk management (QRM) principles applied

Style and layout • SOPs in defined format • Signed and dated

Activities to be All activities should be covered by Written SOPs followed forcovered by SOPs SOPs and include: prequalification, purchas- • prequalification ing, storage, distribution, • purchasing complaints, recalls, • receiving and storage identifying and • distribution reporting substandard/ • training spurious/falsely-labelled/ • handling of complaints falsified/counterfeit • handling of recalls products; • document/record control including distribution and retrieval of SOPs • self-inspection • monitoring of environmental conditions (e.g. temperature) • monitoring supplier performance • identifying and reporting Change control SSFFC medical products • evaluating offers received • ordering product(s) from supplier or manufacturer • change control • variations • corrective and preventive action (CAPA)

List of prequalified • Current, authorized, access- A controlled list isproducts, manufac- controlled list maintainedturers and suppliers • Based on the outcome of evaluation • Contains required information • Product-, manufacturing site- and supplier-specific (where relevant) • A key person responsible


337



Maintenance of • Records of all operations kept Records are available records • Sufficient space for archiving for review • Access controlled • Retention period appropriate Contract • Written contracts for delegated Written, valid agreements arrangements activities in place

Module II: PrequalificationPrequalification is one of the key elements in ensuring purchase and supply of pharmaceutical products of acceptable quality. The prequalification process can be subdivided into two major parts, i.e., product-related assessment and manufacturer-related inspection.


Principles • Documented policy and procedures for prequalification • Include assessment of product and manufacturers/ suppliers • If delegated – written agreement in place

Key persons and • Responsible personnel identified Qualified, trained personnelresponsibilities • Independent from the purchasing perform prequalification personnel activities (including • Job descriptions assessment and • Communication between evaluation inspections and inspections

Evaluation of product information Quality assurance/ (Evaluators) prequalification • List of evaluators and purchasing • Suitable qualifications and experience independent of one • Job descriptions another (personnel • Contracted external evaluators used and reporting) (confidentiality, conflict of interest and financial resources, references)

Inspection of manufacturing sites (Inspectors) • List of inspectors • Job descriptions • Qualified, trained, experienced • Contracted inspectors – confidentiality and no conflict of interest


338



Key steps in Step 1. Soliciting information Evaluation of product dataprequalification • Procedures for preparation of and information as welldefined detailed, clear specifications; as the criteria used soliciting information; receiving to approve or reject and processing information a product • Policy and procedure for handling late submissions • Recording of data received Ensuring compliance • Procedure for submitting product with GMP information publicly available and accessible • Product information to be submitted defined (as a minimum, see product questionnaire)

Step 2: Receive product information • Written procedures for receiving, identification, marking files, containers and samples, and sufficient space for unpacking and storage • Procedure to ensure traceability of product information • Personnel available

Step 3: Screen product information • SOP: screen for completeness • A screening form used • Record of screening kept • Outcome communicated to manufacturer/supplier

Step 4: Evaluate product information • Follow SOP to evaluate against requirement • Time frames • Evaluation report for each product exists • Outcome communicated to the manufacturer/supplier • Response invited where needed • Outcome accepted or rejected • Evaluation report kept as record • Samples analysed if needed (see also monitoring below)

Step 5: Plan, prepare and perform inspections General points • Evidence of GMP compliance • Site of manufacture known • Site inspection policy • Contract manufacturing sites known Control over active pharmaceutical ingredients (APIs) (inspection risk based)


339



Key steps in Planprequalification • SOP and recording system for defined inspection planning(continued) • Procedure and data reviewed as part of preparation for inspection (e.g., site master file)

Conduct • SOP: how to perform an inspection • Scope: data and information verified and WHO GMP compliance assessed • If not done – conditions for waiving on-site inspections

Inspection report • Inspection report for each site inspected • Outcome communicated • CAPA requested, received and reviewed • Conclusion or outcome • Copy of report kept

Step 6: Finalize assessment process • Written procedure followed • Covers product evaluation plus laboratory results and inspection outcome • Responsible persons (decision-taking) and reasons for decision • Outcome communicated • List of prequalified products, manufacturers and suppliers • Agreement between PA and supplier/manufacturer • List reviewed and updated at regular intervals

Cost recovery • If used, transparent procedure • Fee-for-services structure

Module III: PurchasingProcurement should be carried out with the aim of purchasing effective, quality assured products and not be focused on price alone. The term “procurement” in this Module relates specifically to the purchase of health sector goods from manufacturers or suppliers. The module describes key activities in purchasing pharmaceutical products, as well as the recommended organizational structure of the procurement agencies which carry out these key activities.


Procurement • Policy: suppliers are selected and Purchasingstrategies monitored through a process that takes prequalified into account product quality, service products reliability and performance, delivery time, ethics, legal status, financial viability and minimum order quantities


340



Procurement Purchase prequalified products strategies (from manufacturers/suppliers) (continued) • Efficient and transparent management • Financial management procedures • Competitive procurement methods • Procedure to calculate lowest possible total cost • Procurement and purchasing procedures are transparent • Independent contract review • Purchasing and tender documents list all pharmaceutical products by their international nonproprietary name (INN) or national generic names • Intellectual property rights are respected in accordance with best practice and national law

Procurement methods • Responses are responsive to the defined terms and conditions and are examined from invited suppliers • Adjudication procedure Adjudication procedure • Explicit criteria for awarding contracts and related records • Informed of the outcome • Restricted tender Use a defined, transparent • Prequalified products and suppliers procurement method • Competitive negotiation • Direct procurement

Key activities • Develop a list or catalogue of products (INN) • Develop specifications for the products Quantification • Methods of product quantification • Quantities purchased based on reliable estimate Procurement method • According to their policy and procedures

Organization and • Personnel with appropriate responsibilities qualifications and training • Job descriptions • Independent from those responsible for prequalification and quality assurance • Procurement planned

Monitoring • Procedure for continuous monitoringperformance of of performance of products,prequalified products, manufacturers and suppliersmanufacturers/ Monitoring may include:suppliers • review of quality control results


341



Monitoring • verification that the product batches Handling out of specificationperformance of supplied have been manufactured in resultsprequalified products compliance with standards and manufacturers/ specifications accepted in the product Monitoring performancesuppliers information through inspection of products, manufacturers (continued) • adverse events and suppliers and action • random samples of batches supplied taken by the PA in case analysed (risk-based approach) of non-compliance • independent testing – reliable quality control laboratory (see selection criteria for quality control laboratory) • certificates of analysis available where appropriate • status of the laboratory (e.g., authorized, accredited) • handling of out-of-specification results • monitoring of complaints • outcome of inspection of manufacturing sites • outcome of reassessment of product information • monitoring of direct and indirect product costs • monitoring of adherence to delivery schedules • contract terms and conditions • tracking system (values of contracts awarded, total purchases, performance)

Donations • Written procedure

Module IV: Receiving and storageThe procurement agency should ensure that pharmaceutical products purchased are received and stored correctly and in compliance with applicable legislation and regulations. Products should be received and stored in such a way that quality and integrity is preserved, batch tra-ceability is maintained and stock can be rotated.


General • Received and stored correctly Procedures followed forarrangements • Quality and integrity is maintained receiving and storage • Batch traceability • Stock rotation Batch traceability • Unidirectional flow • Security of materials and products • Subcontracting

Pre-shipment quality • Batches released by the manu- Batch release withcontrol facturer (certificate of analysis (CoA)) CoA (meeting • Batches additionally tested (risk-based specifications) approach) prior to shipment to PA • Selection criteria for quality control laboratory


342



Receiving stock • Receiving and dispatch bays Goods received and • Incoming containers cleaned, quarantined checked according to • Review of CoAs an appropriate SOP – • Released for use or distribution supported by records (responsible person involved) Checks on receipt: Products released by • order, delivery note, labels and transport responsible person conditions, integrity of packages and seals and uniformity of containers Visual inspection for: • contamination; tampering and damage; expiry date, compliance with labelling, packaging instructions • suspect containers and damaged containers – recorded and investigated

Post-procurement • Random sampling for independent Action taken in case-control laboratory analysis of non-conforming • Selection criteria for quality control product laboratory • SOP and national legislation • Representative samples – sampling plans and instructions (risk assessment) • Appropriately trained and qualified personnel

Rejected materials • SOP for rejected products Rejected materials kept • Separate storage or validated separately, access computerized system controlled and handled • Action approved by authorized appropriately personnel and recorded

Storage of Personnelmaterials/ • Trainedproducts • Personal hygiene and sanitation • Appropriate garments Storage areas • No unauthorized access • Sufficient space • Adequate ventilation, temperature and relative humidity • Conditions checked, monitored & recorded • Segregation of rejected, expired, recalled or returned stock • Toilet and washing facilities separated from storage areas • Narcotics/psychotropic medicines as per national legislation • SOP for fire control • No smoking and eating • SOP and records for cleaning • Waste management • Pest-control • SOP for handling spillages


343



Storage of Storage conditions Access controlled andmaterials/ • As established by the manufacturer sufficient spaceproducts • Orderly, batch segregation, stock rotation, (continued) first expired-first out (FEFO) Appropriate conditions • Stored off the floor for storage • Space to permit cleaning and inspection • Pallets in good state of cleanliness & repair • Stacking of products without damage • Freeze-sensitive products – use monitoring devices • Cold rooms (qualification, temperature mapping, alarm, monitoring, records, back-up system in case of failure) Monitoring of storage conditions • Temperature mapping protocol and report • Calibrated sensors/devices • Ongoing monitoring with records • Out-of-limit and out-of-trend results investigated, action taken Miscellaneous and hazardous materials • Rodenticides, insecticides, fumigating agents and sanitizing materials • Toxic substances and flammable materials

Re-packaging • If performed – compliance with national Compliance with nationaland re-labelling legislation and WHO GMP legislation and WHO GMP

Stock control • Validated stock control system Stock control in place • Batch number control and expiry dating (e.g., reconciliation, • Periodic stock reconciliation obsolete materials, • Significant stock discrepancies investigated recalled products, • Records maintained returned goods, • Damaged containers handled FEFO and waste) Control of obsolete and outdated materials and products • SOP • Regular checks Recalled materials and products • SOP • Written records of actions with signatures • Products identified, recorded, reconciled and stored separately • Decision by appropriately qualified and experienced member of staff Returned goods • SOP • Quarantined and assessed • Resale conditions • Destruction in compliance with national requirements • Records


344



Stock control Waste materials(continued) • SOP • Safe storage while awaiting disposal • Toxic substances and flammable materials • No accumulation • Safe disposal, national regulations

Documentation: • SOPs for activities Record keepingwritten instructions • Handling of expired stock ensuring traceabilityand records • Ensuring batch traceability (e.g., receiving, issuing, • Records for storage conditions, precautions expired goods) • National regulations concerning labels and containers • Comprehensive records of all activities • Retention of records

Module V: DistributionThe PA (or contracted party) should have a well-managed distribution system meeting the objectives of ensuring constant supply of quality medicines. Distribution should be conducted in accordance with general principles of GMP.


General • Constant supply of medicines • Minimize medicines losses (spoilage and expiry) • Accurate inventory records • Prevent theft and fraud

Transport conditions • Transport process has no negative impact Appropriate on product transport conditions • Required storage conditions maintained • Temperature excursions – risk assessment

Cold chain • Validated process Cold chain validated, • Applied where needed maintained and • Appropriate containers monitored • Packaging procedure • Cooling agents used • Calibrated monitoring devices • Monitoring records reviewed, maintained

Dispatch procedures • Compliance with legislation Compliance with • Authorized recipients legislation • Procedures in place • Special packaging requirements observed Authorized recipients where needed • Dispatch and transport after receipt of a delivery order

Dispatch containers • Provide protection • Appropriately labelled • Prevent theft (e.g., locked/wrapped)


345



Dispatch records • Detailed records kept (e.g., date, Records ensure customer name and address; product name traceability of goods and batch number and quantity) • Products and batches traceable • Discrepancies investigated

Port of entry • Storage conditions met • Temperature-sensitive products handled appropriately • Security measures in place (e.g., prevent theft, fraud and bribery)

Module VI: ReassessmentQuality of products and services should be continuously monitored. This process includes reas-sessment.


Reevaluation of • Reinspection frequency based on risk Reinspection policymanufacturers assessment and procedure followed • Within five-year cycle • Change control • Mechanism for suspension and withdrawal

Reevaluation of • Reevaluation procedure Reevaluation of productproducts • Within five-year cycle policy and procedure • Variations procedure followed

Monitoring • Written procedureperformance of • Covers continuous monitoring, periodic contractors review and renewal of contracts

• System for documenting service problems

References1. World Health Organization. Expert Committee on Specifications for Pharmaceutical Preparations. Annex 6. Technical Report Series, No. 937, 2006.

2. The Global Fund to Fight AIDS, TB and Malaria. http://www.theglobalfund.org

3. World Health Organization. WHO Drug Informa-tion, Vol. 26, No. 3, 2012. at http://who.int/druginfor-mation


346


Safety and Efficacy IssuesContaminated dextromethorphanWorld Health Organization — On 24 January 2013, a WHO Drug Alert was issued following the discovery in Pakistan of two types of locally produced cough syrup containing the contaminated active pharmaceutical ingredient (API) dextro-methorphan.

This incident led to the death of approxi-mately 50 persons in Pakistan, all with a history of drug addiction, who had been abusing dextromethorphan-containing syrup for many years without any reported unexpected adverse reactions. The subsequent investigation found that manufacturers in Pakistan were obtaining the dextromethorphan API from a source in India.

Full laboratory testing of the dextro-methorphan showed that it was conta-minated with levomethorphan, the enantiomer of dextromethorphan, which is a potent opioid analgesic internationally controlled under Schedule 1 of the Single Convention on Narcotic Drugs (1961).

In January 2013, as a result of this incident, the Indian regulatory authorities suspended the manufacture, distribution, sale or use of the dextromethorphan in question.

WHO called on all countries to increase vigilance concerning dextromethorphan in general and to ensure that the API met all required quality specifications.

On 26 September 2013, WHO was notified of suspected drug intoxication involving eleven paediatric patients in Paraguay. All of the patients were experiencing influenza-like symptoms

and had consumed medical products produced by a local manufacturer containing dextromethorphan. The children were aged from 2–9 years and serious adverse reactions includedaltered consciousness, cyanosis, respiratory distress and seizures. Onset of symptoms occurred from 2–7 hours after ingesting dextromethorphan. Since then, the number of patients experiencingadverse reactions rose to 44 confirmed cases, ranging in age from 5 months to 48 years. There was one fatality that may be linked to the event.

The Paraguayan Ministry of Health issued warnings concerning the medicines thought to be connected to this incident.Investigations by the Paraguayan authorities subsequently indicated the source of the API dextromethorphan to be the same Laboratories in India. The batch number of the dextromethorphan API used by the Paraguayan manufacturer was the same as one of the contaminated batches found in Pakistan. However, the Paraguayan manufacturer appears to have ordered the API in 2012, prior to events in Pakistan.

According to the local manufacturer in Paraguay none of the products have been exported, however they could possibly be available in neighbouring countries through local traders and travellers.

WHO advises extra vigilance for the API dextromethorphan and strongly urges that extreme caution be exercised byimporting countries and manufacturers. Dextromethorphan should be carefully tested for the presence of the conta-minant levomethorphan, and it should meet the recognized specifications.

347


Samples of contaminated dextromethor-phan API from the original Pakistan incident have been analysed at the request of WHO and revealed limits of levomethorphan varying between 9.5% to 22.6%. All of the samples tested in both incidents have failed to comply with the requirements for the specific opticalrotation as specified in the monograph for dextromethorphan hydrobromide published in The International Pharma-copeia.

Reference: WHO Information Exchange System ([email protected]). Drug Alert, Nos.126 & 129, 17 October 2013 at http://www.who.int/medicines/publications/drugalerts/drugalertindex/en/.

Falsified artemether andlumefantrine circulating in CameroonWorld Health Organization — A WHO Drug Alert has been circulated concerning falsified batches of Coartem® that are circulating in Western and Central Africa.Coartem® is a fixed-dose artemesinin based combination therapy (ACT) (artemether 20 mg and lumefantrine 120 mg) used for the treatment of Plasmodium falciparum malaria. The genuine product is manufactured by Novartis and is a WHO prequalified medicine.

On 5 November 2013, Novartis informed WHO of further falsified versions of Coartem® recently circulating in Cameroon as follows:

Batch Number: NOF 2153Manufacturing Date 01.2013Expiry Date: 11. 2015Batch Number F2929Manufacturing Date: 01.2012Expiry Date: 01.2016

The packaging of both batches is in English and bears the falsified green leaf logo of the Global Fund Affordable Medicines Facility – Malaria (AMFm) Programme.

Details of falsified batches of Coartem® circulated by WHO in May 2013 are as follows:

Batch number: F1901Manufacturing Date: 01.2012Expiry Date: 01.2014

The packaging is in English and bears a falsified stamp of the Nigerian National Medicines Regulatory Agency, NAFDAC.

Batch Number: F2261Manufacturing Date: 01.2012Expiry Date: 01.2014

The packaging is in English and bears the falsified green leaf logo of the Affordable Medicines Facility – Malaria (AMFm) Programme. Novartis has informed WHO that this batch has also been seen againrecently in Cameroon.

All four batches are packaged for adult use and distribution within the public sector. The falsified batches contain little or no active pharmaceutical ingredient and are therefore ineffective.

Some of these batches have been found in a number of West and Central African countries in hospitals and street markets. Increased vigilance throughout the regionis strongly advised. Hospitals, clinics, and pharmacies should check their stocks for these batches and report any suspicions to their national medicines regulatory authority. Reference: WHO Information Exchange System ([email protected]). Drug Alert No.130, 8 November 2013 at http://www.who.int/medicines/publications/drugalerts/drugalertindex/en/.

Ponatinib: increased reports of serious blood clots United States of America — The Food and Drug Administration (FDA) is investigating the increased frequency of reports of serious and life-threatening blood clots and severe narrowing of

Safety and Efficacy Issues

348


Intravenous tigecycline: increased risk of death United States of America — The Food and Drug Administration (FDA) is warning that an additional analysis shows an increased risk of death when intravenous tigecycline (Tygacil®) is used for approved or non-approved uses.

Healthcare professionals should reserve tigecycline for use in situations when alternative treatments are not suitable. Tigecycline is approved to treat complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia. Tigecycline is not indicated for treatment of diabetic foot infection or for hospital-acquired or ventilator-associated pneumonia.

In 2010, FDA informed the public that a meta-analysis of 13 Phase III and IV trials showed a higher risk of death among patients receiving Tygacil® compared to other antibacterial drugs. The increased risk was greatest in patients treated for ventilator-associated pneumonia, a use for which FDA has not approved the drug.

Since 2010, FDA has analysed data from ten clinical trials conducted only for FDA-approved uses showed a higher risk of death among patients receiving Tygacil® compared to other antibacterials. In general, the deaths resulted from worsening infections, complications of infection, or other underlying conditions.

Reference: FDA Drug Safety Communication, 27 August 2013 at http://www.fda.gov/Drugs/DrugSafety.htm

Cinacalcet: hypocalcaemia and arrhythmiaCanada — A safety review of the drug cinacalcet (Sensipar®) has identified a possible link to arrhythmia associated with low blood calcium. Cinacalcet is used for treating disorders of the

blood vessels of patients taking ponatinib (Iclusig®). Health care professionals should consider whether the benefits of ponatinib treatment are likely to exceed the risks.

Ponatinib is used to treat adults diag-nosed with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia, who are no longer benefiting from previous treatment or who do not tolerate other treatment.

At the time of approval in December 2012, the Iclusig® label contained information about the risks of blood clots. In clinical trials conducted before approval, serious arterial blood clots occurred in eight percent of Iclusig®-treated patients and venous blood clots occurred in three percent of patients. In the most recent clinical trial data submitted by the manufacturer to FDA, at least 20 percent of all participants treated with ponatinib have developed blood clots or narrowing of blood vessels.

Data from clinical trials and postmarket adverse event reports show that serious adverse events have occurred in patients treated with ponatinib, including heart attacks resulting in death, worsening coronary artery disease, stroke, narrowing of large arteries of the brain, severe narrowing of blood vessels in the extremities, and the need for urgent surgical procedures to restore blood flow. Other problems include congestive heart failure and loss of blood flow to extremities resulting in tissue death requiring amputation. Newly identified serious adverse reactions have also been reported including decreased vision and clots in blood vessels of the eye. These adverse events were seen in all age groups treated and in those with and without cardiovascular risk factors.

Reference: FDA Drug Safety Communication, 11 October 2013 at http://www.fda.gov/Drugs/DrugSafety/ucm370945.htm


349


parathyroid gland that result in abnormal blood calcium levels. It is well known to cause hypocalcemia and this risk is clearly outlined on the Canadian Sensipar® label.

Hypocalcemia can cause QT prolongation and arrhythmia which can be serious and may lead to sudden death. Stronger warnings have been added to the drug label to inform of the risk of QT prolongation and arrhythmia associated with use.

Healthcare professionals should prescribe cinacalcet with caution in patients with other risk factors for QT prolongation, such as known congenital long QT syndrome, or in patients who are taking other drugs known to cause QT prolongation. For patients treated with cinacalcet for chronic kidney disease and receiving dialysis, reduce dose or stop use if low blood calcium, signs of QT prolongation, or arrhythmia continue. For these patients, cinacalcet should not be started if they have severe hypocalcemia.

Reference: Health Canada Important Safety Information, 15 October 2013 at http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/36267a-eng.php

Ofatumumab and rituximab: reactivation of HBV infectionUnited States of America — The Food and Drug Administration (FDA) has approved changes to the prescribing information for ofatumumab (Arzerra®) and rituximab (Rituxan®) to warn of the risk of reactivation of hepatitis B virus (HBV) infection. The revised labelling will also include additional recommendations for screening, monitoring and managing patients. Both ofatumumab and rituximab are used to treat certain cancers of the blood and lymph system. Rituximab is also approved to treat other medical conditions, including rheumatoid arthritis. Both drugs suppress the immune system.

In patients with prior HBV infection, HBV reactivation may occur when the body’s immune system is impaired. Infection can cause serious liver problems, including liver failure and death. The risk of HBV reactivation is already described in the labelling for both drugs; however, cases continue to occur, including deaths.

Reference: FDA Drug Safety Communication, 25 August 2013 at http://www.fda.gov/Drugs/DrugSafety/ucm366406.htm

Hydroxyethyl-starch solutions: only for hypovolaemia European Union — The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed its review of hydroxyethyl-starch (HES) solutions following an assessment of new information and commitments from companies for additional studies and risk minimization activities. The Committee confirmed that HES solutions must no longer be used to treat patients with sepsis or burn injuries, or critically ill patients, because of an increased risk of kidney injury and mortality. HES solutions may, however, continue to be used in patients to treat hypovolaemia caused by acute blood loss, provided that appropriate measures are taken to reduce potential risks and that additional studies are carried out.

The review of HES solutions was initially triggered by the German medicines agency, the Federal Institute for Drugs and Medical Devices (BfArM), following studies showing an increased risk of mortality in patients with sepsis and an increased risk of kidney injury requiring dialysis in critically ill patients following treatment with HES solutions.

Reference: EMA Press Release, 11 Octo-ber 2013 at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/10/news_detail_001917.jsp&mid=WC0b01ac058004d5c1


350


requirements for all extended-release and long-acting (ER/LA) opioid analgesics intended to treat pain.

The updated indication states that ER/LA opioids are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

The updated indication further clarifies that, because of the risks of addiction, abuse, and misuse, even at recommended doses, and because of the greater risks of overdose and death, these drugs should be reserved for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain; ER/LA opioid analgesics are not indicated for as-needed pain relief.

The FDA is also requiring a new boxed warning on ER/LA opioid analgesics to caution that chronic maternal use of these products during pregnancy can result in neonatal opioid withdrawal syndrome.

Reference: FDA News Release, 10 Septem-ber 2013 at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements

Carbamazepine: HLA-B*1502 genotype testing Singapore — The Ministry of Health (MOH) has announced that genotyping for the HLA-B*1502 allele prior to the initiation of carbamazepine (CBZ) therapy in new patients of Asian ancestry is now considered the standard of care. These new recommendations by MOH and the Health Sciences Authority (HSA) have been made in consultation with experts in various fields such as neurology, psychiatry and dermatology, following the review of findings from local and international studies.

Artesunate: haemolytic anaemia World Health Organization — Injectable artesunate is a life-saving therapy for patients with severe Plasmodium falciparum malaria and provides a substantial reduction of mortality. In the two largest randomized controlled trials conducted in patients with severe malaria, parenteral artesunate treatment reduced deaths by 34.7% (Asia) and by 22.5% (Africa) compared with parenteral quinine. WHO currently recommends artesunate (intravenous or intramuscular) as the first line treatment for the initial management of severe malaria.

A number of cases of delayed haemolytic anaemia have been identified following treatment of severe malaria with injectable artesunate. In March 2013, the Medicines for Malaria Venture (MMV) convened a meeting of experts to review the available evidence on delayed haemolytic anaemia following treatment with injectable artesunate.

The full report of the expert meeting is now available on the MMV web site together with an information note which reflects the current WHO position based on the outcome of the review meeting and consultation with the GMP Technical Expert Group on Malaria Chemotherapy.

Reference: Medicines for Malaria Venture. Information Note, 13 October 2013 at (1) http://www.who.int/entity/malaria/publications/atoz/who_note_delayed_haemolytic_anaemia_oct13.pdf. (2) http://www.who.int/malaria/publications/atoz/who_note_haemolytic_anaemia/en/index.html. (3) http://www.mmv.org/newsroom/events/expert-group-meeting- safety-profile-injectable-artesunate.

Opioid analgesics: new safety warningsUnited States of America — The Food and Drug Administration (FDA) has announced class-wide safety labelling changes and new postmarket study


351


Confirmed PRCA cases associated with epoetin alfa accounted for 90% of total epoetin alfa-associated PRCA cases in the HSA Pharmacovigilance database since the re-instatement of the subcutaneous route for Eprex® in April 2009. This is a disproportionately high number of PRCA cases reported compared to the baseline reporting trend. During this period, nine PRCA cases were reported from two local healthcare institutions. All cases were reported with subcutaneous use of Eprex® in chronic kidney disease patients with duration of onset ranging from seven months to 19 months. Reference: HSA Safety Alert, 29 August 2013 at http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/safety_information/product_safety_alerts/Safety_Alerts_2013/recommendations_for.html

Sunitinib malate: cutaneous reactionsCanada — A statement has been added to the product monograph indicating a potential association between sunitinib malate (Sutent®) and severe cutaneous reactions suggestive of Stevens-Johnson syndrome (SJS) and toxic epidermalnecrolysis (TEN). If signs or symptoms are present, treatment should be discontinued. If the diagnosis of SJS or TEN is confirmed treatment must not be restarted.

Sunitinib malate is indicated for the treatment of gastrointestinal stromal tumour after failure of imatinib mesylate treatment due to resistance or intolerance. It is also indicated for the treatment of metastatic renal cell carcinoma of clear cell histology and for the treatment of patients with unresectable locally advanced or metastatic, welldifferentiated pancreaticneuroendocrine tumours, whose disease is progressive.

CBZ has been registered in Singapore since 1988 and is currently available as Tegretol® and six generic products. It is indicated for the treatment of epilepsy and other conditions such as diabetic neuropathy, trigeminal neuralgia and bipolar disorders. While CBZ is an effective drug and the drug of choice for several conditions, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which are associated with significant mortality and long-term morbidity, have been reported with its use.

Between 2003 and 2012, HSA received 131 local serious reports of CBZ-induced SJS/TEN (average of 15 reports per year). Since the beginning of 2013, HSA has received five reports of SJS/TEN associated with the use of CBZ. A one-time HLA-B*1502 genotyping test helps distinguish high-risk patients who should avoid CBZ from low-risk patients who are able to continue to use this low-cost yet effective medicine.

SJS and TEN often begin with flu-like symptoms, followed by development of a red or purplish rash and painful ulcers of mucous membranes. The skin lesions then progress to epidermal necrosis and detachment. These conditions require hospitalization and can be life-threatening and even fatal.

Reference: HSA Safety Alert, 29 August 2013 at http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/safety_information/product_safety_alerts/Sa-fety_Alerts_2013/recommendations_for.html

Epoetin alfa: increase in pure red cell aplasiaSingapore — The Health Sciences Authority (HSA) has advised of an unexpected increase in local cases of antibody-mediated pure red cell aplasia (PRCA) associated with subcutaneous administration of epoetin alfa (Eprex®) during the period 2012 and 2013.


352


Reference: Health Canada. Advisories, War-nings and Recalls, 9 September 2013 at http://www.hcsc.gc.ca

Panitumumab: RAS status before treatmentUnited Kingdom — The Medicines and Healthcare Products Regulatory Agency (MHRA) has announced that evidence of wildtype rat sarcoma viral oncogene (RAS) status is required before initiating treatment with panitumumab (Vectibix®) alone or in combination with other chemotherapy in the treatment of metastatic colorectal cancer. Inferiorprogression-free survival and overall survival have been shown in patients with RAS mutations beyond KRAS exon 2 who received panitumumab combined with oxaliplatin-containing (Folfox®) chemotherapy versus Folfox® alone.

These findings emphasize that panitumumab is contraindicated in combination with oxaliplatin-based chemotherapy in patients with mutant RAS or in whom RAS status is unknown.

Reference: Medicines and Healthcare Products Regulatory Agency (MHRA). Drug Safety Update, Volume 7, Issue 2, September 2013 at http://www.mhra.gov.uk

Fentanyl patches: colour changes to avoid exposure United States of America — The Food and Drug Administration (FDA) is requiring colour changes to the writing on fentanyl (Duragesic®) pain patches in an effort to prevent accidental exposure. Used fentanyl patches require proper disposal after use.

FDA continues to learn of deaths from accidental exposure to fentanyl patches and is requiring the manufacturer to print the name and strength of the drug on the patch in long-lasting ink, in a color that is clearly visible to patients and caregivers.

Reference: FDA Drug Safety Communication, 23 August 2013 at http://www.fda.gov/Drugs/DrugSafety/ucm368902.htm

Ornidazole: adverse eye effects New Zealand — Since 1987, the Centre for Adverse Reactions Monitoring (CARM) has received 10 reports where the patient experienced eye problems — mainly described as visual impairment and blurred vision — following treatment with ornidazole, used to treat bacterial infections.

Visual impairment and/or blurred vision can affect the user’s ability to drive or operate machinery. Anyone experiencing these problems should not drive or operate machinery.

Reference: Medsafe Monitoring Communica-tion,1 November 2013 at http://www.medsafe.govt.nz/Projects/B2/monitoring-communications.asp#1-November-2013.

Statins: risk of acute kidney injuryNew Zealand — Medsafe has identified a possible signal of acute kidney injury (without rhabdomyolysis) with the use of high-dose statins following a review of published literature. Myopathy or rhabdomyolysis is a well-known adverse effect of statin therapy, with acute kidney injury occurring secondary to these symptoms. Recent studies however have suggested that there is a risk of acute kidney injury occurring without prior or concurrent onset of myopathy or rhabdomyolysis. The overall benefit-risk balance of statins remains positive.

The Centre for Adverse Reactions Monitoring (CARM) has received a total of 38 reports which fulfil the criteria for acute kidney injury with statins. Of these, 24 also report rhabdomyolysis or creatine kinase elevations, which are suggestive of muscle problems.

Acute kidney injury is defined in different ways, from acute renal failure with tubular


353


necrosis or unspecified, through to need for renal replacement therapy such as haemodialysis, peritoneal dialysis or kidney transplantation.

Reference: Medsafe Monitoring Communica-tion,1 November 2013 at http://www.medsafe.govt.nz/Projects/B2/monitoring-communications.asp#1-November-2013.

Low molecular weight heparin:risk of spinal column bleeding and paralysis United States of America — The Food and Drug Administration (FDA) is recommending that health care professionals carefully consider the timing of spinal catheter placement and removal in patients taking anticoagulant drugs, such as enoxaparin, and delay dosing of anticoagulant medications for some time interval after catheter removal to decrease the risk of spinal column bleeding and subsequent paralysis after spinal injections, including epidural procedures and lumbar punctures. These new timing recommendations, which can decrease the risk of epidural or spinal hematoma, will be added to the labelling of anticoagulant drugs known as low molecular weight heparins, including Lovenox® and generic enoxaparin products and similar products.

Health care professionals and institutions involved in performing spinal/epidural anesthesia or spinal punctures should determine, as part of a pre-procedure checklist, whether a patient is receiving anticoagulants and identify the appropriate timing of enoxaparin dosing in relation to catheter placement or removal. To reduce the potential risk of bleeding, consider both the dose and the elimination half-life of the anticoagulant:

For enoxaparin, placement or removal of a spinal catheter should be delayed for at least 12 hours after administration of prophylactic doses such as those used for prevention of deep vein thrombosis.


Longer delays (24 hours) are appropriate to consider for patients receiving higher therapeutic doses of enoxaparin (1 mg/kg twice daily or 1.5 mg/kg once daily).

A post-procedure dose of enoxaparin should usually be given no sooner than 4 hours after catheter removal. In all cases, a benefit-risk assessment should consider both the risk for thrombosis and the risk for bleeding in the context of the procedure and patient risk factors.

Epidural or spinal hematomas are a known risk of enoxaparin in the setting of spinal procedures and are already described in warnings and precautions for Lovenox® and generic enoxaparin products. However, these serious adverse events continue to occur.

It is important to note that all anticoagulants carry the risk of causing spinal bleeding when used in conjunction with epidural/spinal anesthesia or spinal puncture. Reference: FDA Drug Safety Communication, 6 November 2013 at http://www.fda.gov/Drugs/DrugSafety/ucm373595.htm

Pazopanib: hepatotoxicityCanada — Healthcare professionals have been reminded that pazopanib hydrochloride (Votrient®) is associated with hepatotoxicity including hepatic failure and fatalities.

Physicians are asked to monitor serum liver tests before initiation and during treatment. Testing of serum liver enzyme and bilirubin levels during treatment has increased in frequency and periodic monitoring should continue after month four.

Pazopanib hydrochloride is a tyrosine kinase inhibitor indicated for treatment of metastatic renal cell (clear cell) carcinoma as first-line systemic therapy or second line systemic therapy after

354


treatment with cytokines for metastatic disease. It is also indicated for treatment of patients with selective subtypes of advanced soft tissue sarcoma who have received prior chemotherapy for metastatic disease, or who have progressed within 12 months after (neo) adjuvant therapy.

Concomitant use of pazopanib hydro-chloride and statins should be under-taken with caution and close monitoring.

Reference: Health Canada. Advisories, War-nings and Recalls, 9 August 2013 at http://www.hcsc.gc.ca

Regadenoson and adenosine: fatal cardiac reactionsUnited States of America — The Food and Drug Administration (FDA) has warn-ed healthcare professionals of the rare but serious risk of heart attack and death with use of the cardiac nuclear stress test agents regadenoson (Lexiscan®) and adenosine (Adenoscan®).

Patients with signs or symptoms of un-stable angina or cardiovascular instability may be at greater risk for serious cardio-vascular adverse reactions.

Regadenoson and adenosine are approved for use during cardiac nuclear stress tests in patients who cannot exercise adequately. They cause blood to flow preferentially to the healthier, unblocked or unobstructed arteries. In some cases, this reduced blood flow can lead to a heart attack, which can be fatal.

Cardiac resuscitation equipment and trained staff should be available before administering regadenoson or adeno-sine.

Spontaneous monitoring systems are useful in detecting signals of relatively rare, serious or unexpected adverse drug reactions. A signal is defined as “reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented pre-viously. Usually, more than a single report is required to generate a signal, depending upon the seriousness of the event and the quality of the information”. All signals must be vaidated before any regulatory decision can be made.

Reference: FDA Drug Safety Communication, 20 November 2013 at http://www.fda.gov/Drugs/DrugSafety/ucm375654.htm

Thiocolchicoside: risk of aneuploidyEuropean Union — The European Medi-cines Agency’s Committee on Human Medicinal Products (CHMP) has recom-mended that thiocolchicoside-containing medicines for use by mouth or injection should be restricted across the European Union.

These medicines are now recommended only as an add-on treatment for painful muscle contractures resulting from spinal conditions in adults and adolescents 16 years of age or older. In addition, the dose of thiocolchicoside by mouth or injection should be restricted.

The review of thiocolchicoside was triggered by the Italian medicines regulatory agency, AIFA, following new experimental evidence which suggested that thiocolchicoside was broken down in the body into a metabolite (M2 or SL59.0955) that could damage dividing cells, resulting in aneuploidy. Aneuploidy is a risk factor for harm to the develop-ing fetus, reduced fertility in men and in theory could increase the risk of develop-ing cancer.

Preparations for local application to the skin, which do not produce substantial levels of M2 in the body, are not affected by this review.

Reference: EMA Press Release, 22 Novem-ber 2013 at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001967.jsp&mid=WC0b01ac058004d5c1


355


Regulatory Action and NewsHelsinki Declaration: 2013 revisionThe World Medical Association (WMA) has adopted and published a revised version of the Helsinki Declaration on biomedical research involving human subjects.

Delegates at the WMA’s 64th annual Assembly in Fortaleza, Brazil, voted overwhelmingly to support the changes which provide for increased protection for vulnerable groups involved in research and include a new provision for com-pensating people harmed as a result of participating in research. In addition, there are expanded requirements for post-study arrangements to ensure that participants involved in research are informed of the results and have access to any beneficial treatments that emerge.

The changes agreed are all about providing a greater degree of protection for those involved in research. The revised Helsinki Declaration requires greater transparency in medical research, more accountability and increased patient safety. The changes place further obligations on research sponsors, on researchers themselves and on host governments to protect research subjects.

This is the seventh time the Helsinki Declaration has been revised since its establishment, with notes of clarification being added in 2002 and 2004. It is the most important set of international ethical regulations in biomedical research currently available and is a core document of the WMA. It was first adopted in 1964 and provides the basis for ethical principles governing medical research involving human subjects.

Reference: World Medical Association Press Release, 19 October 2013 at http://www.wma.net/en/20activities/10ethics/10helsinki/index

EudraCT: new version launchedEuropean Union — The European Medicines Agency has launched a new version of the European Clinical Trials Database (EudraCT). This new version, EudraCT V9, marks the initial step of a process through which summary clinical trial results will be made publicly available through the EU Clinical Trials Register (EU CTR).

EudraCT is a database used by national authorities to enter protocol-related information on clinical trials submitted by clinical trial sponsors but also includes protocol-related information on clinical trials in third countries if they are included in a Paediatric Investigation Plan (PIP).

EudraCT already contains protocol-related information submitted by sponsors for interventional clinical trials conducted in European Economic Area countries and/or in third countries, when the clinical trial is part of an agreed PIP. As of today, clinical-trial sponsors are encouraged to register on the EudraCT web site to start uploading summary results. Results posted by sponsors in EudraCT will start to become publicly available once the Agency has launched the complementary new version of the EU CTR towards the end of the year. The content and level of detail of the summary results is set out in a European Commission guideline and in its technical guidance.

This initial release of EudraCT will be followed by further updates to the system in 2014 which will provide improved

356

WHO Drug Information Vol. 27, No. 4, 2013Regulatory Action and News

PQP General Guidelines for Application Fees provides more information about the fee structure for applications received on or after 1 September 2013 and is available at http://www.who.int/prequal/info_general/documents/guidelines/application_fees/PQP_application_fees_September2013.pdf

Reference: WHO Prequalification of Medicines Programme. WHO Press Release, http://www.who.int/prequal

EudraGMDP database: improved information-sharingEuropean Union/Japan — The Japanese Ministry of Health, Labour and Welfare (MHLW) and the European Medicines Agency’s Pharmaceuticals and Medical Devices Agency (PMDA) have started entering information on good manufacturing practice (GMP) compliance related to Japanese manufacturers into the EudraGMDP database. This is the first time that information from a non-European regulator has started to be added to EudraGMDP. The initiative is expected to speed up regulatory processes and save time for importers, manufacturers and regulatory authorities.

This development is part of the mutual recognition agreement (MRA) between the European Union (EU) and Japan. It allows the European Medicines Agency (EMA), European national competent authorities and Japanese authorities to use information in EudraGMDP instead of issuing original paper GMP certificates for a number of regulatory procedures, such as marketing-authorization applications or variation applications, including the addition of a new manufacturer. The EU and Japanese regulatory authorities will now accept a reference to a EudraGMDP entry, or a downloadable file or print-out from the database, within the scope of the EU–Japan MRA.

functionalities for sponsors and EU regulatory authorities. With the launch of these further iterations of EudraCT by mid-2014, the modalities and timing of posting of result-related information as described in the EC guideline will apply, and sponsors will then be required to post result-related information.

The EMA supports international standardization of data requirements for clinical trial registration. The Agency will make the data descriptions and technical specifications available to enable stakeholders to build systems that can generate structured data sets and upload them electronically into EudraCT.

Reference: EMA Press Release, 11 Octo-ber 2013 at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/10/news_detail_001918.jsp&mid=WC0b01ac058004d5c1

WHO PQP now charging application feesWorld Health Organization — The WHO Prequalification of Medicines Programme (PQP) has been externally funded until now and was able to operate successfully through the generosity of donor organiza-tions. However, PQP is no longer able to rely solely on this funding.

PQP is not moving toward a full cost recovery model but is looking to achieve a balance between external and internal funding. Over the next few years, WHO will continue to assess this balance and make adjustments as needed. Although this may appear to be a potential disincentive to manufacturers seeking prequalification of their products, fees have been set below those currently being charged by the WHO vaccines and diagnostics prequalification programmes and flexibility has been introduced whereby manufacturers who provide adequate justification may be exempted from fees or charged a reduced fee.

357

WHO Drug Information Vol. 27, No. 4, 2013 Regulatory Action and News

The regulatory procedures concerned by these new measures depend on the legal frameworks in Japan and the EU, and they are clarified in relevant notices from the regulators. The EU and Japanese authorities may still request original paper GMP certificates when GMP compliance information cannot be accessed via EudraGMDP.

The EMA offers ‘read and write’ access to EudraGMDP to the regulatory authorities of all countries with which the EU has an MRA or an agreement on conformity assessment and acceptance of industrial products (ACAA). Most of these countries are already using the information in EudraGMDP for their own regulatory procedures; the Japanese authorities are the first to take the initiative to enter data into EudraGMDP.

Reference: EMA Press Release, 7 October 2013 at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013

Medical device identification system United States of America — The Food and Drug Administration (FDA) has announced a final rule for the unique device identification system (UDI) that, once implemented, will provide a consistent way to identify medical devices. The UDI system has the potential to improve the quality of information in medical device adverse events reports, which will help the FDA identify product problems more quickly, better target recalls, and improve patient safety.

The UDI system consists of two core items. The first is a unique number assigned by the device manufacturer to the version or model of a device, called a unique device identifier. This identifier will also include production-specific information such as the product lot or batch number, expiration date, and manufacturing date when that information appears on the label.

The second component is a publicly searchable database called the Global Unique Device Identification Database (GUDID) that will serve as a reference catalogue for every device with an identifier. No identifying patient information will be stored in this device information center. The UDI system will enhance the ability to quickly and efficiently identify marketed devices when recalled, improve the accuracy and specificity of adverse event reports and provide a foundation for a global, secure distribution chain, helping to address counterfeiting and diversion. It will also offer a clear way of documenting device use in electronic health records and clinical information systems. The UDI system is a key component of the National Medical Device PostMarket Surveillance System proposed in September 2012. In general, high-risk medical devices (Class III) will be required to carry unique device identifiers on their label and packaging within one year and this number and corresponding device information must be submitted to the new database. Manufacturers will have three years to act for most Class II (moderate risk) devices. Manufacturers of Class I devices not exempt from UDI requirements will have five years to act.


Macitentan approved for pulmonary arterial hypertensionUnited States of America — The Food and Drug Administration (FDA) has approved macitentan (Opsumit®), a new adult treatment for pulmonary arterial hypertension (PAH). Macitentan is an endothelin receptor blocker.

Similar to other members of its drug class, Opsumit® carries a boxed warning

358


outside the body, includes disposable components and a control/monitor unit. The device works by removing certain lipoproteins from the patient’s blood. The Liposorber LA-15 System® was first approved in the United States in 1996 for lowering low density lipoprotein cholesterol in certain patients with familial hypercholesterolemia (FH).

Reference: FDA News Release, 10 October 2013 at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370931.htm Riociguat approved for pulmonary hypertension

United States of America — The Food and Drug Administration (FDA) has approved riociguat (Adempas®) for adult treatment of two forms of pulmonary hypertension.

Riociguat is a soluble guanylate cyclase stimulator intended for patients with chronic thromboembolic pulmonary hypertension (CTEPH) after surgery or patients who cannot undergo surgery, to improve their ability to exercise. Riociguat is also indicated for patients with pulmonary arterial hypertension (PAH) to improve their ability to exercise and to delay clinical worsening of their condition.

Adempas® carries a boxed warning alerting patients and healthcare professionals that the drug should not be used in pregnant women. Female patients can receive the drug only through the Adempas® Risk Evaluation and Mitigation Strategy (REMS) Pro-gramme. This requires that:

• Prescribers should be certified.

• All female patients should be enrolled and comply with applicable pregnancy testing and contraception requirements before initiating treatment.

• Pharmacies should be certified to dis-pense Adempas®.

alerting that the drug should not be used in pregnant women. Female patients can receive the drug only through the Opsumit® Risk Evaluation and Mitigation Strategy (REMS) Programme. This requires that:

• Prescribers should be certified.

• All female patients should be enrolled and comply with applicable pregnancy testing and contraception requirements before initiating treatment.

• Pharmacies should be certified to dis-pense Opsumit®.

Common side effects observed include anaemia, nasopharyngitis, sore throat, bronchitis, headache, flu and urinary tract infection.

Reference: FDA News Release, 18 October 2013 at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm371362

Liposorber Apheresis System® approved for paediatric glomerulosclerosisUnited States of America — The Food and Drug Administration (FDA) has approved Liposorber LA-15 System® to treat paediatric patients with primary focal segmental glomerulosclerosis (FSGS) either before transplant, or after renal transplantation in which there is recurrence of FSGS.

FSGS is a chronic kidneys disease which causes excessive loss of protein from the blood into the urine leading to nephrotic syndrome and kidney failure. A majority of children with primary FSGS will progress to end stage renal disease and will require either kidney dialysis or kidney transplant. About one quarter to one half of FSGS patients that receive a kidney transplant will have a recurrence of FSGS in their transplanted kidney.

The Liposorber LA-15 System®, a blood processing system that is used

359


dying from the disease. It is to be used in combination with trastuzumab and other chemotherapy prior to surgery and may be followed by chemotherapy after surgery. Following surgery, patients should continue to receive trastuzumab to complete one year of treatment.

The confirmatory trial for this accelerated approval is being conducted in partici-pants with HER2-positive breast cancer who had prior breast cancer surgery and are at high risk of having their cancer return. More than 4800 participants are enrolled in this trial, which will provide further data on efficacy, safety and long-term outcomes. Results are expected in 2016.

The most common side effects reported in participants receiving pertuzumab plus trastuzumab and docetaxel were hair loss, diarrhoea, nausea and a decrease in white blood cells. Other significant side effects included decreased cardiac function, infusion-related reactions, hypersensitivity reactions and anaphylaxis.


Paclitaxel: expanded use for late-stage pancreatic cancerUnited States of America — The Food and Drug Administration (FDA) has expanded the approved uses of paclitaxel protein-bound particles for injectable suspension, albumin-bound (Abraxane®), to treat patients with metastatic pancre-atic cancer.

Abraxane® is intended for use with gemcitabine in patients with pancreatic cancer that has spread to other parts of the body.

Common side effects observed in Abraxane® plus gemcitabine treated participants include neutropaenia,

Common side effects observed in patients treated with riociguat included headache, dizziness, dyspepsia, peripheral edema, nausea, diarrhoea and vomiting. Reference: FDA News Release, 8 October 2013 at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements

Vortioxetine approved for major depressive disorderUnited States of America — The Food and Drug Administration (FDA) has approved vortioxetine (Brintellix®) to treat adults with major depressive disorder.

The most common side effects reported by participants taking vortioxetine in clinical trials included nausea, constipa-tion and vomiting. Brintellix® and other antidepressant drugs have a boxed warning and a medication guide alerting patients and healthcare professionals that antidepressants can increase the risk of suicidal thoughts and behavior in children, adolescents and young adults ages 18 to 24 during initial treatment.


Pertuzumab approved as neo-adjuvant breast cancer treatmentUnited States of America — The Food and Drug Administration (FDA) has granted accelerated approval to pertuzumab (Perjeta®) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neo-adjuvant setting). Perjeta® was approved in 2012 for the treatment of patients with advanced or metastatic HER2-positive breast cancer.

Perjeta’s new use is intended for patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer who are at high risk of having their cancer return or metastasize, or of

360


thrombocytopaenia, fatigue, peripheral neuropathy, nausea, alopecia, peripheral edema, diarrhoea, pyrexia, vomiting, rash and dehydration. The most common serious side effects were pyrexia, dehydration, pneumonia and vomiting. Other clinically important serious side effects included sepsis and pneumonitis.

Paclitaxel was also approved to treat breast cancer in 2005 and non-small cell lung cancer in 2012.


Lipid injectable emulsion approved for parenteral nutritionUnited States of America — The Food and Drug Administration (FDA) has approved lipid injectable emulsion, USP (Clinolipid®) for parenteral nutrition in adults, providing a source of calories and essential fatty acids for patients who are unable to eat or drink.

Clinolipid® is a lipid emulsion that contains a mixture of refined olive oil and refined soybean oil which should be used with caution in patients with pre-existing liver disease or liver insufficiency. Clinolipid® should not be used in patients with a known hypersensitivity to egg or soybean proteins, or in those with hyperlipidaemia. The most common side effects in patients treated with Clinolipid® during clinical trials included infectious complications, nausea and vomiting, excess lipids in the blood, high blood sugar, low levels of protein in the blood and abnormal liver function tests. Clinolipid® is not indicated for use in pre-term infants. The product carries a warning about the risk of death in pre-term infants after infusion of intravenous lipid emulsions. Neither is Clinolipid®

indicated for use in other paediatric patients because it is not known what amount of essential fatty acids meet the nutritional needs of children. Reference: FDA News Release, 3 October 2013 at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements

Ibrutinib approved for mantle cell lymphomaUnited States of America — The Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica®) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.

MCL is a rare form of non-Hodgkin lym-phoma and represents about six percent of all non-Hodgkin lymphoma cases in the United States. By the time MCL is diag-nosed, it usually has already spread to the lymph nodes, bone marrow and other organs.

Ibrutinib is intended for patients with MCL who have received at least one prior therapy. It works by inhibiting the enzyme needed by the cancer to multiply and spread. Imbruvica® is the third drug approved to treat MCL. Velcade® (2006) and Revlimid® (2013) are also approved to treat the disease. The most common side effects reported in participants receiving ibrutinib are thrombocytopenia, diarrhoea, neutrope-nia, anemia, fatigue, musculoskeletal pain, edema, upper respiratory infection, nausea, bruising, dyspnea, constipa-tion, rash, abdominal pain, vomiting, and decreased appetite. Other clinically significant side-effects include bleeding, infections, kidney problems and the development of other types of cancers.

Reference: FDA News Release, 13 Novem-ber 2013 at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements

361


previously untreated patients as well as patients with advanced treatment his-tories and resistant to multiple classes of HIV medicines. It also demonstrated a high barrier to resistance.

Dolutegravir has been recommended for marketing approval together with a risk management plan (RMP) which covers the risk of infrequent but potentially severe hypersensitivity reactions.

The EMA is currently consulting on new draft guidance for development of these medicines, taking into account changes in the therapeutic landscape.


Delamanid and para-aminosalicylic acid approved for multidrug-resistant tuberculosisEuropean Union —The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the authorization of delamanid (Deltyba®) and para-aminosalicylic acid (Para-aminosalicylic acid Lucane®), two treatment options for use in combination with other medicines against multidrug-resistant tuberculosis.

Multidrug-resistant tuberculosis is defined as tuberculosis caused by Mycobacterium tuberculosis that is resistant to at least isoniazid and rifampicin, which are two antituberculosis medicines used in standard treatment. Approximately 450 000 cases of multidrug-resistant tuberculosis occur globally every year, which corresponds to approximately 5% of the world’s annual burden of tuberculosis. In the European Union, tuberculosis is an orphan indication. It was estimated in 2011 to occur in 2.3 out of 10 000 people.

Eslicarbazepine acetate approved for adult seizuresUnited States of America — The Food and Drug Administration (FDA) has approved eslicarbazepine acetate (Aptiom®) as an add-on medication to treat seizures associated with epilepsy.

Eslicarbazepine acetate is approved for the treatment of partial seizures, the most common type of seizure seen in people with epilepsy.

The most common side effects reported by patients receiving eslicarbazepine acetate in clinical trials included dizzi-ness, drowsiness, nausea, headache, double-vision, vomiting, fatigue and loss of coordination. These and other side effects and recommendations for monitor-ing are described in the drug label. Like other antiepileptic drugs, esli-carbazepine acetate may cause suicidal thoughts or actions in a very small num-ber of people.

Reference: FDA News Release, 8 Novem-ber 2013 at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements

Dolutegravir approved for HIV European Union — The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorization for dolutegravir (Tivicay®) in combination with other antiretroviral medicines for the treatment of adults and adolescents over twelve years of age infected with human immunodeficiency virus (HIV).

Dolutegravir can be used in adult patients with and without resistance to the integrase class and in adolescents infected with HIV-1 without resistance to the integrase class.

Dolutegravir has demonstrated its efficacy in large scale studies covering

362


Deltyba®: The CHMP recommended granting a conditional marketing authorization for Deltyba® (delamanid), for the treatment of adult patients with pulmonary infections due to multidrug-resistant tuberculosis when an effective treatment regimen cannot otherwise be devised for reasons of resistance or tolerability. Additional studies on the long-term effectiveness of Deltyba® need to be conducted.

Para-aminosalicylic acid Lucane®: The Committee also recommended granting a marketing authorization for Para-amino-salicylic acid Lucane® against multidrug-resistant tuberculosis in adults and paediatric patients when an effective treatment regimen cannot otherwise be devised for reasons of resistance or tolerability.

Para-aminosalicylic acid, of which Para-aminosalicylic acid Lucane® is a new formulation, was the second medicine to be introduced for the treatment of tuberculosis, in 1946, and was part of standard-of-care treatment until the 1970s. Its use resumed in the 1990s with the emergence of multidrug-resistant tuberculosis.


Sofosbuvir approved for chronic hepatitis CEuropean Union — The European Medicines Agency’s Committee for Medicinal Products for Human use (CHMP) has recommended granting a

marketing authorization for sofosbuvir (Sovaldi®) for use in combination with other medicinal products for the treatment of chronic hepatitis C (HCV) in adults.

Sofosbuvir is the first representative of a new class of antivirals that act as inhibitors of an essential enzyme of HCV, the NS5B ribonucleic acid polymerase. This medicine provides the first interferon-free treatment option for chronic hepatitis C.

Furthermore, when sofosbuvir is used in combination with pegylated interferon as well as ribavirin, shortened treatment duration down to 12 weeks (compared to 24–48 weeks with the current standard of care) is possible and provides high efficacy. This is of value considering the side-effect profile of interferon.

HCV infection is the most common single cause of liver transplantation in the EU. However, patients who do undergo liver transplantation due to hepatitis C have a worse prognosis than patients who do so for other reasons because recurrence of the virus in the graft is near-universal and often aggressive. For many of these patients, there are currently no approved treatment options that are likely to be effective.

In clinical trials, Sovaldi® in combination with ribavirin has shown its capacity to prevent reinfection of the graft, and thus provides a treatment option for patients with HCV infection who are on the waiting list for liver transplantation.


363


Recent Publications, Information and EventsWHO Good Governance for Medicines Model Framework The World Health Report identifies ten leading causes of health system inefficiency, four of which are related to medicines: price, quality, use and waste.

In most countries, expenditure on pharmaceuticals comprises a large proportion of the health budget. Effective management and good governance in the pharmaceutical sector is therefore an essential element to improving efficiency and making a sustainable contribution to health systems strengthening and universal health coverage. Growing numbers of public health officials in ministries of health, medicines regulatory authorities and national procurement departments recognize the need for institutions and personnel to work in a more transparent and accountable environment in accordance with ethical professional practices.

Thirty-six countries are participating in the Good Governance for Medicines Programme (GGM) and are applying the principles of determining the strengths and weaknesses of a country's pharmaceutical system and developing and applying appropriate interventions. A recent evaluation of the programme confirms the need for strong support to countries for strengthening governance in the pharmaceutical sector.

To further support country efforts, WHO has published the Good Governance for Medicines Model Framework. This guideline can be adapted according to country needs and proposes a combination of discipline-based and values-based strategies for effective,

efficient, ethical, transparent and accountable management of pharma-ceutical systems. The first edition of the framework was published in 2008 and since revised by experts and country representatives building on their experience of work already undertaken. The updated version is now available atwww.who.int/medicines/areas/policy/goodgovernance/

Reference: Good Governance for Medicines Model Framework at http://www.who.int/medicines/areas/policy/goodgovernance/

Transparency of clinical trial data In the context of on-going negotiations on the European Union Clinical Trials Regulation and the European Medicines Agency’s (EMA’s) work towards the proactive publication of clinical trial data, HAI Europe has published a policy paper Protecting citizens’ health: transparency of clinical trial data on medicines in the EU, with the objective of shaping the debate towards greater data transparency.

Many adverse drug reactions, including deaths, could have been avoided had the public known about the undisclosed effects of medicines. In addition, open access to trial data can facilitate independent re-analyses of claimed efficacy and comparison between therapies. The transparency of clinical trial data also responds to an ethical obligation. According to the Declaration of Helsinki, authors have the duty to make publicly available the results of their studies: whether positive, negative or inconclusive. The policy paper argues that increased public knowledge on the effects of medicines plays an

364

WHO Drug Information Vol. 27, No. 4, 2013Recent Publications, Information and Events

unquestionable role in the strengthening and protection of public health.

Reference: Health Action International (HAI) Europe Policy Paper. Protecting citizens’ health: transparency of clinical trial data on medicines in the EU at http://bit.ly/1a9Xrga

Drug-resistant TB treatments: more support neededMédecins Sans Frontières (MSF) and the International Union Against Tuberculosis and Lung Disease have released the third edition of the drug-resistant TB drug report DR-TB Drugs Under the Microscope. The report covers the issues faced in accessing DR-TB drugs, including the high price of the new drug bedaquiline. A currently recommended DR-TB treatment regimen costs any-where between US$ 3000 – 5000 per person per treatment. The treatment has awful side effects, is effective only half the time and lasts around two years — with people taking as many as 14 600 pills.

Also relaunched is the Test me, treat me DR-TB Manifesto which asks people to sign on to support people receiving treatment, better treatment options, and funding to scale up treatment. The manifesto can be accessed at http://www.msfaccess.org/TBmanifesto/.

MSF is one of the largest nongovern-mental organizations providing DR-TB care. In 2012, MSF treated 29 000 patients for TB in 30 countries, and1780 patients for DR-TB in 18 countries. The mission of the International Union Against Tuberculosis and Lung Disease is to bring innovation, expertise, solutions and support to address health challenges in low- and middle-income populations.

Reference: DR-TB Drugs Under the Microscope. MSF Press Release, athttp://www.msfaccess.org/content/dr-tb-drugs-under-microscope3rd-edition.

2013 WHO Global Tuberculosis ReportThe World Health Organization has identified five priority action areas that could make a rapid difference between now and 2015 to strengthening the fight against tuberculosis (TB). The 2013 TB report calls for more attention to multidrug-resistant TB (MDR-TB) and better strategies to reach those who are being missed by the system.

The WHO-recommended actions are based on new data from almost 200 countries and territories. It documents how TB treatment has saved the lives of more than 22 million people, and how both the numbers of people ill with TB and those who died from the disease fell in 2012.

The report also identifies the challenges still ahead to help control the disease.

Reference: TDR eNewsletter, 25 October 2013 at http://www.who.int/tdr/news/2013/global-TB-report/en/index.html

International Pharmacopoeia: fourth editionThe International Pharmacopoeia contains a collection of recommended procedures for the determination of pharmaceutical substances, excipients and dosage forms and is intended to serve as source material for reference or adaptation. The Third Supplement has now been added to the Fourth Edition of The International Pharmacopoeia.

New, revised and withdrawn texts New and revised texts are introduced in the section on Supplementary information for ten monographs on pharmaceutical substances, thirty-one monographs on dosage forms, two general monographs, ten methods of analysis and six texts. A list of the new, revised and withdrawn texts is provided as an annex.

365

WHO Drug Information Vol. 27, No. 4, 2013 Recent Publications, Information and Events

Artemisinin and its derivatives should no longer be used as monotherapy and fixed-dose combination formulations are now recommended. The 47th meeting of the Expert Committee on Specifications for Pharmaceutical Preparations therefore decided to withdraw these monographs.

Pharmacopoeial Discussion Group (PDG) harmonized general textsA number of PDG texts have been adopted and include:

• Residue on ignition/sulphated ash

• Test for extractable volume for parenteral preparations

• Disintegration

• Test for particulate contamination: sub-visible particles

• Microbiological examination of non- sterile products: acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use

• Microbial examination of non-sterile products: tests for specified micro- organism

• Test for sterility

• Tablet friability

• Bulk and tapped density of powders

• Bacterial endotoxins test

• Microbial examination of non-sterile products: microbial enumeration tests

Reproductions from the European PharmacopoeiaThe following new tests have also been published in the European Pharma-copoeia:

• Measurement of consistency by penetrometry

• Resistance to crushing of tablets

Infrared Reference SpectraMany monographs in The International Pharmacopoeia include an identification test using infrared spectroscopy. Such tests usually allow comparison either with a spectrum obtained from an International Chemical Reference Substance (ICRS) or with an International Infrared Reference Spectrum (IIRS). Nine additional spectra were added.

International Chemical Reference SpectraThe release procedure for ICRS was revised and is included in the Supplementary information.

Complete information on the texts and access to The International Pharmacopoeia is available online at the WHO Medicines web site.

Reference: Fourth Edition of The International Pharmacopoeia. WHO Medicines web site at http://www.who.int/medicines/publications/pharmacopoeia/en/.

366


Consultation DocumentsThe International Pharmacopoeia

Dissolution testing of tablets and capsules

Draft revision for inclusion in the supplementary information section of The International Pharmacopoeia (September 2013). Please address any comments to Technologies, Standards and Norms, Essential Medicines and Health Products, World Health Organization, 1211 Geneva 27, Switzerland. Or e-mail to [email protected]. All working documents are posted for comment at http://www.who.int/medicines.

IntroductionThe revision of chapter 5.5 Dissolution test for solid, oral dosage forms, as published in The International Pharmacopoeia*, was based on the internationally-harmonized dissolution test developed by the Pharmacopoeial Discussion Group (PDG) which comprises representatives from the European Pharmacopoeia, the Japanese Pharmacopoeia and the United States Pharmacopeia. The revised general method presents the Paddle and Basket methods for dissolution testing. Two other general methods contained in the PDG text, namely the Reciprocating-cylinder method and the Flow-through cell have not, so far, been adopted for The International Pharmacopoeia.

*Note from the Secretariat: It is intended to publish revised chapter 5.5 Dissolution test for solid, oral dosage forms, adopted in October 2012 at the 47th WHO Expert Committee on Specifications for Pharmaceutical Preparations, together with this text in the next supplment or edition of The International Pharmacopoeia. It is not the intention of The International Pharmacopoeia to apply retrospectively the test conditions and acceptance criteria of the revised dissolution test or to change specifications for existing products. Table 1 lists monographs with dissolution tests, which were developed applying previous versions of chapter 5.5 and which are thus not subject to the internationally-harmonized provision. In the elaboration of new monographs and revision of individual monographs in The International Pharmacopoeia the principles of the revised test, e.g. to base acceptance criteria on “Q” values (dissolution limits), will be applied.

Table 1. Monographs on solid, oral dosage forms with dissolution test conditions and specifications elaborated before chapter 5.5 Dissolution test for solid, oral dosage forms, were revised to encompass the internationally-harmonized procedure.

Amodiaquine tabletsArtemether capsulesArtemether tablets

367

WHO Drug Information Vol. 27, No. 4, 2013 The International Pharmacopoeia

Artenimol tabletsArtesunate tabletsCarbamazepine tabletsChloroquine phosphate tabletsChloroquine sulfate tabletsDoxycycline capsulesDoxycycline tabletsEfavirenz, emtricitabine and tenofovir tabletsEmtricitabine and tenofovir tabletsEmtricitabine capsulesErythromycin ethylsuccinate tabletsErythromycin stearate tabletsEthambutol hydrochloride tabletsGriseofulvin tabletsIbuprofen tabletsIndinavir capsulesIndometacin tabletsIsoniazid tabletsIsoniazid and ethambutol hydrochloride tabletsLevonorgestrel and ethinylestradiol tabletsLopinavir and ritonavir tabletsMetronidazole tabletsPhenoxymethylpenicillin potassium tabletsPhenytoin sodium tabletsPyrazinamide tabletsQuinine bisulfate tabletsQuinine sulfate tabletsRifampicin capsulesRifampicin tabletsRitonavir tabletsSaquinavir tabletsSulfadoxine and pyrimethamine tabletsSulfamethoxazole and trimethoprim tabletsTenofovir tablets

Objective of dissolution testingWhile the ultimate objective of dissolution testing is to ensure adequate and reproducible bioavailability, the objective of the dissolution tests prescribed in the individual monographs of The International Pharmacopoeia is to obtain information about the drug-release characteristics of a particular formulation or batch of a product under standardized test conditions. Compliance with the test provides an assurance that most of the active ingredient will be dissolved in an aqueous medium within a reasonable amount of time when the preparation is subject to a mild agitation. Compliance with the dissolution test does not by itself guarantee bioavailability.

Standardized conditions and limits are considered appropriate for a pharmacopoeial test that is intended to apply to a monograph covering multisource products.

Policy of The International PharmacopoeiaMonographs on tablet and capsule preparations listed in Table 1 include a dissolution test, either with or without further information on the test conditions. As a test method

368

WHO Drug Information Vol. 27, No. 4, 2013The International Pharmacopoeia

spectrophotometry is typically employed. In case a dissolution test is prescribed an additional disintegration test is not required.

In the elaboration of new tablet and capsule monographs and revision of existing monographs decisions on dissolution and disintegration testing will be taken in agreement with the guidance given by the International Conference on Harmonisation (ICH) on the application of dissolution testing to medicinal products (see http://www.ich.org). The monograph will contain a dissolution test and/or a disintegration test. For rapidly dissolving (dissolution > 80% in 15 minutes at pH 1.2, 4.0 and 6.8) dosage forms containing active ingredients which are highly soluble throughout the physiological range (dose: solubility volume < 250 ml from pH 1.2 to 6.8), disintegration is substituted for dissolution. Disintegration is most appropriate when a relationship to dissolution has been established or when disintegration is shown to be more discriminating than dissolution.

When the disintegration test can be substituted for the dissolution test monographs on dosage forms will specify a choice between A (dissolution test) and B (disintegration test). If the disintegration requirement is not met dissolution testing has to be performed.

Test conditionsFollowing a decision made at the 45th Expert Committee meeting a standardized dissolution test is applied to conventional-release tablet and capsule formulations containing highly soluble active ingredients (Class I and III of the Biopharmaceutics Classification System (BCS)). The following conditions for a single-time test using the Paddle method are preferred:

– dissolution medium: dissolution buffer pH 6.8; – volume of medium: 500 ml; – rotation speed: 75 rpm; – sampling time: 30 min.

When test conditions are not specified in the individual monograph it is recommended to apply similar test conditions. If the Basket method is used a rotation speed of 100 rpm is recommended. For conventional-release tablet and capsule formulations containing poorly water-soluble active ingredients (Class II and IV of the BCS). (Classification of active ingredients included in the WHO Model List of Essential Medicines is provided by WHO in Technical Reprt Series, No. 937, Annex 7 (2006).) decisions on the appropriate test conditions are taken on a case-to-case basis. A single-point dissolution test is normally applied. Because of the low aqueous solubility dissolution medium of volume 900 ml and addition of a surfactant may be needed. The concentration of active ingredient at 100% dissolution should not exceed approximately 35% saturation. For delayed-release dosage forms two-stage testing according to the procedure in 5.5 Dissolution test for solid, oral dosage forms is applied. It is important to consider the population of individuals who will be taking the dosage form when designing the test, e.g. administration of the dosage form to achlorhydric patients may require testing for resistance of the product against gastric juice at elevated pH, for example, pH 3.5.

369


For sustained-release dosage forms the appropriate test conditions and sampling procedures are specified in the monograph. Three time-points are applied.

Acceptance criteriaThe revised dissolution test contains acceptance criteria for conventional-release, delayed-release and sustained-release dosage forms. The acceptance criteria are identical to those stated in the internationally harmonized dissolution test. The harmonized dissolution limits (Q-values) are applied in new and revised monographs (i.e., monographs on solid, oral dosage forms containing a dissolution test, but not listed in Table 1).

The three-level acceptance criteria, i.e. S1, S2 and S3 for conventional-release dosage forms, are not applied in monographs listed in Table 1; acceptance criteria for a two-stage test (6+6 dosage units) are specified in some monographs. For dosage forms for which the monograph require compliance with 5.5 Dissolution test for solid, oral dosage forms, but without specification of test conditions, it is recommended to apply a test using Q = 75% and the three-level acceptance criteria.

General monograph on parenteral preparations.Test for bacterial endotoxins (3.4)

Draft for inclusion in the revised General Monograoh on Parenteral Preparations in The International Pharmacopoeia (September 2013). Please address any comments to Technologies, Standards and Norms, Essential Medicines and Health Products, World Health Organization, 1211 Geneva 27, Switzerland. Or e-mail to [email protected]. All working documents are posted for comment at http://www.who.int/medicines.

During the forty-seventh meeting of the Expert Committee on Specifications for Pharmaceutical Preparations in October 2012 a revision of the general monograph on parenteral preparations was adopted.

One of the major changes to the monograph on parenteral preparations was the required compliance of all parenteral preparations with the test for bacterial endotoxins (or, where justified, pyrogens). As a consequence individual monographs on injectable dosage forms in The International Pharmacopoeia (Ph.Int.) were investigated with a view to add a limit for bacterial endotoxins to each monograph that currently does not include such a requirement.

The limits proposed are calculated using the following approaches (for details see Table 2).

• For the monograph on Ergometrine hydrogen maleate injection, the limit given in The International Pharmacopoeia for the respective pharmaceutical substance (for paren-teral use) was applied to the strength of the respective dosage form listed in the WHO Model List of Essential Medicines (EML).

• For the monographs on Ephedrine sulfate injection, Magnesium sulfate injection, Oxytocin injection, Prednisolone sodium phosphate injection and Zidovudine intra-

The International Pharmacopoeia

370


venous infusion, the limits given in the respective monographs of the United States Pharmacopeia (USP) were taken and applied to the strength of the respective dosage forms listed in the EML.

• For the monographs on Artemether injection, Artemotil injection, Melarsoprol injec-tion, Pentamidine isetionate powder for injections and Quinine dihydrochloride injec-tion the endotoxin limits were calculated using recommendations given in Chapter 3.4 Test for bacterial endotoxins:

Ph.Int. monographs on parenteral Proposed limits for the preparations currently lacking limits bacterial endotoxins test for the bacterial endotoxins test

1 Artemether injection not more than 1.56 IU of endotoxin per mg Artemether

2 Artemotil injection not more than 1.04 IU of endotoxin per mg Artemotil

3 Ephedrine sulfate injection not more than 85 IU of endotoxin per ml

4 Ergometrine hydrogen maleate not more than 140 IU of endotoxin injection per ml

5 Melarsoprol injection not more than 50 IU of endotoxin per ml

6 Magnesium sulfate injection not more than 45 IU of endotoxin per ml

7 Oxytocin injection not more than 357 IU of endotoxin per ml

8 Pentamidine isetionate not more than 1.25 IU of powder for injection* endotoxin per mg pentamidine isetionate

9 Prednisolone sodium phosphate not more than 5.0 IU of for injection** endotoxin per mg prednisolone sodium phosphate

10 Quinine dihydrochloride injection not more than 300 IU of endotoxin per ml

11 Zidovudine intravenous infusion not more than 10 IU of endotoxin per ml

* The title of the monograph should also be changed to Pentamidine isetionate for injection.** The title of the monograph should also be changed to Prednisolone sodium phosphate for injection.

Table 1. Proposed limits for the bacterial endotoxins test for Ph.Int. monographs on parenteral preparations currently lacking such a specification

371


the endotoxin limit for parenteral preparations, defined on the basis of dose, is equal to:

Kendotoxin limit = — M

K = threshold pyrogenic dose of endotoxin per kilogram of body mass (i.e. 5.0 IU per kg for any route of administration other than intrathecal)

M = maximum recommended bolus dose of product per kilogram of body mass. (When the product is to be injected at frequent intervals or infused continuously, M is the maximum total dose administered in a single hour period.)

In case the EML recommends different strengths of the same medicine the endotoxin limit is specified per mg active ingredient (see Artemether injection and Artemotil injection); in case only one strength is listed the limit is defined per ml (injection solution) (see Melarsoprol injection and Quinine dihydrochloride injections). For powders for injections the endotoxin limit is given per mg of active ingredient.

Additional changesIn the new general monograph on Parenteral preparations the statement is made that:

“For powders and concentrates for injections and intravenous infusions, the amount of the preparation to be tested and the nature and volume of the liquid in which it is to be dissolved, suspended or diluted is specified in the individual monograph.”

It is proposed to delete this sentence since the preparation of the sample solution is sufficiently described in Chapter 3.4. The harmonized text requires that the samples should be dissolved or diluted in aqueous solutions so that the final solutions do not exceed the maximum valid dilution (MVD). In the monograph on Metronidazole injection the following provision for the test for bacterial endotoxins is made:

“Carry out the test as described under 3.4 Test for bacterial endotoxins. Dilute the injection, if necessary, with water LAL to give a solution containing 5 mg per ml (solution A). Solution A contains not more than 3.5 IU of endotoxin per ml. Carry out the test using the maximum valid dilution of solution A calculated from the declared sensitivity of the lysate used in the test.”

This sentence should be changed to read:

“Carry out the test as described under 3.4 Test for bacterial endotoxins; contains not more than 3.5 IU of endotoxin per ml.” Same rationale applies as given above.

For endotoxin limits already specified in The International Pharmacopoeia two phrases are used:

“… not more that x IU of endotoxin per mg/ml …” “… not more that x IU of endotoxin RS per mg/ml …”


372


Tabl

e 2.

Dat

a us

ed in

the

calc

ulat

ion

of b

acte

rial e

ndot

oxin

lim

its

Ph.In

t. m

onog

raph

s En

doto

xin

limits

in

Info

on

stre

ngth

of

Info

on

dosa

ge a

nd

K

Mla

ckin

g en

doto

xin

resp

ectiv

e U

SP

dosa

ge fo

rm

rout

e of

app

licat

ion

limit

mon

ogra

phs

(EM

L or

PH

.INT)

Arte

met

her i

njec

tion

No

USP

mon

ogra

ph

17th

EM

L: 8

0 m

g/m

l in

1-m

l In

tram

uscu

lar i

njec

tion

5

3.2

ampo

ule

(oily

inje

ctio

n);

For a

dults

, arte

suna

te 2

.4 m

g/kg

BW

IV o

r IM

IU

/kg

mg/

kg

Ph

.Int.:

80

mg/

ml i

n 1-

ml

give

n on

adm

issi

on (t

ime

= 0)

, the

n at

12

h an

d

am

poul

e (o

ily in

ject

ion)

, 24

h, t

hen

once

a d

ay is

the

reco

mm

ende

d

ot

her a

vaila

ble

stre

ngth

s:

treat

men

t. Ar

tem

ethe

r, or

qui

nine

, is

an

40

mg/

ml (

paed

iatri

c fo

rmu-

ac

cept

able

alte

rnat

ive

if pa

rent

eral

arte

suna

te

la

tion)

, 60

mg/

ml,

100

mg/

is

not

ava

ilabl

e: a

rtem

ethe

r 3.2

mg/

kg B

W IM

ml (

adul

t for

mul

atio

n).

give

n on

adm

issi

on th

en 1

.6 m

g/ k

g BW

per

day

*.

Arte

mot

il in

ject

ion

No

USP

mon

ogra

ph

Not

on

the

17th

EM

L Ar

tece

f® 1

50 m

ust o

nly

be a

pplie

d vi

a IM

rout

e.

5 4.

8

Ph

. Int

.: Av

aila

ble

stre

ngth

s:

3-da

y tre

atm

ent c

ours

e In

itial

dos

e: in

ject

ion

IU/k

g m

g/kg

50 m

g/m

l (pa

edia

tric

form

u-

of 4

.8 m

g ar

tem

otil

per k

g BW

eve

nly

divi

ded

latio

n), 7

5 m

g/m

l, 15

0 m

g/m

l ov

er b

oth

ante

rior t

high

s. F

ollo

w-u

p do

ses:

(adu

lt fo

rmul

atio

n)

1.6

mg

per k

g BW

afte

r 6, 2

4, 4

8 an

d 72

hou

rs

in

alte

rnat

ing

thig

hs.

Ephe

drin

e su

lfate

N

ot m

ore

than

1.7

N

ot o

n th

e 17

th E

ML.

in

ject

ion

USP

End

otox

in U

nits

Ph

. Int

.: St

reng

th 5

0 m

g/m

l

per m

g of

eph

edrin

e

sulfa

te

. Er

gom

etrin

e hy

drog

en N

o U

SP m

onog

raph

Ph

. Int

.: Er

gom

etrin

e hy

drog

en

mal

eate

inje

ctio

n

mal

eate

for p

aren

tera

l use

con

-

ta

ins

not m

ore

than

700

.0 IU

of

endo

toxi

n R

S pe

r mg

Stre

ngth

in

EML:

200

μg/

ml

Mel

arso

prol

inje

ctio

n N

o U

SP m

onog

raph

17

th E

ML:

Inje

ctio

n: 3

.6%

sol

u-

Trea

tmen

t of T

. bru

cei r

hode

sien

se a

nd

5 3.

6

tio

n (1

80 m

g in

5 m

l am

poul

e)

T. b

ruce

i gam

bien

se w

ith m

enin

go e

ncep

halit

ic

IU/k

g m

g/kg

in

volv

emen

t (se

e ab

ove)

, by

slow

IV in

ject

ion,

AD

ULT

and

CH

ILD

, dos

e gr

adua

lly in

crea

sed

fro

m 1

.2 m

g/kg

to m

axim

um o

f 3.6

mg/

kg d

aily

in

cou

rses

of 3

–4 d

ays

with

inte

rval

s of

7–1

0

days

bet

wee

n co

urse

s; a

ltern

ativ

ely

for T

. bru

cei

ga

mbi

ense

infe

ctio

n, 2

.2 m

g/kg

dai

ly fo

r 10

days

.

373


Ph.In

t. m

onog

raph

s En

doto

xin

limits

in

Info

on

stre

ngth

of

Info

on

dosa

ge a

nd

K

Mla

ckin

g en

doto

xin

resp

ectiv

e U

SP

dosa

ge fo

rm

rout

e of

app

licat

ion

limit

mon

ogra

phs

(EM

L or

PH

.INT)

Mag

nesi

um s

ulfa

te

Not

mor

e th

an 0

.09

17

th E

ML:

500

mg

of

inje

ctio

n U

SP E

ndot

oxin

Uni

ts

mag

nesi

um s

ulfa

te h

epta

-

per m

g of

mag

ne-

hydr

ate

per m

l in

2 or

10

ml

si

um s

ulfa

te

ampo

ule

(M

gSO

4·7H

2O)

Oxy

toci

n in

ject

ion

Not

mor

e th

an 3

5.7

17

th E

ML:

10

IU in

1 m

l.

Endo

toxi

n U

nits

per

USP

Oxy

toci

n U

nit

Pent

amid

ine

N

o m

onog

raph

17

th E

ML:

Pow

der f

or in

ject

ion:

Vi

scer

al le

ishm

ania

sis

(unr

espo

nsiv

e to

, or

5 4

iset

iona

te

20

0 m

g (a

s is

etio

nate

) in

vial

. in

tole

rant

of,

antim

onia

l com

poun

ds),

by d

eep

IM

IU/k

g m

g/kg

pow

der f

or in

ject

ion

inje

ctio

n or

by

IV in

fusi

on, A

DU

LT a

nd C

HIL

D,

4

mg/

kg 3

tim

es a

wee

k fo

r 5–2

5 w

eeks

or l

on

ger,

until

2 c

onse

cutiv

e sp

leni

c as

pira

tes

14

da

ys a

part

are

nega

tive

(see

pag

e 18

6)

Pr

edni

solo

ne s

odiu

m

Not

mor

e th

an 5

.0 IU

N

ot in

17t

h EM

L. S

treng

th in

phos

phat

e in

ject

ion

U

SP E

ndot

oxin

Uni

ts

12th

EM

L: p

redn

isol

one

pe

r mg

pred

niso

lone

po

wde

r for

inje

ctio

n, 2

0 m

g,

phos

phat

e 25

mg

(as

sodi

um p

hosp

hate

or s

odiu

m s

ucci

nate

) in

vial

.

Qui

nine

dih

ydro

- N

o m

onog

raph

17

th E

ML

: Inj

ectio

n: 3

00 m

g Tr

eatm

ent o

f mul

tidru

g-re

sist

ant P

. fal

cipa

rum

5

5ch

lorid

e in

ject

ion

qu

inin

e hy

droc

hlor

ide/

ml i

n

mal

aria

(in

patie

nts

unab

le to

take

qui

nine

by

IU/k

g m

g/kg

2

ml a

mpo

ule.

m

outh

), by

slo

w IV

infu

sion

, (ov

er 4

hou

rs)

AD

ULT

, ini

tially

20

mg/

kg q

uini

ne d

ihyd

roch

lorid

e

follo

wed

by

10 m

g/kg

eve

ry 8

hou

rs;

CH

ILD

, ini

tially

20

mg/

kg q

uini

ne d

ihyd

ro

chlo

ride

follo

wed

by

10 m

g/kg

eve

ry 1

2 ho

urs;

in

itial

dos

e sh

ould

be

halv

ed in

pat

ient

s w

ho h

ave

re

ceiv

ed q

uini

ne, q

uini

dine

or m

efloq

uine

dur

ing

th

e pr

evio

us 1

2–24

hou

rs (s

ee p

age

198)

Zido

vudi

ne IV

N

ot m

ore

than

1.0

IU

Stre

ngth

in 1

7th

EML:

in

fusi

on

of U

SP E

ndot

oxin

so

lutio

n fo

r IV

infu

sion

U

nits

per

mg

of

inje

ctio

n: 1

0 m

g/m

l in

20 m

l

zido

vudi

ne

vial

374


OH

CNH

CI CI

O

NO2 nH2O-

All expressions using “IU of endotoxin RS” should be changed to “IU of endotoxin” as it is sufficient to require that the WHO International Standard for endotoxin has to be used as a standard (or an endotoxin reference standard that has been calibrated against this standard, see 3.4 Test for bacterial endotoxins, section Preparation of standard endotoxin stock solution).

NiclosamidumNiclosamide

Niclosamide, anhydrousNiclosamide monohydrate

Draft revision of a monograph for inclusion in The International Pharmacopoeia (September 2013). Please address any comments to Technologies, Standards and Norms, Essential Medicines and Health Products, World Health Organization, 1211 Geneva 27, Switzerland. Or e-mail to [email protected]. All working documents are posted for comment at http://www.who.int/medicines.

Note from the Secretariat. Niclosamide suffers pseudopolymorphic and polymorphic transformations when exposed to different conditions. Following investigations into these transitions by a WHO Collaborating Centre it is proposed to revise the monographs on Niclosamide and Niclosamide tablets. Deleted sections are indicated by […].

Molecular formula. C13H8C12N2O4 (anhydrous); C13H8C12N2O4,H2O (monohydrate).

Relative molecular mass. 327.1 (anhydrous); 345.1 (monohydrate)

Graphic formula

n = 0 (anhydrous)n = 1 (monohydrate)

Chemical name. 2’,5-Dichloro-4’-nitrosalicylanilide; 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide; CAS Reg. No. 50-65-7 (anhydrous).

2’,5-Dichloro-4’-nitrosalicylanilide monohydrate; 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide monohydrate; CAS Reg. No. 73360-56-2 (monohydrate).

[…]


375


Additional information. Anhydrous Niclosamide is hygroscopic. Niclosamide monohydrate may exhibit polymorphism.

[…]

Identity tests

• Either test A alone or tests B and C may be applied.

A. Carry out the examination as described under 1.7 Spectrophotometry in the infrared region. For the anhydrous substance the infrared absorption spectrum is concordant with the spectrum obtained from niclosamide RS which has been dried at 100–105 °C for 4 h, or with the reference spectrum of niclosamide. For the monohydrate, dry the substance to be examined and the niclosamide RS at 100–105 °C for 4 h. The infrared absorption spectrum of the dried substance is concordant with the spectrum obtained from the dried niclosamide RS or with the reference spectrum of niclosamide. The infrared absorption spectrum is concordant with the reference spectrum of a relevant form of niclosamide.

[…]

Niclosamidi compressiNiclosamide tablets

[…]

Identity testsHeat a quantity of the powdered tablets equivalent to 0.5 g of Niclosamide with 25 ml of ethanol (~750 g/l) TS, filter while hot and evaporate to dryness on a water-bath. Dry the residue at 100–105 °C for 4 h.

The residue complies either with test A alone or with tests B, C and D.

A. Carry out the examination with the dried residue as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from niclosamide RS, which has been dried at 100–105 °C for 4 h, or with the reference spectrum of niclosamide.

[…]

Sulfamethoxazoli et trimethoprimi infusio intravenoSulfamethoxazole and trimethoprim intravenous infusion

Draft revision of a monograph for inclusion in The International Pharmacopoeia (July 2013). Please address any comments to Technologies, Standards and Norms, Essential Medicines and Health Products, World Health Organization, 1211 Geneva 27, Switzerland. Or e-mail to [email protected]. All working documents are posted for comment at http://www.who.int/medicines.


376


Category. Antibacterials.

RequiRements

Comply with the monograph for Parenteral preparations.

Definition. Sulfamethoxazole and Trimethoprim intravenous infusion is a sterile solution containing Trimethoprim and sodium derivative of Sulfamethoxazole. It is prepared immediately before use by diluting Sulfamethoxazole and Trimethoprim sterile concentrate according to the manufacturers’ instructions.

sulfamethoxazole and tRimethopRim steRile concentRate

Description. A colourless or slightly yellow solution.

Storage: Sulfamethoxazole and Trimethoprim sterile concentrate should be kept in tightly-closed, single-dose, light-resistant glass-containers.

Additional information. Strengths in the current WHO Model List of Essential Medicines: 80 mg per ml Sulfamethoxazole, 16 mg per ml Trimethoprim in 5 ml or 10 ml ampoule. Strengths in the current WHO Model List of Essential Medicines for Children: 80 mg per ml Sulfamethoxazole, 16 mg per ml Trimethoprim in 5 ml or 10 ml ampoule.

RequiRements

Comply with the monograph for Parenteral preparations.

Definition. Sulfamethoxazole and Trimethoprim sterile concentrate is a sterile solution containing Trimethoprim and the sodium derivative of Sulfamethoxazole. It contains not less than 90.0% and not more than 110.0% of the amounts of Sulfamethoxazole (C10H11N3O3S). and Trimethoprim (C14H18N4O3). stated on the label.

Identity tests

Either tests A or D together with E and F, or tests B and C may be applied.

A. Carry out test A.1 or, where UV detection is not available, test A.2.

A.1 Carry out the test as described under 1.14.1. Thin-layer chromatography, using silica gel R6 as the coating substance and a mixture of 100 volumes of dichloromethane R, 10 volumes of methanol R and 5 volumes of dimethylformamide R as the mobile phase. Apply separately to the plate 5 µl of each of the following two solutions in methanol R. For solution (A) evaporate to dryness on a steam bath a volume of the concentrate, containing about 0.16 g of Sulfamethoxazole, shake the residue with 8 ml of methanol R and filter. For solution (B) use 20 mg of sulfamethoxazole RS and 4 mg of trimethoprim RS per ml. After removing the plate from the chromatographic chamber allow it to dry exhaustively in air or in a current of cool air. Examine the chromatogram in ultraviolet light (254 nm).

The principal spots obtained with solution (A) correspond in position, appearance and intensity to those obtained with solution (B).


377


A.2 Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R5 as the coating substance and the conditions described above under test A.1. Spray the plate with potassium iodobismuthate TS2 solution.

The principal spots obtained with solution (A) correspond in position, appearance and intensity to those obtained with solution (B).

B. Add drop-wise to 75 ml of hydrochloric acid (~3.65 g/l) TS a volume of the concentrate containing about 0.8 g of Sulfamethoxazole, stirring continuously. Allow the suspension to stand for 5 minutes and filter through a sintered-glass filter. Wash the residue with 10 ml of water R, recrystallize from ethanol (~750 g/l) TS and dry at 105 °C. Dissolve the residue in a minimum volume of sodium carbonate (~50 g/l) TS, add hydrochloric acid (~36.5 g/l) TS drop-wise until precipitation is complete, filter, wash the residue sparingly with water R and dry at 105 °C. Carry out the test as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum of the residue is concordant with the spectrum obtained from sulfamethoxazole RS or with the reference spectrum of sulfamethoxazole.

C. To a volume of the concentrate containing about 80 mg of Trimethoprim add 30 ml of sodium hydroxide (~4 g/l) TS and extract with two quantities, each of 50 ml, of dichloromethane R. Wash the combined extracts with two quantities, each of 10 ml, of sodium hydroxide (~4 g/l) TS and then with 10 ml of water R. Shake with 5 g of anhydrous sodium sulfate R, filter and evaporate the filtrate to dryness. Carry out the test as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum of the residue is concordant with the spectrum obtained from trimethoprim RS or with the reference spectrum of trimethoprim.

D. See the test described under Assay method A. The retention times of two principal peaks in the chromatogram obtained with solution (1) correspond to those in the chromatogram obtained with solution (2).

E. Dilute a volume of concentrate containing about 80 mg of sulfamethoxazole to 10 ml with water R. Add 1 ml of sodium hydroxide (~4 g/l) TS and 3 ml of 1% copper sulphate (~10g/l) TS drop by drop, until the colour change is complete. Green precipitates are produced.

F. Evaporate a volume of concentrate containing 32 mg of trimethoprim to dryness on a water bath. To the residue, add a drop of ammonium vanadate TS, a dark brown colour is produced.

pH value (1.13). pH of the solution, 9.5–11.0

Bacterial endotoxins. Carry out the test described under 3.4 Test for bacterial endotoxins, contains not more than 6 IU of endotoxin per mg Sulfamethoxazole.

Related substances

Trimethoprim-related substances

Carry out the test as described under 1.14.1. Thin-layer chromatography, using silica gel R4 as the coating substance and a mixture of 97 volumes of chloroform R, 7.5 volumes of methanol R and 1 volume of ammonia (~260 g/l) TS as the mobile


378


phase. Apply separately to the plate 10 µl of each of the following three solutions. For solution (A) transfer an accurately measured volume of the concentrate, containing about 48 mg of Trimethoprim, to a glass-stoppered, 50 ml centrifuge tube. Add 15 ml of hydrochloric acid (~2.19 g/l) TS and mix. Add 15 ml of dichloromethane R, shake for 30 seconds and centrifuge for 3 minutes. Transfer the supernatant layer to a 125 ml separator. Extract the dichloromethane layer in the centrifuge tube with 15 ml of hydrochloric acid (~2.19 g/l) TS, centrifuge and add the aqueous layer to the separator. Add 2 ml of sodium hydroxide (~100 g/l) TS to the solution in the separator and extract with three 20 ml portions of dichloromethane R, collecting the organic layer in a 125 ml conical flask. Evaporate the dichloromethane under a stream of nitrogen to dryness. Dissolve the residue in 1.0 ml of a mixture of equal volumes of dichloromethane R and methanol R (solvent mixture). For solution (B) use 48 mg of trimethoprim RS per ml solvent mixture. For solution (C) dilute an accurately measured volume of solution (B) with the solvent mixture to obtain a solution of 240 µg of trimethoprim RS per ml. After removing the plate from the chromatographic chamber allow it dry in air, spray with ferric chloride/potassium ferricyanide TS1 and examine the chromatogram in ultraviolet light (254 nm).

Trimethoprim and related substances have the following Rf values: trimethoprim about 0.5; and the trimethoprim degradation product about 0.6–0.7. In the chromatogram obtained with solution (A) any spot corresponding to the trimethoprim degradation product is not greater in size and intensity than the spot obtained with solution (C) (0.5%). Disregard any spots due to concentrate excipients at about Rf 0.1.

Sulfamethoxazole related substances

Either test A or test B may be applied.

A. Carry out the test as described under 1.14.1. Thin-layer chromatography, using silica gel R5 as the coating substance. As the mobile phase use a mixture of 25 volumes of ethanol/methanol (95/5) TS, 25 volumes of heptane R, 25 volumes of dichloromethane R and 7 volumes of glacial acetic acid R. Apply separately to the plate 10 µl of each of the following five solutions. For solution (A) transfer an accurately measured volume of the concentrate, containing about 160 mg of Sulfamethoxazole, to an evaporating dish. Evaporate the sample to dryness using a steam bath. Reconstitute the residue with 16 ml of ammonia/ethanol/methanol (1/95/5) TS. For solution (B) use 10 mg of sulfamethoxazole RS per ml ammonia/ethanol/methanol (1/95/5) TS. For solution (C) use 0.05 mg of sulfanilamide R per ml ammonia/ethanol/methanol (1/95/5) TS. For solution (D) use 0.03 mg of sulfanilic acid R per ml ammonia/ethanol/methanol (1/95/5) TS. For solution (E) dissolve 10 mg of sulfamethoxazole RS in 1.0 ml of a solution containing 0.05 mg of sulfanilamide R and 0.03 mg of sulfanilic acid R per ml of ammonia/ethanol/methanol (1/95/5) TS. After removing the plate from the chromatographic chamber allow it dry in air, spray with 4-dimethylaminobenzaldehyde TS7, allow the plate to stand for 15 minutes and examine the chromatogram.

In the chromatogram obtained with solution (A) any spot corresponding to sulfanilamide is not greater in size or intensity than the spot obtained with solution (C) (0.5%) and any spot corresponding to sulfanilic acid is not greater in size or intensity than the spot obtained with solution (D) (0.3%). The test is not valid unless the chromatogram obtained with solution (E) shows three clearly separated principal spots.


379


B. Carry out the test described under 1.14.4 High performance liquid chromatography, using the conditions given below under Assay method A.

Prepare the following solutions. For solution (1) transfer 1.0 ml of the concentrate containing 80 mg of Sulfamethoxazole into a test tube. Add 7 ml of the mobile phase and mix. Transfer 5.0 ml of this solution to a 100 ml volumetric flask, dilute with the mobile phase to volume, mix and filter. For solution (2) prepare 5 mg/ml of sulfanilamide R in ammonia/methanol (10/90) TS. Dilute 5.0 ml of this solution to 50.0 ml with the mobile phase. For solution (3) prepare 3 mg/ml of sulfanilic acid R in ammonia/methanol (10/90) TS. Dilute 5.0 ml of this solution to 50.0 ml with mobile phase. For solution (4) transfer 1.0 ml of each of solution (2) and (3) into a 200 ml volumetric flask and make up to volume with mobile phase. For solution (5) accurately weigh 50 mg of sulfamethoxazole RS in a 100 ml volumetric flask and dilute with solution (4) to volume.

Inject separately 20 µl each of solutions (1), (4) and (5) and record the chromatogram for 1.5 times the retention time of sulfamethoxazole.

In the chromatogram obtained with solution (5) the three principal peaks are eluted at the following relative retention times with reference to sulfamethoxazole (retention time about 11 minutes): sulfanilic acid about 0.2; sulfanilamide about 0.3. The test is not valid unless for solution (5) the resolution factor between the peaks due to sulfanilic acid and to sulfanilamide is at least 5.0 and the resolution factor between the peaks due to sulfanilamide and sulfamethoxazole is at least 10.

Measure the areas of the peak responses obtained in the chromatograms from solution (1) and (4). In the chromatogram obtained with solution (1): the area of any peak corresponding to sulfanilic acid is not more than the area of the peak due to sulfanilic acid in the chromatogram obtained with solution (4) (0.3%), and the area of any peak corresponding to sulfanilamide is not greater than the area of the peak due to sulfanilamide in the chromatogram obtained with solution (4) (0.5%).

Assay

Either method A or methods B and C may be applied.

A. Carry out the test as described under 1.14.4 High-performance liquid chromato-graphy, using a stainless steel column (25 cm x 4.6 mm) packed with particles of base-deactivated silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (5 µm). (Hypersil BDS C18 has been found suitable). As the mobile phase use a solution prepared as follows: mix 1400 ml of water R, 400 ml of acetonitrile R and 2.0 ml of triethylamine R in a 2000 ml volumetric flask. Allow to equilibrate to room temperature and adjust with acetic acid (~10 g/l) TS to pH 5.9. Dilute to volume with water R and filter.

Prepare the following solutions. For solution (1) transfer an accurately measured volume of the concentrate containing about 80 mg of Sulfamethoxazole into a 50 ml volumetric flask. Add methanol R to volume and mix. Transfer 5.0 ml of this solution to a 50 ml volumetric flask, dilute with the mobile phase to volume, mix and filter. For solution (2) prepare a solution of 0.32 mg of trimethoprim RS and 1.60 mg of sulfamethoxazole RS per ml methanol R. Dilute 5.0 ml of this solution to 50.0 ml with the mobile phase.


380


Operate with a flow rate of 1.0 ml per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 254 nm. Inject separately 20 µl each of solutions (1) and (2) and record the chromatogram for 1.5 times the retention time of sulfamethoxazole. In the chromatogram obtained with solution (2) the two principal peaks elute in the order: Trimethoprim (retention time about 6 minutes); Sulfamethoxazole (retention time about 11 minutes). The test is not valid unless the resolution factor between the peaks due to sulfamethoxazole and to trimethoprim is at least 5.0.

Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2) and calculate the content of Sulfamethoxazole (C10H11N3O3S) and Trimethoprim (C14H18N4O3) in the concentrate, using the declared content of C10H11N3O3S and C14H18N4O3 in sulfamethoxazole RS and trimethoprim RS.

B. To an accurately measured volume of the concentrate, containing about 48 mg of Trimethoprim, add 30 ml of sodium hydroxide (~4 g/l) TS and extract with four quantities, each of 50 ml, of dichloromethane R, washing each extract twice with a quantity of 10 ml of sodium hydroxide (~4g/l) TS. Combine the dichloromethane extracts and extract with four quantities of 50 ml of acetic acid (~60 g/l) TS. Wash the combined aqueous extracts with 5 ml of dichloromethane R and dilute to 250.0 ml with acetic acid (~60 g/l). To 10.0 ml of this solution add 10 ml of acetic acid (~60 g/l) and dilute to 100.0 ml with water R. Measure the absorbance of the resulting solution at the maximum at 271 nm.

Calculate the amount of Trimethoprim (C14H18N4O3) using the absorptivity value of 20.4

C. To an accurately measured volume of the concentrate containing about 0.4 g of Sulfamethoxazole add 60 ml of water R and 10 ml of hydrochloric acid (~420 g/l) TS. Add 3 g of potassium bromide R, cool in ice and titrate slowly with sodium nitrite (0.1 mol/l) VS, stirring constantly and determining the end-point potentiometrically.

Each ml of sodium nitrite (0.1 mol/l) VS is equivalent to 25.33 mg of Sulfamethoxazole (C10H11N3O3S).

New reagents needed to be added to Ph.Int.:

Ethanol/methanol (95/5) TSProcedure. To 5 ml of methanol R add 95 ml of dehydrated ethanol R.

Ammonia/ethanol/methanol (1/95/5) TSProcedure. To 1 ml of ammonia (~206 g/l) TS add 99 ml of Ethanol / methanol (95/5) TS.

Ammonia/methanol (10/90) TSProcedure. To 10 ml of ammonia (~206 g/l) TS add 90 ml of methanol R.

Acetic acid (~10 g/l) TSAcetic acid (~300 g/l) TS, diluted with water to contain about 10 g of C2H4O per litre.


A = 2041%–––1cm

381


C

C

O

HH

H

O

O

O

CH3

CH3

CH3

CH3

CH3

H

H

Hydrochloric acid (~3.65 g/l) TS Hydrochloric acid (~250 g/l) TS, dilute with water to contain 3.65 g of HCl in 1000 ml.



Sodium hydroxide (~4 g/l) TS A solution of sodium hydroxide R containing about 4 g/l of NaOH (approximately 0.1 mol/l).

Sodium hydroxide (~ 100 g/l) TSA solution of sodium hydroxide R containing about 100 g/l of NaOH (approximately 2.5 mol/l).

Ferric chloride/potassium ferricyanide TS1Procedure. Dissolve 2 g of ferric chloride R and 0.5 g of potassium ferricyanide R in sufficient water to produce 20 ml.

Note. Ferric chloride/potassium ferricyanide TS2 must be freshly prepared.

4-Dimethylaminobenzaldehyde TS7Dissolve 0.1 g of 4-dimethylaminobenzaldehyde R in 1 ml of hydrochloric acid (~420 g/l) TS, dilute with ethanol (~750 g/l) to produce 100 ml.

Ammonium vanadate TSDissolve 0.5 g of Ammonium vanadate in 1.5 ml water and dilute to 100 ml with sulfuric acid.

Copper(II) Sulfate (10 g/L) TSA solution of Copper(II) sulfate R containing 10 g of CuSO4 per litre.

Medroxyprogesterone acetateDraft revision of a monograph for inclusion in The International Pharmacopoeia (September 2013). Please address any comments to Technologies, Standards and Norms, Essential Medicines and Health Products, World Health Organization, 1211 Geneva 27, Switzerland. Or e-mail to [email protected]. All working documents are posted for comment at http://www.who.int/medicines.


382


C24H34O4

Relative molecular mass. 386.5

Chemical name. 17-Hydroxy-6α-methylpregn-4-ene-3,20-dione acetate; 17-(acetyloxy)-6α-methylpregn-4-ene-3,20-dione; CAS Reg. No. 71-58-9.

Description. A white or almost white, crystalline powder; odourless or almost odourless.

Solubility. Practically insoluble in water; soluble in acetone R and dioxan R; slightly soluble in ethanol (~750 g/l) TS, methanol R and ether R.

Category. Progestogen.

Storage. Medroxyprogesterone acetate should be kept in a tight container, protected from light.

RequiRements

Definition. Medroxyprogesterone acetate contains not less than 97.0% and not more than the equivalent of 103.0% of C24H34O4, calculated with reference to the dried substance.

Identity tests

Either tests A and C or test B and C may be applied.

A. Carry out the examination as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from medroxyprogesterone acetate RS or with the reference spectrum of medroxyprogesterone acetate.

B. Carry out test B.1 or, where UV detection is not available, test B.2.

B.1 Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica R5 as the coating substance and a mixture of 10 volumes of dichloromethane R and 1 volume of ethyl acetate R as the mobile phase. Apply separately to the plate 10 μl of each of the following three solutions in dichloromethane R. For solution (A) use 5 mg of Medroxyprogesterone acetate per ml. For solution (B) use 5 mg of medroxyprogesterone acetate RS per ml. For solution (C) use 5 mg of medroxyprogesterone acetate RS and 0.2 mg of medroxyprogesterone acetate impurity F RS per ml. After removing the plate from the chromatographic chamber, heat it at 120 °C for 30 minutes, spray with 4-toluenesulfonic acid/ethanol TS and heat further at 120 °C for 10 minutes. Allow the plate to cool and examine the chromatogram in ultraviolet light (365 nm). The test is not valid unless the chromatogram obtained with solution (C) shows two clearly separated spots.

The principal spot obtained with solution (A) corresponds in position, appearance and intensity to that obtained with solution (B).


383


B.2 Carry out the test as described under 1.14.1 Thin-layer chromatography, using the conditions described under test B.1, but spray the plate with a mixture of equal volumes of sulfuric acid R and ethanol (~750 g/l) TS and heat further at 120 °C for 10 minutes. Allow the plate to cool and examine the chromatogram in daylight. The test is not valid unless the chromatogram obtained with solution (C) shows two clearly separated spots.

The principal spot obtained with solution (A) corresponds in position, appearance and intensity to that obtained with solution (B).

C. Use 20 mg; it yields the reaction described under 2.1 General identification tests as characteristic of acetylated substances.

Specific optical rotation. Use a 10 mg/ml solution in acetone R; [a]20 °C = +47° to +53°.

Sulfated ash. Not more than 1.0 mg/g.

Loss on drying. Dry at 105 °C for 3 hours; it loses not more than 10 mg/g.

Impurity F

Either method A or method B may be applied.

A. Carry out the test as described under 1.14.4 High-performance liquid chromatography, using a stainless steel column (10 cm × 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (3 µm). (Welch Ultimate XB-C18 has been found suitable).

As the mobile phase, use a solution prepared as follows: mix 44 volumes of water R and 56 volumes of acetonitrile R.

For solution (1) dissolve 20 mg of Medroxyprogesterone acetate in 5.0 ml of acetonitrile R and dilute to 10.0 ml with water R. For solution (2) use 0.01 mg of medroxyprogesterone acetate impurity F RS per ml.

Operate with a flow rate of 1.0 ml per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 200 nm.

Inject 25 µl of solution (1) and (2). In the chromatogram obtained with solution (2), impurity F is eluted at a relative retention of about 1.8 with reference to medroxyprogesterone acetate (retention time about 8 minutes).

In the chromatogram obtained with solution (1), the area of any peak corresponding to impurity F is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.5%).

B. Carry out the test as described under 1.14.1. Thin-layer chromatography, using silica gel R5 as the coating substance and a mixture of 10 volumes of tetrahydrofuran R, 45 volumes of tert-butyl methyl ether R and 45 volumes of heptane R as the mobile phase.


384


Apply separately to the plate 10 l of each of the following two solutions in dichloro-methane R. For solution (A) use 20 mg of Medroxyprogesterone acetate per ml. For solution (B) use 20 mg of medroxyprogesterone acetate RS and 0.1 mg of medroxyprogesterone acetate impurity F RS per ml.

Develop the plate for a distance of about 10 cm. Allow it to dry in air and carry out a second development in the same direction using a freshly prepared mobile phase. After removing the plate from the chromatographic chamber, heat it at 100 °C to 105 °C for 30 minutes and spray with 4-toluenesulfonic acid/ethanol TS. Heat again at 120 °C for 10 minutes, allow to cool and examine the chromatogram in ultraviolet light (365 nm).

In the chromatogram obtained with solution (B) impurity F has a Rf value of about 0.78 and medroxyprogesterone acetate a Rf value of about 0.70. The test is not valid unless the chromatogram obtained with solution (B) shows two clearly separated spots. In the chromatogram obtained with solution (A) any spot due to impurity F is not more intense than the corresponding spot in the chromatogram obtained with solution (B) (0.5%).

Related substances. Prepare fresh solutions and perform the tests without delay.

Carry out the test as described under 1.14.4 High-performance liquid chromatography, using a stainless steel column (25 cm × 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (5 µm). (Altima C18 has been found suitable.)

Maintain the column temperature at 45 °C.

As the mobile phase, use a solution prepared as follows: mix 15 volumes of tetrahydrofuran R, 23 volumes of acetonitrile R and 65 volumes of water R and filter.

Prepare the following solutions in the dissolution solvent prepared in mixing equal volumes of acetonitrile R and water R.

For solution (1) dissolve 20 mg of Medroxyprogesterone acetate in the dissolution solvent and dilute to 10.0 ml with the solvent mixture. For solution (2) dilute 1.0 ml of solution (1) to 100.0 ml with the solvent mixture. For solution (3) dilute 1.0 ml of solution (2) to 10.0 ml with the solvent mixture. For solution (4) use 2 mg of medroxyprogesterone acetate RS and 0.01 mg of medroxyprogesterone acetate impurity G RS per ml.


Inject separately 20 µl of solution (1), (2), (3) and (4). Record the chromatogram for about twice the retention time of medroxyprogesterone acetate in solution (2).

The following peaks are eluted at the following relative retention with reference to the peak of medroxyprogesterone acetate (retention time about 27 minutes): impurity A about 0.3; impurity I about 0.5; impurity H about 0.65; impurity B about 0.7; impurity C about 0.8; impurity G about 0.85; impurity D about 0.9; impurity E about 0.95.The test is not valid unless in the chromatogram obtained with solution (4) the resolution factor between the peaks due to impurity G and due to medroxy-progesterone acetate is at least 3.3.


385


O

R1

R3

R2

H

O

OCH3

CH3

CH3

H H

In the chromatogram obtained with solution (1):

• The area of any peak corresponding to impurity D is not greater than the area of the principal peak obtained with solution (2) (1.0%);

• The area of any peak corresponding to impurity B is not greater than 0.7 times the area of the principal peak obtained with solution (2) (0.7%);

• The area of any peak corresponding to impurity A, when multiplied by a correction factor of 1.5, is not greater than 3 times of the area of the principal peak obtained with solution (3) (0.3%);

• The area of any peak corresponding to impurity G, when multiplied by a correction factor of 2.6, is not greater than 2 times of the area of the principal peak obtained with solution (3) (0.2%);

• The area of any peak corresponding to impurity C, E or I is not greater than 2 times the area of the principal peak obtained with solution (3) (0.2%);

• The area of any other impurity peak is not greater than the area of the principal peak obtained with solution (3) (0.1%);

• The sum of the areas (corrected, where necessary) of all the peaks, other than the principal peak, is not greater than 1.5 times the area of the principal peak obtained with solution (2) (1.5%). Disregard any peak with an area less than 0.5 times the area of the principal peak obtained with solution (3) (0.05%).

AssayDissolve about 0.1 g, accurately weighed, in ethanol (~750g/l) TS to produce 100 ml; dilute 1.0 ml of this solution to 100 ml with the same solvent.

Measure the absorbance of the diluted solution in a 1 cm layer at the maximum at about 241 nm and calculate the content of C24H34O4 using the absorptivity value of 42.6

Impurities

A. R1=OH, R2= CH3, R3=CO-CH3; 6-hydroxy-6-methyl-3,20-dioxopregn-4-en-17-yl acetate (6-hydroxymedroxyprogesterone acetate),


A = 4261%–––1cm

386


O

HCH3

H

O

OO

CH3

CH3

CH3

CH3

H H

O

HCH3

CH3

H

O

O

O

CH3

CH3

CH3

H

H H

O

CH3

CH3

H

O

O

O

CH3

CH3

CH3

H H

B. R1=R2=H, R2=CH3; 17-hydroxy-6-methylpregn-4-ene-3,20-dione (medroxyprogesterone),

C. 6,17a-dimethyl-3,17-dioxo-D-homoandrost-4-en-17a-yl acetate,

D. R1=CH3, R2=H, R3=CO-CH3; 6-methyl-3,20-dioxopregn-4-en-17-yl acetate (6-epimedroxyprogesterone acetate),

E. R1+R2=CH2, R3=CO-CH3; 6-methylidene-3,20-dioxopregn-4-en-17-yl acetate (6-methylenehydroxyprogesterone acetate),

F. 6-methyl-3,20-dioxo-5-pregnan-17-yl acetate (4,5-dihydromedroxyprogesterone acetate),

G. 6-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate (megestrol acetate),


387


N NN

NF

F

C

OH

N

N H2 H2CC

CH3

O

O

H

OH

CH3

H H

H

CH3

CH3

H. R1=R2=H, R3=CO-CH3; 3,20-dioxopregn-4-en-17-yl acetate (hydroxyprogesterone acetate)

I. (17ab)-17a-hydroxy-6,17a-dimethyl-D-homoandrost-4-ene-3,17-dione.

Reference substances to be established

medroxyprogesterone acetate RSmedroxyprogesterone acetate impurity F RSmedroxyprogesterone acetate impurity G RS

FluconazoliFluconazole


C13H12F2N6O

Relative molecular mass. 306.3

Chemical name. 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; CAS Reg. No.86386-73-4.


388


Description. A white or almost white, crystalline powder.

Solubility. Slightly soluble in water, freely soluble in methanol, soluble in acetone.

Category. Antifungal.

Storage. Fluconazole should be kept in a tightly closed container, stored below 30 ℃.

Additional information. Fluconazole is hygroscopic and exhibits polymorphism.

RequiRements

Definition. Fluconazole contains not less than 99.0% and not more than 101.0% of C13H12F2N6O, calculated with reference to the dried substance.

Identity tests

Either test A alone or tests B and C may be applied.

A. Carry out the examination as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from fluconazole RS or with the reference spectrum of fluconazole. If the spectra thus obtained are not concordant, repeat the test using the residues obtained by separately dissolving the test substance and fluconazole RS in a small amount of dichloromethane R and evaporating to dryness. The infrared absorption spectrum is concordant with the spectrum obtained from fluconazole RS.

B. Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R6 as the coating substance and a mixture of 80 volumes of dichloromethane R, 20 volumes of methanol R, and 1 volume of ammonia (~260 g/l) TS as the mobile phase. Apply separately to the plate 10 μl of each of the following three solutions in methanol R. For solution (A) use 10 mg of Fluconazole per ml. For solution (B) use 10 mg of fluconazole RS per ml. For solution (C) use a solution containing 10 mg of fluconazole RS per ml and 1 mg of fluconazole impurity C RS per ml. After removing the plate from the chromatographic chamber, allow it to dry in a current of air and examine the chromatogram in ultraviolet light (254 nm).

The principal spot obtained with solution (A) corresponds in position, appearance and intensity with that obtained with solution (B). The test is not valid unless the chromatogram obtained with solution (C) shows two clearly separated spots.

C. The absorption spectrum (1.6) of a 200 μg/ml solution in ethanol R, when observed between 230 nm and 300 nm, exhibits maxima at about 261 nm and 267 nm and a minimum at about 264 nm; the ratio of the absorbance of a 1 cm layer at the maximum at about 261 nm to that at the minimum at about 264 is about 1.4.

Clarity and colour of solution. A solution of 1.0 g in 20 ml of methanol R is clear and colourless.

Heavy metals

Either test A or test B may be applied.


389


A. Use 1.0 g for the preparation of the test solution as described under 2.2.3 Limit test for heavy metals, Procedure 3; determine the heavy metals content according to Method A; not more than 10 μg/g.

B. Use 1.0 g for the preparation of the test solution in methanol as described under 2.2.3 Limit test for heavy metals, Procedure 2; determine the heavy metals content according to Method A; not more than 10 μg/g.

Sulfated ash (2.3). Not more than 1.0 mg/g, using Method B and a platinum crucible.

Loss on drying. Dry to constant weight at 105 ℃; it loses not more than 5 mg/g.

Related substances

Carry out the test as described under 1.14.4 High-performance liquid chromatography, using a stainless steel column (25 cm × 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically bonded octadecylsilyl groups (5 µm) (Capcell Pak® C18 MGII (4.6 x 250 mm, 5µm) has been found suitable.) As the mobile phase, use a mixture of 86 volumes of a (0.63 g/l) solution of ammonium formate R and 14 volumes of acetonitrile R.

Prepare the following solutions in the mobile phase. For solution (1) use 10 mg of Fluconazole per ml. For solution (2) dilute 5 ml of solution (1) to 100 ml, then dilute l ml of this solution to 10 ml. For solution (3) use 0.1 mg of fluconazole impurity C RS per ml. For solution (4), transfer 1.0 ml of solution (3) to a 10 ml volumetric flask, add 1.0 ml of solution (1) and make up to volume.


Inject separately 20 µl each of solutions (1), (2), (3) and (4). Record the chromatograms for about 3.5 times the retention time of fluconazole.

The peaks are eluted at the following relative retentions with reference to fluconazole (retention time about 11 minutes): impurity B about 0.4; impurity A about 0.5; impurity C about 0.8.

The test is not valid, unless in the chromatogram obtained with solution (4) the resolu-tion between the peaks due to impurity C and fluconazole is at least 3.0.

In the chromatogram obtained with solution (1),

• The area of any peak corresponding to impurity A is not is not greater than 0.8 times the area of the principal peak in the chromatogram obtained with solution (2) (0.4 %),

• The area of any peak corresponding to impurity B, when multiplied by a correction factor of 1.5 is not greater than 0.3 times the area of the principal peak in the chroma-togram obtained with solution (3) (0.3 %),

• The area of any peak corresponding to impurity C is not is not greater than 0.1 times the area of the principal peak in the chromatogram obtained with solution (3) (0.1 %),


390


N NN

NF

F

C

OH

N

N H2 CH2C

FN

NN

NN

N

C

CH2N

NN

HO

H2C

N

N

N

N

N N


• The area of any other peak, other than the principal peak, is not greater than 0.2 times the area of the principal peak in the chromatogram obtained with solution (2) (0.1 %),

• The sum of the corrected area of any peak corresponding to impurity B and the areas of all other peaks, other than the principal peak, is not greater than 1.2 times the area of the principal peak in the chromatogram obtained with solution (2) (0.6 %). Dis-regard any peak with an area less than 0.1 times the area of the principal peak in the chromatogram obtained with solution (2) (0.05 %).

AssayDissolve about 0.1 g, accurately weighed, in 50 ml of anhydrous acetic acid R and titrate with perchloric acid (0.1 mol/l) VS as described under 2.6 Non-aqueous titration, Method A, determining the end-point potentiometrically.

Each ml of perchloric acid (0.1 mol/l) VS is equivalent to 15.32 mg of C13H12F2N6O.

Impurities

A. (2RS)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(4H-1,2,4-triazol-4-yl)propan-2-ol,

B. 2-[2-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol,

C. 1,1’-(1,3-phenylene)di-1H-1,2,4-triazole,

and enantiomer

391


F

C

OH

H2 H2N N

N

N

N

N

CC

N

NF

C

O

NF

H3C

C

R

OH

F

F

H2C

H2CN

N

N

C

O

F

F

SO3HH2C H2C

N

NN


and enantiomer

D. 2-(4-fluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol,

E. 1-[(6RS)-4,6-difluoro-6-(1H-1,2,4-triazol-1-yl)cyclohexa-1,4-dienyl]ethanone,

F. R=OH:(2RS)-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl) propan-2-diol,H. R=Br:(2RS)-1-bromo-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl) propan-2-ol,

G.[3-[[(2RS)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl]1H-1,2,4-triazol-1-yl)]methanesulfonic acid,

and enantiomer

and enantiomer

392


H2N N NN

NF

F

C

OH

N

N H2 CH2C

I. 4-amino-1-[(2RS)-2-(2,4-difluorophenyl)-2-hydroxy-3(1H-1,2,4-triazol-1-yl)propyl]- 4H-1,2,4-triazolium.

[Note from Secretariat: chemical names and structures to be confirmed.]

Reference substances to be established:

Fluconazole RSFluconazole impurity C RS

Fluconazoli capsulaeFluconazole capsules



Storage. Fluconazole capsules should be kept in a tightly closed container and stored at a temperature not exceeding 30 °C.

Additional information. Strengths in the current WHO Model List of Essential Medicines: 50 mg. Strength in the current WHO Model List of Essential Medicines for Children: 50 mg.

RequiRements

Comply with the monograph for «Capsules».

Definition. Fluconazole capsules contain Fluconazole. They contain not less than 90.0% and not more than 110.0% of the amount of fluconazole (C13H12F2N6O) stated on the label.

Identity tests

Either tests A and C or tests B and C may be applied.


and enantiomer

393


A. Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R6 as the coating substance and a mixture of 80 volumes of dichloro-methane R, 20 volumes of methanol R, and 1 volume of ammonia (~260 g/l) TS as the mobile phase. Apply separately to the plate 10 μl of each of the following three solutions in methanol R. For solution (A) shake a quantity of the mixed contents of the capsules, containing about 100 mg of Fluconazole, with 10 ml of methanol R, filter, and use the clear filtrate. For solution (B) use 10 mg of fluconazole RS per ml. For solution (C) use a mixture of 10 mg of fluconazole RS and 10 mg of fluconazole impurity C RS per ml. After removing the plate from the chromatographic chamber, allow it to dry in a current of air, and examine the chromatogram in ultraviolet light (254 nm).

The principal spot obtained with solution (A) corresponds in position, appearance and intensity with that obtained with solution (B). The test is not valid, unless the chromatogram obtained with solution (C) shows two clearly separated spots.

B. Carry out the test as described under 1.14.4 High-performance liquid chroma-tography, using the conditions given under Assay method B. The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to that of the principal peak in the chromatogram obtained with solution (2).

C. To a quantity of the capsule content, containing 2 mg of Fluconazole, add 10 ml of ethanol R, shake and filter. The absorption spectrum (1.6) of the resulting solution, when observed between 230 nm and 300 nm, exhibits maxima at 261 nm and 267 nm and a minimum at about 264 nm. The ratio of the absorbance of a 1 cm layer at the maximum at about 261 nm to that at the minimum at about 264 is about 1.4.

Related substances Carry out the test as described under 1.14.4 High-performance liquid chromatography, using the conditions given under Assay method B. Prepare the following solutions in the mobile phase. For solution (1) use an amount of the mixed contents of 20 capsules to produce a solution containing 10 mg of Fluconazole per ml and filter the solution. For solution (2) dilute 5 volumes of solution (1) to 100 volumes, then dilute l volume of this solution to 10 volumes. For solution (3) use 0.1 mg of fluconazole impurity C RS per ml. For solution (4), transfer 1.0 ml of solution (3) to a 10 ml volumetric flask, add 1.0 ml of solution (1) and make up to volume.

Operate with a flow rate of 1.0 ml per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of about 260 nm.

Inject separately 20 μl each of solutions (1), (2), (3) and (4). Record the chromato-grams for about 3.5 times the retention time of fluconazole.

The peaks are eluted at the following relative retentions with reference to fluconazole (retention time about 11minutes): impurity B about 0.4; impurity A about 0.5; impurity C about 0.8.

The test is not valid, unless in the chromatogram obtained with solution (4), the resolution between the peaks due to impurity C and to fluconazole is at least 3.0



394


• The area of any peak corresponding to impurity A is not greater than 0.8 times the area of the principal peak in the chromatogram obtained with solution (2) (0.4%);

• The area of any peak corresponding to impurity B, when multiplied by a correction factor of 1.5 is not greater than 0.3 times the area of the principal peak in the chroma-togram obtained with solution (3) (0.3%);

• The area of any peak corresponding to impurity C is not greater than 0.1 times the area of the principal peak in the chromatogram obtained with solution (3) (0.1%);

• The area of any other impurity peak, other than the principle peak, is not greater than 0.4 times the area of the principal peak in the chromatogram obtained with solution (2) (0.2%),

• The sum of the corrected area of any peak corresponding to impurity B and the areas of all peaks, other than the peak due to fluconazole, is not greater than 2 times the area of the principal peak in the chromatogram obtained with solution (2) (1.0%). Dis-regard any peak with an area less than 0.1 times the area of the principal peak in the chromatogram obtained with solution (2) (0.05%).

Dissolution testCarry out the test as described under 5.5 Dissolution test for solid oral dosage forms, using as the dissolution medium, 500 ml of hydrochloric acid (~4 g/l) TS, rotating the basket at 100 revolutions per minute. At 45 minutes withdraw a sample of about 10 ml of the medium through a suitable 0.45 μm filter. Measure the absorbance (1.6) of a 1 cm layer of the filtered solution, suitably diluted if necessary, at the maximum at 261 nm. At the same time measure the absorbance (1.6) at the maximum at 261 nm of a solution containing 0.1 mg of fluconazole RS per ml in the dissolution medium, using the same solution as the blank.

For each of the capsules tested, calculate the total amount of fluconazole (C13H12F2N6O) in the medium from the absorbances obtained and from the declared content of C13H12F2N6O in fluconazole RS. Use the requirements as described under 5.5 Dissolution test for solid oral dosage forms, Acceptance criteria to evaluate the results: The amount in solution is not less than 75% (Q) of the amount declared on the label.

Assay

Either test A or B may be applied.

A. Mix the contents of 20 capsules and transfer a quantity containing about 50 mg of Fluconazole, accurately weighed, to a 10 ml volumetric flask, and dilute to volume with hydrochloric acid (~4 g/l) TS. Shake to dissolve, filter a portion of this solution and dilute 10 ml of the filtered solution to 25 ml with the same solution. Measure the absorbance of a 1 cm layer at the maximum at about 261 nm.

At the same time measure the absorbance of a solution of 0.2 mg of fluconazole RS per ml of hydrochloric acid (~4 g/l) TS, prepared and examined in the same manner, and calculate the percentage content of fluconazole (C13H12F2N6O) in the capsules, using the declared content of C13H12F2N6O in fluconazole RS.


395


B. Carry out the test as described under 1.14.4 High-performance liquid chromato-graphy, using a stainless steel column (25 cm × 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically bonded octadecylsilyl groups (5μm). (Capcell Pak® C18 MGII (4.6x250 mm, 5µm) has been found suitable.) As the mobile phase, use a mixture of 86 volumes of a (0.63 g/l) solution of ammonium formate R and 14 volumes of acetonitrile R. Prepare the following solutions in the mobile phase. For solution (1) use an amount of the mixed contents of 20 capsules to produce a solution containing 0.5 mg of Fluconazole per ml and filter the solution. For solution (2) use 0.5 mg of fluconazole RS per ml. For solution (3) use a solution containing 0.01 mg of fluconazole impurity C RS per ml and 1 mg of fluconazole RS per ml.

Operate with a flow rate of 1.0 ml per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of about 260 nm.

Inject separately 20 μl of each of solutions (1), (2) and (3). The test is not valid, unless in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity C and to fluconazole is at least 3.0.

Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2), and calculate the percentage content of fluconazole (C13H12F2N6O) in the capsules, using the declared content of C13H12F2N6O in fluconazole RS.

Fluconazoli injectioFluconazole injection


Description. A clear, colourless solution.


Storage. Fluconazole injection should be kept in a tightly closed container, protected from light.

Additional information. Strength in the current WHO Model List of Essential Medicines: 2 mg/ml in vial.

RequiRements

Complies with the monograph for «Parenteral preparations».


396


Definition. Fluconazole injection is a sterile solution of Fluconazole in Water for injections.

The solution is sterilized by a suitable method (see 5.8 Methods of sterilization). Fluconazole injection contains not less than 90.0% and not more than 110.0% of the amount of fluconazole (C13H12F2N6O) stated on the label.

Identity tests

Either test A and C or test B and C may be applied.

A. Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R6 as the coating substance and a mixture of 80 volumes of dichloro-methane R, 20 volumes of methanol R, and 1 volume of ammonia (~260 g/l) TS solution as the mobile phase. Apply separately to the plate 20 μl of each of the following three solutions. For solution (A) use the injection to be examined. For solution (B) use 2 mg of fluconazole RS per ml in methanol R. For solution (C) use a mixture of 2 mg of fluconazole RS per ml and 2 mg of fluconazole impurity C RS per ml in methanol R. After application allow the spots to dry in a current of air. Develop the plate. After removing the plate from the chromatographic chamber, allow it to dry in a current of air, and examine the chromatogram in ultraviolet light (254 nm).

The principal spot obtained with solution (A) corresponds in position, appearance and intensity with that obtained with solution (B). The test is not valid, unless the chromatogram obtained with solution (C) shows two clearly separated spots.

B. Carry out the test as described under 1.14.4 High-performance liquid chromato-graphy, using the conditions given under Assay. The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to that of the principal peak in the chromatogram obtained with solution (2).

C. Dilute a volume of the injection containing 2 mg of Fluconazole to 10 ml with water R. The absorption spectrum (1.6) of the resulting solution, when observed between 230 nm and 300 nm, exhibits maxima at 261 nm and 267 nm, and a minimum at about 264 nm. The ratio of the absorbance of a 1 cm layer at the maximum at about 261 nm to that at the minimum at about 264 is about 1.4.

pH value (1.3). pH of the injection, 4.0–6.0.

Related substances

Carry out the test as described under 1.14.4 High-performance liquid chromatography, using the conditions given below under Assay. Prepare the following solutions in the mobile phase. For solution (1) use the injection to be examined. For solution (2) dilute 5 volumes of solution (1) to 100 volumes, then dilute l volume of this solution to 10 volumes. For solution (3) use 0.02 mg of fluconazole impurity C RS per ml. For solution (4) mix 1 volume of solution (3) with 1 volume of solution (1).


397


Inject separately 20 μl each of solutions (1), (2), (3) and (4). Record the chromato-grams for about 3.5 times the retention time of fluconazole.

The peaks are eluted at the following relative retentions with reference to fluconazole (retention time about 11 minutes): impurity B about 0.4; impurity A about 0.5; impurity C about 0.8.

The test is not valid unless, in the chromatogram obtained with solution (4), the resolution between the peaks due to impurity C and to fluconazole is at least 3.0


• The area of any peak corresponding to impurity A is not greater than 0.8 times the area of the principal peak in the chromatogram obtained with solution (2) (0.4%),

• The area of any peak corresponding to impurity B, when multiplied by a correction factor of 1.5 is not greater than 0.3 times the area of the principal peak in the chroma-togram obtained with solution (3) (0.3%);

• The area of any peak corresponding to impurity C is not greater than 0.1 times the area of the principal peak in the chromatogram obtained with solution (3) (0.1%);

• The area of any other impurity peak, other than the principal peak, is not greater than 0.4 times the area of the principal peak in the chromatogram obtained with solution (2) (0.2%),

• The sum of the corrected area of any peak corresponding to impurity B and the areas of all peaks, other than the peak due to fluconazole, is not greater than 2 times the area of the principal peak in the chromatogram obtained with solution (2) (1.0 %). Disregard any peak with an area less than 0.1 times the area of the principal peak in the chromatogram obtained with solution (2) (0.05%).

AssayCarry out the test as described under 1.14.4 High-performance liquid chromatography, using a stainless steel column (25 cm × 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (5μm). (Capcell Pak® C18 MGII (4.6x250 mm, 5µm) has been found suitable.)

As the mobile phase, use a mixture of 86 volumes of a (0.63 g/l) solution of ammonium formate R and 14 volumes of acetonitrile R.

Prepare the following solutions in the mobile phase. For solution (1) dilute 5.0 ml of the injection to be examined to 20.0 ml. For solution (2) use 0.5 mg of fluconazole RS per ml. For solution (3) use a solution containing 0.01 mg of fluconazole impurity C RS per ml and 1 mg of fluconazole RS per ml.


Inject separately 20 μl of each of solutions (1), (2) and (3). The test is not valid, unless in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity C and due to fluconazole is at least 3.0.

398


Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2), and calculate the percentage content of fluconazole (C13H12F2N6O) in the injection, using the declared content of C13H12F2N6O in fluconazole RS.

Bacterial endotoxins. Carry out the test as described under 3.4 Test for bacterial endotoxins,; contains not more than 0.416 IU of endotoxin RS per mg of Fluconazole.


WHO Drug Information, Vol. 27, No. 4, 2013 Proposed INN: List 110

399

International Nonproprietary Names for Pharmaceutical Substances (INN) Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–109) and Recommended (1–70) International Nonproprietary Names can be found in Cumulative List No. 15, 2013 (available in CD-ROM only). The statements indicating action and use are based largely on information supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will neither be revised nor included in the Cumulative Lists of INNs.

Dénominations communes internationales des Substances pharmaceutiques (DCI) Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d'autres listes de Dénominations communes internationales proposées (1–109) et recommandées (1–70) dans la Liste récapitulative No. 15, 2013 (disponible sur CD-ROM seulement). Les mentions indiquant les propriétés et les indications des substances sont fondées sur les renseignements communiqués par le fabricant. Elles ne visent qu'à donner une idée de l'utilisation potentielle des nouvelles substances au moment où elles sont l'objet de propositions de DCI. L'OMS n'est pas en mesure de confirmer ces déclarations ni de faire de commentaires sur l'efficacité du mode d'action ainsi décrit. En raison de leur caractère provisoire, ces informations ne figureront pas dans les listes récapitulatives de DCI.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI) De conformidad con lo que dispone el párrafo 3 del "Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas", se comunica por el presente anuncio que las denominaciones detalladas en las páginas siguientes están sometidas a estudio por la Organización Mundial de La Salud como Denominaciones Comunes Internacionales Propuestas. La inclusión de una denominación en las listas de las DCI Propuestas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–109) y Recomendadas (1–70) se encuentran reunidas en Cumulative List No. 15, 2013 (disponible sólo en CD-ROM). Las indicaciones sobre acción y uso que aparecen se basan principalmente en la información facilitada por los fabricantes. Esta información tiene por objeto dar una idea únicamente de las posibilidades de aplicación de las nuevas sustancias a las que se asigna una DCI Propuesta. La OMS no está facultada para respaldar esas indicaciones ni para formular comentarios sobre la eficacia de la acción que se atribuye al producto. Debido a su carácter provisional, esos datos descriptivos no deben incluirse en las listas recapitulativas de DCI.

Proposed INN: List 110 WHO Drug Information, Vol. 27, No. 4, 2013

400

Proposed International Nonproprietary Names: List 110 Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in WHO Drug Information, i.e., for List 110 Proposed INN not later than 29 May 2014. Publication date: 30 January 2014

Dénominations communes internationales proposées: Liste 110 Des observations ou des objections formelles à l'égard des dénominations proposées peuvent être adressées par toute personne au Programme des Dénominations communes internationales de l'Organisation mondiale de la Santé dans un délai de quatre mois à compter de la date de leur publication dans WHO Drug Information, c'est à dire pour la Liste 110 de DCI Proposées le 29 mai 2014 au plus tard. Date de publication : 30 janvier 2014

Denominaciones Comunes Internacionales Propuestas: Lista 110 Cualquier persona puede dirigir observaciones u objeciones respecto de las denominaciones propuestas, al Programa de Denominaciones Comunes Internacionales de la Organización Mundial de la Salud, en un plazo de cuatro meses, contados desde la fecha de su publicación en WHO Drug Information, es decir, para la Lista 110 de DCI Propuestas el 29 de mayo de 2014 a más tardar. Fecha de publicación: 30 de enero de 2014

Proposed INN (Latin, English, French, Spanish) DCI Proposée DCI Propuesta

Chemical name or description: Action and use: Molecular formula Chemical Abstracts Service (CAS) registry number: Graphic formula Nom chimique ou description: Propriétés et indications: Formule brute Numéro dans le registre du CAS: Formule développée Nombre químico o descripción: Acción y uso: Fórmula molecular Número de registro del CAS: Fórmula desarrollada

abametapirum abametapir 5,5'-dimethyl-2,2'-bipyridinyl

chelating agent

abamétapir 5,5'-diméthyl-2,2'-bipyridinyle chélateur

abametapir 5,5'-dimetil-2,2'-bipiridinilo agente quelante

C12H12N2

1762-34-1

N

H3C

NCH3

acidum bempedoicum bempedoic acid 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid

antihyperlipidaemic

acide bempédoïque acide 8-hydroxy-2,2,14,14-tétraméthylpentadécanedioïque antihyperlipidémiant


401

ácido bempedoico ácido 8-hidroxi-2,2,14,14-tetrametilpentadecanodióco antihiperlipémico

C19H36O5

738606-46-7

OH

CO2H

H3C CH3

HO2C

H3C CH3

aclerastidum aclerastide [3-(L-2-aminohexanoic acid)]angiotensin II-(1-7)-peptide

wound healing promoter

aclérastide [3-(acide L-2-aminohexanoïque)]angiotensine II-(1-7)-peptide promoteur de la guérison des plaies

aclerastida [3-(ácido L-2-aminohexanoico)]angiotensina II-(1-7)-péptido promotor de la curación de las heridas

C42H64N12O11

227803-63-6

Asp Arg Nle Tyr Ile His Pro OH7

H

aducanumabum # aducanumab immunoglobulin G1-kappa, anti-[Homo sapiens amyloid beta (Abeta,

Aβ) peptide], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-453) [Homo sapiens VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ6*03) [8.8.17] (1-124) -IGHG1*03 (CH1 (125-222), hinge (223-237), CH2 (238-347), CH3 (348-452), CHS K2>del (453)) (125-453)], (227-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (233-233'':236-236'')-bisdisulfide immunomodulator

aducanumab immunoglobuline G1-kappa, anti-[Homo sapiens peptide amyloïde bêta (Abêta, Aβ)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-453) [Homo sapiens VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ6*03) [8.8.17] (1-124) -IGHG1*03 (CH1 (125-222), charnière (223-237), CH2 (238-347), CH3 (348-452), CHS K2>del (453)) (125-453)], (227-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (233-233'':236-236'')-bisdisulfure immunomodulateur

aducanumab inmunoglobulina G1-kappa, anti-[péptido amiloide beta de Homo sapiens (Abeta, Aβ)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma1 (1-453) [Homo sapiens VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ6*03) [8.8.17] (1-124) -IGHG1*03 (CH1 (125-222), bisagra (223-237), CH2 (238-347), CH3 (348-452), CHS K2>del (453)) (125-453)], (227-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (233-233'':236-236'')-bisdisulfuro inmunomodulador


402

1384260-65-4 Heavy chain / Chaîne lourde / Cadena pesada

QVQLVESGGG VVQPGRSLRL SCAASGFAFS SYGMHWVRQA PGKGLEWVAV 50IWFDGTKKYY TDSVKGRFTI SRDNSKNTLY LQMNTLRAED TAVYYCARDR 100GIGARRGPYY MDVWGKGTTV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450SPG 453

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPKLLIYA 50ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYSTPLTFGG 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 151-207 268-328 374-432 22''-96'' 151''-207'' 268''-328'' 374''-432''Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (h 5-CL 126) 227-214' 227''-214''' Inter-H-H (h 11, h 14) 233-233'' 236-236''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH CH2 N84.4:304, 304''

alpelisibum alpelisib (2S)-N1-{4-methyl-5-[1-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-

4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide antineoplastic

alpélisib (2S)-N1-{4-méthyl-5-[1-(1,1,1-trifluoro-2-méthylpropan-2-yl)pyridin- 4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide antinéoplasique

alpelisib (2S)-N1-{4-metil-5-[1-(1,1,1-trifluoro-2-metilpropan-2-il)piridin-4-il]-1,3-tiazol-2-il}pirrolidina-1,2-dicarboxamida antineoplásico

C19H22F3N5O2S 1217486-61-7

N

F3C

NS

HNN

O

CH3H3C

HO

NH2

CH3

andexanetum alfa # andexanet alfa des-(6-39)-human blood-coagulation factor X light chain (98-108')-

disulfide with [185'-alanine (S>A)]human activated factor Xa heavy chain, produced in Chinese hamster ovary (CHO) cells (glycoform alfa) factor Xa inhibitors’ neutralizing agent

andexanet alfa (98-108')-disulfure entre la dès-(6-39)-chaîne légère du facteur X de coagulation humain et la [185'-alanine (S>A)]chaîne lourde du facteur Xa activé de coagulation humain glycosylé, produit par les cellules ovariennes de hamster chinois (CHO) (glycoforme alfa) agent de neutralisation des inhibiteurs du facteur Xa


403

andexanet alfa (98-108')-disulfuro entre la des-(6-39)-cadena ligera del factor X de coagulación humano y la [185'-alanina (S>A)]cadena pesada del factor Xa activado de coagulación humano glicosilado, producido por cultivo de células ováricas de hamster chino (CHO) (glicoforma alfa) agente de neutralización de los inhibidores del factor Xa

1262449-58-0

HO2CCO2H

NH2H

HO H

Light chain / Chaîne légère / Cadena ligeraANSFLFWNKY KDGDQCETSP CQNQGKCKDG LGEYTCTCLE GFEGKNCELF 50TRKLCSLDNG DCDQFCHEEQ NSVVCSCARG YTLADNGKAC IPTGPYPCGK 100QTLER 105

Heavy chain / Chaîne lourde / Cadena pesadaIVGGQECKDG ECPWQALLIN EENEGFCGGT ILSEFYILTA AHCLYQAKRF 50'KVRVGDRNTE QEEGGEAVHE VEVVIKHNRF TKETYDFDIA VLRLKTPITF 100'RMNVAPACLP ERDWAESTLM TQKTGIVSGF GRTHEKGRQS TRLKMLEVPY 150'VDRNSCKLSS SFIITQNMFC AGYDTKQEDA CQGDAGGPHV TRFKDTYFVT 200'GIVSWGEGCA RKGKYGIYTK VTAFLKWIDR SMKTRGLPKA KSHAPEVITS 250'SPLK 254'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro7'-12' 16-27 21-36 27'-43' 38-47 55-6662-75 77-90 98-108' 156'-170' 181'-209'

Modified residue / Résidu modifié / Resto modificado D 29

(3R)-3-hydroxyAsp

Glycosylation sites (* confirmed) / Sites de glycosylation (* confirmé) / Posiciones deglicosilación (* confirmada)Ser-56 Ser-72 Ser-76 Thr-82 *Thr-249'

apabetalonum apabetalone 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxyquinazolin-

4(3H)-one antiatherosclerosis

apabétalone 2-[4-(2-hydroxyéthoxy)-3,5-diméthylphényl]-5,7-diméthoxyquinazolin-4(3H)-one antiathérosclérose

apabetalona 2-[4-(2-hidroxietoxi)-3,5-dimetilfenil]-5,7-dimetoxiquinazolin- 4(3H)-ona antiaterosclerosis

C20H22N2O5

1044870-39-4

NH

N

O

CH3

CH3

OOH

OCH3

H3CO


404

apatorsenum apatorsen all-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-

methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridine antineoplastic

apatorsen tout-P-ambo-2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyluridine antinéoplasique

apatorsén todo-P-ambo-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metiluridina antineoplásico


405

C224H304N79O116P19S19

1002331-21-6

(3'5')d(P-thio)(rG-rG-rG-rA-mC-G-mC-G-G-mC-G- mC-T-mC-G-G-rU-rC-rA-rU) Modified nucleosides / Nucléosides modifiés / Nucleosidos modificados:

O

HO O

OH

N N

N

N NH2

OCH3

O

HO O

OH

N N

NH

N O

H2N

OCH3

N

HNO O

O

HO O

OH

CH3

OCH3

G

A

U

N

NO NH2

O

HO

OH

CH3

dmC

N

NO NH2

O

HO

OH

CH3

C

O

OCH3

astodrimerum astodrimer N2,N6-bis{N2,N6-bis[N2,N6-bis(N2,N6-bis{N2,N6-bis[(3,6-

disulfonaphthalen-1-yloxy)acetyl]-L-lysyl}-L-lysyl)-L-lysyl]-L-lysyl}- N1-(diphenylmethyl)-L-lysinamide anti-infective

astodrimère N2,N6-bis{N2,N6-bis[N2,N6-bis(N2,N6-bis{N2,N6-bis[(3,6-disulfonaphthalén-1-yloxy)acétyl]-L-lysyl}-L-lysyl)-L-lysyl]-L-lysyl}- N1-(diphénylméthyl)-L-lysinamide anti-infectieux

astodrímero N2,N6-bis{N2,N6-bis[N2,N6-bis(N2,N6-bis{N2,N6-bis[(3,6-disulfonaftalen-1-iloxi)acetil]-L-lisil}-L-lisil)-L-lisil]-L-lisil}-N1-(difenilmetil)-L-lisinamida antiinfeccioso

C583H641N63O287S64

1379746-42-5

AK

A

AK

A AK

A

KA

A

AK

A

AK

A AK

A

KA

AA

KA

KA

A

AK

A

KA

A

KA

A

AK

A

AK

A

AK

A

K K K

K

K

K

K

K

K

K K

K

KK

K

NH

O C

O

SO3HHO3S

=

C

NHH

NH

O

=KA


406

batefenterolum batefenterol 1-(3-{[2-chloro-4-({[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-

1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)- 5-methoxyphenyl]amino}-3-oxopropyl)piperidin-4-yl (1,1-biphenyl- 2-yl)carbamate bronchodilator

batéfentérol (1,1-biphényl-2-yl)carbamate de 1-(3-{[2-chloro-4-({[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)éthyl]amino}méthyl)- 5-méthoxyphényl]amino}-3-oxopropyl)pipéridin-4-yle bronchodilatateur

batefenterol (1,1-bifenil-2-il)carbamato de 1-(3-{[2-cloro-4-({[(2R)-2-hidroxi- 2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil]amino}metil)- 5-metoxifenil]amino}-3-oxopropil)piperidin-4-ilo broncodilatador

C40H42ClN5O7

743461-65-6

HN

OHH

HO

HN

O

HN O

Cl

H3CO

N

O O

HN

bimekizumabum # bimekizumab immunoglobulin G1-kappa, anti-[Homo sapiens IL17A (interleukin

17A) and Homo sapiens IL17F (interleukin 17F)], humanized monoclonal antibody; gamma1 heavy chain (1-455) [humanized VH (Homo sapiens IGHV3-7*01 (88.70%) -(IGHD)-IGHJ1*01) [8.8.18] (1-125) -Homo sapiens IGHG1*01 (CH1 (126-223), hinge (224-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (126-455)], (228-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-13*02 (80.00%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimer (234-234":237-237")-bisdisulfide immunomodulator

bimékizumab immunoglobuline G1-kappa, anti-[Homo sapiens IL17A (interleukine 17A) et Homo sapiens IL17F (interleukine 17F)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-455) [VH humanisé (Homo sapiens IGHV3-7*01 (88.70%) -(IGHD)-IGHJ1*01) [8.8.18] (1-125) -Homo sapiens IGHG1*01 (CH1 (126-223), charnière (224-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (126-455)], (228-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-13*02 (80.00%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (234-234":237-237")-bisdisulfure immunomodulateur


407

bimekizumab inmunoglobulina G1-kappa, anti-[Homo sapiens IL17A (interleukina

17A) et Homo sapiens IL17F (interleukina 17F)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-455) [VH humanizado (Homo sapiens IGHV3-7*01 (88.70%) -(IGHD)-IGHJ1*01) [8.8.18] (1-125) -Homo sapiens IGHG1*01 (CH1 (126-223), bisagra (224-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (126-455)], (228-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV1-13*02 (80.00%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (234-234":237-237")-bisdisulfuro inmunomodulador

1418205-77-2

Heavy chain / Chaîne lourde / Cadena pesadaEVQLVESGGG LVQPGGSLRL SCAASGFTFS DYNMAWVRQA PGKGLEWVAT 50ITYEGRNTYY RDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCASPP 100QYYEGSIYRL WFAHWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL 150GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200LGTQTYICNV NHKPSNTKVD KKVEPKSCDK THTCPPCPAP ELLGGPSVFL 250FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR 300EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ 350PREPQVYTLP PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK 400TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS 450LSPGK 455

Light chain / Chaîne légère / Cadena ligeraAIQLTQSPSS LSASVGDRVT ITCRADESVR TLMHWYQQKP GKAPKLLIYL 50VSNSEIGVPD RFSGSGSGTD FRLTISSLQP EDFATYYCQQ TWSDPWTFGQ 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 152-208 269-329 375-433 22''-96'' 152''-208'' 269''-329'' 375''-433''Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (h 5-CL 126) 228-214' 228''-214''' Inter-H-H (h 11, h 14) 234-234'' 237-237''


bococizumabum # bococizumab immunoglobulin G2-kappa, anti-[Homo sapiens PCSK9 (proprotein

convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, NARC1, NARC-1, proprotein convertase 9, PC9)], humanized monoclonal antibody; gamma2 heavy chain (1-444) [humanized VH (Homo sapiens IGHV1-46*01 (90.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-118) -Homo sapiens IGHG2*01 (CH1 (119-216), hinge (217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-13*02 (91.00%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimer (220-220":221-221":224-224":227-227")-tetrakisdisulfide antihyperlipidaemic


408

bococizumab immunoglobuline G2-kappa, anti-[Homo sapiens PCSK9 (proprotéine convertase subtilisine/kexine type 9, convertase 1 régulée par l'apoptose neuronale, NARC1, NARC-1, proprotéine convertase 9, PC9)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-444) [VH humanisé (Homo sapiens IGHV1-46*01 (90.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-118) -Homo sapiens IGHG2*01 (CH1 (119-216), charnière (217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-13*02 (91.00%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (220-220":221-221":224-224":227-227")-tétrakisdisulfure antihyperlipidémiant

bococizumab inmunoglobulina G2-kappa, anti-[Homo sapiens PCSK9 (proproteína convertasa subtilisina/kexina tipo 9, convertasa 1 regulada por la apoptosis neuronal, NARC1, NARC-1, proproteína convertasa 9, PC9)], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-444) [VH humanizada (Homo sapiens IGHV1-46*01 (90.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-118) -Homo sapiens IGHG2*01 (CH1 (119-216), bisagra(217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (Homo sapiens IGKV1-13*02 (91.00%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (220-220":221-221":224-224":227-227")-tetrakisdisulfuro antihiperlipémico

1407495-02-6

Heavy chain / Chaîne lourde / Cadena pesadaQVQLVQSGAE VKKPGASVKV SCKASGYTFT SYYMHWVRQA PGQGLEWMGE 50ISPFGGRTNY NEKFKSRVTM TRDTSTSTVY MELSSLRSED TAVYYCARER 100PLYASDLWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF PPKPKDTLMI 250SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV 300SVLTVVHQDW LNGKEYKCKV SNKGLPSSIE KTISKTKGQP REPQVYTLPP 350SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS 400FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK 444

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDRVT ITCRASQGIS SALAWYQQKP GKAPKLLIYS 50ASYRYTGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCQQ RYSLWRTFGQ 100GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 145-201 258-318 364-422 22''-96'' 145''-201'' 258''-318'' 364''-422''Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (CH1 10-CL 126) 132-214' 132''-214''' Inter-H-H (h 4, h 5, h 11, h 14) 220-220'' 221-221'' 224-224'' 227-227''


brincidofovirum brincidofovir 3-(hexadecyloxy)propyl hydrogen ({(1S)-1-[(4-amino-2-oxopyrimidin-

1(2H)-yl)methyl]-2-hydroxyethoxy}methyl)phosphonate antiviral


409

brincidofovir ({(1S)-1-[(4-amino-2-oxopyrimidin-1(2H)-yl)méthyl]-

2-hydroxyethoxy}methyl)hydrogénophosphonate de 3-(hexadécyloxy)propyle antiviral

brincidofovir ({(1S)-1-[(4-amino-2-oxopirimidin-1(2H)-il)metil]- 2-hidroxietoxi}metil)hidrógenofosfonato de 3-(hexadeciloxi)propilo antiviral

C27H52N3O7P

444805-28-1

N

N

HHO

O

NH2

O PO O

OHO H3C

canoctakinum # canoctakin recombinant DNA derived, human interleukin 8 (CXCL8) mutein,

produced in Escherichia coli: [44,48,97,98-tetra-L-lysine]human interleukin 8 precursor-(34-99)-peptide anti-inflammatory

canoctakine mutéine de l’interleukine 8 humaine (CXCL8), produite dans Escherichia coli à partir d’ADN recombinant: [44,48,97,98-tétra-L-lysine]précurseur de l’interleukine 8 humaine-(34-99)-peptide anti-inflammatoire

canoctakina muteína de la interleukina 8 humana (CXCL8), producida en Escherichia coli a partir de ADN recombinante: [44,48,97,98-tetra-L-lisina]precursor de la interleukina 8 humana- (34-99)-péptido antiinflamatorio

C340H565N99O94S4

1019859-03-0

CQCIKTY SKPKHPKKIK 50ELRVIESGPH CANTEIIVKL SDGRELCLDP KENWVQRVVE KFLKRAKKS 99Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro34-61 36-77

censavudinum censavudine 1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-

5-methylpyrimidine-2,4(1H,3H)-dione antiviral

censavudine 1-[(2R,5R)-5-éthynyl-5-(hydroxyméthyl)-2,5-dihydrofuran-2-yl]- 5-méthylpyrimidine-2,4(1H,3H)-dione antiviral

censavudina 1-[(2R,5R)-5-etinil-5-(hidroximetil)-2,5-dihidrofuran-2-il]- 5-metilpirimidina-2,4(1H,3H)-diona antiviral


410

C12H12N2O4

634907-30-5

O N

HN

HO

O O

CH3

HC

cimaglerminum alfa # cimaglermin alfa recombinant DNA derived glial growth factor 2(GGF2), produced in

Chinese hamster ovary (CHO) cells (glycoform alfa): [253-L-glutamine(R>Q variant 009307)]human pro-neuregulin-1 membrane-bound isoform 9 precursor-(51-422)-peptide growth factor

cimaglermine alfa facteur de croissance 2 glial, produit par des cellules ovariennes de hamster chinois (glycoforme alfa) : [253-L-glutamine(R>Q variant 009307)]précurseur de l’isoforme 9 de la pro-neuréguline-1, se liant à la membrane, humain-(51-422)-peptide obtenu par culture de cellules ovariennes d’hamster chinois (CHO), glycoforme alfa facteur de croissance

cimaglermina alfa factor de crecimiento glial 2, producido por células ováricas de hamster chino (glicoforma alfa): [253-L-glutamina(R>Q variante 009307)]precursor de la isoforma 9 de la pro-neuregulina-1, que se une a la membrana, humano-(51-422)-péptido obtenido por cultivo de células ováricas de hamster chino (CHO), glicoforma alfa factor de crecimiento

1350717-96-2

Sequence / Séquence /SsecuenciaGNEAAPAGAS VCYSSPPSVG SVQELAQRAA VVIEGKVHPQ RRQQGALDRK 50AAAAAGEAGA WGGDREPPAA GPRALGPPAE EPLLAANGTV PSWPTAPVPS 100AGEPGEEAPY LVKVHQVWAV KAGGLKKDSL LTVRLGTWGH PAFPSCGRLK 150EDSRYIFFME PDANSTSRAP AAFRASFPPL ETGRNLKKEV SRVLCKRCAL 200PPQLKEMKSQ ESAAGSKLVL RCETSSEYSS LRFKWFKNGN ELNRKNKPQN 250IKIQKKPGKS ELRINKASLA DSGEYMCKVI SKLGNDSASA NITIVESNAT 300STSTTGTSHL VKCAEKEKTF CVNGGECFMV KDLSNPSRYL CKCPNEFTGD 350RCQNYVMASF YSTSTPFLSL PE 372

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro12-146 195-198 222-277 313-327 321-341 343-352

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)Asn-87 Asn-164 Asn-285 Asn-291 Asn-298

cipargaminum cipargamin (1'R,3'S)-5,7'-dichloro-6'-fluoro-3'-methyl-2',3',4',9'-

tetrahydrospiro[indole-3,1'-pyrido[3,4-b]indol]-2(1H)-one antimalarial

cipargamine (1'R,3'S)-5,7'-dichloro-6'-fluoro-3'-méthyl-2',3',4',9'-tétrahydrospiro[indole-3,1'-pyrido[3,4-b]indol]-2(1H)-one antipaludique


411

cipargamina (1'R,3'S)-5,7'-dicloro-6'-fluoro-3'-metil-2',3',4',9'-tetrahidrospiro[indol-3,1'-pirido[3,4-b]indol]-2(1H)-ona antipalúdico

C19H14Cl2FN3O

1193314-23-6

HN

O

NHHN

CH3

H

Cl

F

Cl

dapirolizumabum pegolum # dapirolizumab pegol immunoglobulin Fab' G1-kappa pegylated, anti-[Homo sapiens

CD40LG (CD40 ligand, CD40L, tumor necrosis factor ligand superfamily member 5, TNFSF5, tumor necrosis factor related activation protein, TRAP, CD154)], pegylated humanized monoclonal antibody; gamma1 heavy chain fragment VH-(CH1-hinge) (1-229) [humanized VH (Homo sapiens IGHV3-74*01 (76.50%) -(IGHD)-IGHJ1*01) [8.7.12] (1-118) -Homo sapiens IGHG1*01 (CH1 (119-216), hinge 1-11 (217-227)) (119-227) -dialanyl (228-229)], (221-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-NL1*01 (83.20%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; conjugated via a linker of the maleimide group (thioether bond with cysteinyl h 11 (227)) to two linear chains of methoxy polyethylene glycol 20 (mPEG20). immunomodulator

dapirolizumab pégol immunoglobuline Fab' G1-kappa pégylé, anti-[Homo sapiens CD40LG (CD40 ligand, CD40L, membre 5 de la superfamille des ligands facteurs de nécrose tumorale, TNFSF5, protéine d'activation apparentée au facteur de nécrose tumorale, TRAP, CD154)], anticorps monoclonal humanisé pégylé; fragment VH-(CH1-charnière) de la chaîne lourde gamma1 (1-229) [VH humanisé (Homo sapiens IGHV3-74*01 (76.50%) -(IGHD)-IGHJ1*01) [8.7.12] (1-118) -Homo sapiens IGHG1*01 (CH1 (119-216), charnière 1-11 (217-227)) (119-227) -dialanyl (228-229)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-NL1*01 (83.20%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; conjugué via un linker du groupe maléimide (liaison thioéther avec cystéinyl h 11 (227)) à deux chaînes linéaires de méthoxy polyéthylène glycol 20 (mPEG20). immunomodulateur


412

dapirolizumab pegol inmunoglobulina Fab' G1-kappa pegilada, anti-[Homo sapiens CD40LG (ligando CD40, CD40L, miembro 5 de la superfamilia de ligandos factores de necrosis tumoral, TNFSF5, proteína de activación relacionada con el factor de necrosis tumoral, TRAP, CD154)], anticuerpo monoclonal humanizado pegilado; fragmento VH-(CH1bisagra) de la cadena pesada gamma1 (1-229) [VH humanizado (Homo sapiens IGHV3-74*01 (76.50%) -(IGHD)-IGHJ1*01) [8.7.12] (1-118) -Homo sapiens IGHG1*01 (CH1 (119-216),bisagra 1-11 (217-227)) (119-227) -dialanil (228-229)], (221-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV1-NL1*01 (83.20%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; conjugado mediante un conector del grupo maleimida (enlace tioéter con cisteinil h 11 (227)) a dos cadenas lineales de metoxi polietilen glicol 20 (mPEG20). inmunomodulador

1416147-64-2

Heavy chain / Chaîne lourde / Cadena pesadaEVQLVESGGG LVQPGGSLRL SCAVSGFSST NYHVHWVRQA PGKGLEWMGV 50IWGDGDTSYN SVLKSRFTIS RDTSKNTVYL QMNSLRAEDT AVYYCARQLT 100HYYVLAAWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200CNVNHKPSNT KVDKKVEPKS CDKTHTCAA 229

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDRVT ITCRASEDLY YNLAWYQRKP GKAPKLLIYD 50TYRLADGVPS RFSGSGSGTD YTLTISSLQP EDFASYYCQQ YYKFPFTFGQ 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-95 145-201Intra-L (C23-C104) 23'-88' 134'-194'Inter-H-L (h 5-CL 126) 221-214'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónNone

Pegylation site / Site de pégylation / Posición de pegilaciónC227

dasotralinum dasotraline (1R,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-

1-amine psychostimulant

dasotraline (1R,4S)-4-(3,4-dichlorophényl)-1,2,3,4-tétrahydronaphthalén- 1-amine psychostimulant

dasotralina (1R,4S)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidronaftalen-1-amina psicoestimulante


413

C16H15Cl2N

675126-05-3

H

NH2

ClCl

H

duvelisibum duvelisib 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-

1(2H)-one antineoplastic, anti-inflammatory

duvélisib 8-chloro-2-phényl-3-[(1S)-1-(7H-purin-6-ylamino)éthyl]isoquinoléin-1(2H)-one antinéoplasique, anti-inflammatoire

duvelisib 8-cloro-2-fenil-3-[(1S)-1-(7H-purin-6-ilamino)etil]isoquinolein- 1(2H)-ona antineoplásico, antiinflamatorio

C22H17ClN6O

1201438-56-3

N

O

NH

N

N

NHN

CH3H

Cl

elbasvirum elbasvir dimethyl N,N'-([(6S)-6H-indolo[1,2-c][1,3]benzoxazine-

3,10-diyl]bis{1H-imdazole-5,2-diyl-(2S)-pyrrolidine-2,1-diyl[(2S)-1-oxo-3-methylbutane-1,2-diyl]})biscarbamate antiviral

elbasvir N,N'-([(6S)-6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis{1H-imidazole-5,2-diyl-(2S)-pyrrolidine-2,1-diyl[(2S)-1-oxo- 3-méthylbutane-1,2-diyl]})biscarbamate de diméthyle antiviral

elbasvir N,N'-([(6S)-6H-indolo[1,2-c][1,3]benzoxazina-3,10-diil]bis{1H-imidazol-5,2-diil-(2S)-pirrolidina-2,1-diil[(2S)-1-oxo-3-metilbutano-1,2-diil]})biscarbamato de dimetilo antiviral


414

C49H55N9O7

1370468-36-2

N

HN

N ON

HN

H3C

N

CH3HN

O

O

O

CH3

H

NH

O

O

N

CH3

CH3

O

CH3

H

H

HH

entasobulinum entasobulin 2-{1-[(4-chlorophenyl)methyl]-1H-indol-3-yl}-2-oxo-N-(quinolin-

6-yl)acetamide β-tubulin polymerization inhibitor, antineoplastic

entasobuline 2-{1-[(4-chlorophényl)méthyl]-1H-indol-3-yl}-2-oxo-N-(quinoléin- 6-yl)acétamide inhibiteur de la polymérisation de la β-tubuline, antinéoplasique

entasobulina 2-{1-[(4-clorofenil)metil]-1H-indol-3-il}-2-oxo-N-(quinolein- 6-il)acetamida inhibidor de la polimerización de la β-tubulina, antineoplásico

C26H18ClN3O2

501921-61-5

O

OHN

N

Cl

N

entospletinibum entospletinib 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-

a]pyrazin-8-amine tyrosine kinase inhibitor, antineoplastic

entosplétinib 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phényl]imidazo[1,2-a]pyrazin-8-amine inhibiteur de la tyrosine kinase, antinéoplasique

entospletinib 6-(1H-indazol-6-il)-N-[4-(morfolin-4-il)fenil]imidazo[1,2-a]pirazin- 8-amina inhibidor de la tirosina kinasa, antineoplásico


415

C23H21N7O

1229208-44-9

N

N

NH

N

N

HN

N

O

etiguanfacinum etiguanfacine ethyl N-{[2-(2,6-dichlorophenyl)acetyl]carbamimidoyl}carbamate

α2-adrenoreceptor agonist

étiguanfacine N-{[2-(2,6-dichlorophényl)acétyl]carbamimidoyl}carbamate d’éthyle agoniste des récepteurs α2-adrénergiques

etiguanfacina N-{[2-(2,6-diclorofenil)acetil]carbamimidoil}carbamato de etilo agonista de los receptores α2-adrenérgicos

C12H13Cl2N3O3 1346686-31-4

NH

NH

O NHCl

Cl

O CH3

O

ferricum derisomaltosum ferric derisomaltose (16)--D-glucopyranan-(16)-D-glucitol iron(III) complex

antianaemic

dérisomaltose ferrique complexe de fer(III) et de (16)--D-glucopyranan-(16)-D-glucitol antianémique

derisomaltosa férrica complejo hierro(III) (16)--D-glucopiranan-(16)-D-glucitol antianémico

(C6H11O5)(C6H10O5)n(C6H13O5) FeIII complex (n = 4.2)

1345510-43-1

O

OH

OH

OH

CH2OH

O

O

OH

OH

OH

CH2

O

CH2OH

OH

OH

OH

OH

CH2

n

n = 4.2

FeIII complex

fimaporfinum fimaporfin 4,4'-(15,20-diphenyl-7,8(or 12,13 or 17,18)-dihydro-

21H,23H-porphine-5,10-diyl)bisbenzenesulfonic acid, mixture of three isomers A, B and C (25%,50%,25%) photosensitizer

fimaporfine acide 4,4'-(15,20-diphényl-7,8(ou 12,13 ou 17,18)-dihydro- 21H,23H-porphine-5,10-diyl)bisbenzènesulfonique, mélange de trois isomères A, B et C (25%,50%,25%) photosensibilisant


416

fimaporfina ácido 4,4'-(15,20-difenil-7,8(o 12,13 o 17,18)-dihidro- 21H,23H-porfirina-5,10-diil)bisbencenosulfónico, mezcla de tres isómeros A, B y C (25%,50%,25%) fotosensibilizante

C44H32N4O6S2

1443547-43-0

NH N

HNN

SO3H

SO3H

1

7

8

12

1317

18

A (7,8-dihydro)

B (12,13-dihydro)

C (17,18-dihydro)

fletikumabum # fletikumab immunoglobulin G4-kappa, anti-[Homo sapiens IL20 (interleukin 20,

IL-20)], human monoclonal antibody; gamma4 heavy chain (1-454) [Homo sapiens VH (IGHV1-3*01 (88.80%) -(IGHD)-IGHJ6*01) [8.8.20] (1-127) -IGHG4*01 (CH1 (128-225), hinge S10>P (235) (226-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (128-454)], (141-214')-disulfide with kappa light chain (1'-214') [Homo sapiens (V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (233-233":236-236")-bisdisulfide immunomodulator

flétikumab immunoglobuline G4-kappa, anti-[Homo sapiens IL20 (interleukine 20, IL-20)], anticorps monoclonal humain; chaîne lourde gamma4 (1-454) [Homo sapiens VH (IGHV1-3*01 (88.80%) -(IGHD)-IGHJ6*01) [8.8.20] (1-127) -IGHG4*01 (CH1 (128-225), charnière S10>P (235) (226-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (128-454)], (141-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens (V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (233-233":236-236")-bisdisulfure immunomodulateur

fletikumab inmunoglobulina G4-kappa, anti-[Homo sapiens IL20 (interleukina 20, IL-20)], anticuerpo monoclonal humano; cadena pesada gamma4 (1-454) [Homo sapiens VH (IGHV1-3*01 (88.80%) -(IGHD)-IGHJ6*01) [8.8.20] (1-127) -IGHG4*01 (CH1 (128-225), bisagra S10>P (235) (226-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (128-454)], (141-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens (V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (233-233":236-236")-bisdisulfuro inmunomodulador


417

1357158-22-5

Heavy chain / Chaîne lourde / Cadena pesadaQVQLVQSGAE VKRPGASVKV SCKASGYTFT NDIIHWVRQA PGQRLEWMGW 50INAGYGNTQY SQNFQDRVSI TRDTSASTAY MELISLRSED TAVYYCAREP 100LWFGESSPHD YYGMDVWGQG TTVTVSSAST KGPSVFPLAP CSRSTSESTA 150ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF 250PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE 300EQFNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP 350REPQVYTLPP SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL 450SLGK 454

Light chain / Chaîne légère / Cadena ligeraAIQLTQSPSS LSASVGDRVT ITCRASQGIS SALAWYQQKP GKAPKLLIYD 50ASSLESGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FNSYPLTFGG 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 154-210 268-328 374-432 22''-96'' 154''-210'' 268''-328'' 374''-432''Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (CH1 10-CL 126) 141-214' 141''-214''' Inter-H-H (h 8, h 11) 233-233'' 236-236''


fosravuconazolum fosravuconazole {(1R,2R)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-

difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy}methyl dihydrogen phosphate antifungal

fosravuconazole dihydrogénophosphate de {(1R,2R)-2-[4-(4-cyanophényl)-1,3-thiazol-2-yl]-1-(2,4-difluorophényl)-1-[(1H-1,2,4-triazol- 1-yl)méthyl]propoxy}méthyle antifongique

fosravuconazol dihidrógenofosfato de {(1R,2R)-2-[4-(4-cianofenil)-1,3-tiazol-2-il]- 1-(2,4-difluorofenil)-1-[(1H-1,2,4-triazol-1-il)metil]propoxi}metilo antifúngico

C23H20F2N5O5PS

351227-64-0

N

NNH CH3

N

S

NC

O

F

F

OP

OOH

OH

gemilukastum gemilukast 4,4'-[4-fluoro-7-(2-{4-[4-(3-fluoro-

2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole- 1,3-diyl]dibutanoic acid leukotriene receptor antagonist, antiasthmatic


418

gémilukast acide 4,4'-[4-fluoro-7-(2-{4-[4-(3-fluoro- 2-méthylphényl)butoxy]phényl}éthynyl)-2-méthyl-1H-indole- 1,3-diyl]dibutanoïque antagoniste des récepteurs aux leucotriènes, antiasthmatique

gemilukast ácido 4,4'-[4-fluoro-7-(2-{4-[4-(3-fluoro-2-metilfenil)butoxi]fenil}etinil)-2-metil-1H-indol-1,3-diil]dibutanoico antagonista de los receptores de los leucotrienos, antiasmático

C36H37F2NO5

1232861-58-3

N

HO2C CH3

CO2HF

O

CH3

F

grapiprantum grapiprant N-{2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-

1-yl)phenyl]ethyl}-N'-[(4-methylphenyl)sulfonyl]urea prostaglandin receptor antagonist

grapiprant N-{2-[4-(2-éthyl-4,6-diméthyl-1H-imidazo[4,5-c]pyridin- 1-yl)phényl]éthyl}-N'-[(4-méthylphényl)sulfonyl]urée antagoniste des récepteurs des prostaglandines

grapiprant N-{2-[4-(2-etil-4,6-dimetil-1H-imidazo[4,5-c]piridin-1-il)fenil]etil}- N'-[(4-metilfenil)sulfonil]urea antagonista de los receptores de las prostaglandinas

C26H29N5O3S

415903-37-6

N

HN

HN

S

N

N

CH3

CH3H3C

H3C

O O O

grazoprevirum grazoprevir (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-

[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro- 8H-7,10-methanocyclopropa[18,19][1,10,3,6] dioxadiazacyclononadeca[11,12-b]quinoxaline-8-carboxamide antiviral


419

grazoprévir (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-éthénylcyclopropyl}-14-méthoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tétradécahydro- 8H-7,10-méthanocyclopropa[18,19][1,10,3,6] dioxadiazacyclononadéca[11,12-b]quinoxaline-8-carboxamide antiviral

grazoprevir (1aR,5S,8S,10R,22aR)-5-terc-butil-N-{(1R,2S)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}-14-metoxi- 3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahidro- 8H-7,10-metanociclopropa[18,19][1,10,3,6] dioxadiazaciclononadeca[11,12-b]quinoxalina-8-carboxamida antiviral

C38H50N6O9S

1350514-68-9

N

H

HN

O

NH

S

O OO

O

H CH2

NHO

H3C

O

H3C CH3

H

N

N

O OCH3

H

H H

icosabutas icosabutate rac-2-[(5Z,8Z,11Z,14Z,17Z)icosa-5,8,11,14,17-pentaen-

1-yloxy]butanoic acid antihyperlipidaemic

icosabutate acide rac-2-[(5Z,8Z,11Z,14Z,17Z)icosa-5,8,11,14,17-pentaén- 1-yloxy]butanoïque antihyperlipidémiant

icosabutato ácido rac-2-[(5Z,8Z,11Z,14Z,17Z)icosa-5,8,11,14,17-pentaen- 1-iloxi]butanoico antihiperlipémico

C24H38O3

1253909-57-7

OCH3

CO2HHCH3

and enantiomeret énantiomèrey enantiómero

idalopirdinum idalopirdine 2-(6-fluoro-1H-indol-3-yl)-N-{[3-(2,2,3,3-

tetrafluoropropoxy)phenyl]methyl}ethanamine serotonin receptor antagonist


420

idalopirdine 2-(6-fluoro-1H-indol-3-yl)-N-{[3-(2,2,3,3-tétrafluoropropoxy)phényl]méthyl}éthanamine antagoniste des récepteurs de la sérotonine

idalopirdina 2-(6-fluoro-1H-indol-3-il)-N-{[3-(2,2,3,3-tetrafluoropropoxi)fenil]metil}etanamina antagonista del receptor de la serotonina

C20H19F5N2O

467459-31-0

NH

HN

O F

F

FF

F

lefamulinum lefamulin (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-

tetramethyl-1-oxodecahydro-3a,9-propanocyclopenta[8]annulen-8-yl [(1R,2R,4R)-4-amino-2-hydroxycyclohexyl)sulfanyl]acetate antibiotic

léfamuline {[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]sulfanyl}acétate de (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-éthényl-5-hydroxy-4,6,9,10-tétraméthyl-1-oxodécahydro-3a,9-propano-3aH-cyclopenta[8]annulén-8-yle antibiotique

lefamulina [(1R,2R,4R)-4-amino-2-hidroxiciclohexil)sulfanil]acetato de (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-etenil-5-hidroxi-4,6,9,10-tetrametil-1-oxodecahidro-3a,9-propanociclopenta[8]anulen-8-ilo antibiótico

C28H45NO5S

1061337-51-6

HO H H CH3

H3C

O

H

CH3H

H3C

H2C

OS

O

HH

HOH

H

H2N

lerimazolinum lerimazoline 2-[(2,4,6-trimethylphenyl)methyl]-4,5-dihydro-1H-imidazole

sympathomimetic

lérimazoline 2-[(2,4,6-triméthylphényl)méthyl]-4,5-dihydro-1H-imidazole sympathomimétique

lerimazolina 2-[(2,4,6-trimetilfenil)metil]-4,5-dihidro-1H-imidazol simpatomimético

C13H18N2

54765-26-3

NH

NCH3

CH3

H3C


421

lifastuzumabum vedotinum # lifastuzumab vedotin immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo

sapiens SLC34A2 (solute carrier family 34 sodium phosphate member 2, sodium/phosphate cotransporter 2B, NaPi2b, NaPi3b)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-450) [humanized VH (Homo sapiens IGHV3-23*04 (85.70%) -(IGHD)-IGHJ5*01) [8.8.13] (1-120) -Homo sapiens IGHG1*03 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimer (229-229":232-232")-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker For the vedotin part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others"*. antineoplastic

lifastuzumab védotine immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[Homo sapiens SLC34A2 (membre 2 de la famille 34 sodium phosphate de transporteurs de solutés, cotransporteur 2B de sodium/phosphate, NaPi2b, NaPi3b)], anticorps monoclonal humanisé conjugué à l'auristatine E; chaîne lourde gamma1 (1-450) [VH humanisé (Homo sapiens IGHV3-23*04 (85.70%) -(IGHD)-IGHJ5*01) [8.8.13] (1-120) -Homo sapiens IGHG1*03 (CH1 R120>K (217) (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) Pour la partie védotine, veuillez-vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others"*. antinéoplasique

lifastuzumab vedotina inmunoglobulina G1-kappa conjugada con la auristatina E, anti-[Homo sapiens SLC34A2 (miembro 2 de la familia 34 sodio fosfato de transportadores de solutos, cotransportador 2B de sodio/fosfato, NaPi2b, NaPi3b)], anticuerpo monoclonal humanizado conjugado con auristatina E; cadena pesada gamma1 (1-450) [VH humanizada (Homo sapiens IGHV3-23*04 (85.70%) -(IGHD)-IGHJ5*01) [8.8.13] (1-120) -Homo sapiens IGHG1*03 (CH1 R120>K (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (229-229":232-232")-bisdisulfuro; conjugado, en una media de 3 a 4 restos cisteinil, con monometilauristatina E (MMAE), mediante un conector separable de tipo maleimidocaproil-valil-citrulinil- p-aminobenciloxicarbonilo (mc-val-cit-PABC) Para la fracción vedotina pueden referirse al documento "INN for pharmaceutical substances: Names for radicals, groups and others"*. antineoplásico


422


EVQLVESGGG LVQPGGSLRL SCAASGFSFS DFAMSWVRQA PGKGLEWVAT 50IGRVAFHTYY PDSMKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARHR 100GFDVGHFDFW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDRVT ITCRSSETLV HSSGNTYLEW YQQKPGKAPK 50LLIYRVSNRF SGVPSRFSGS GSGTDFTLTI SSLQPEDFAT YYCFQGSFNP 100LTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200VTHQGLSSPV TKSFNRGEC 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 147-203 264-324 370-428 22''-96'' 147''-203'' 264''-324'' 370''-428''Intra-L (C23-C104) 23'-93' 139'-199' 23'''-93''' 139'''-199''' Inter-H-L (h 5-CL 126) * 223-219' 223''-219''' Inter-H-H (h 11, h 14) * 229-229'' 232-232'' *Two or three of the inter-chain disulfide bridges are not present, an average of 3 to 4 cysteinyl being conjugated each via a thioether bond to a drug linker.*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 à 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif. *Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 a 4 cisteinil está conjugada a conectores de principio activo.


lotilanerum lotilaner 3-methyl-N-{2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}-5-[(5S)-5-

(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol- 3-yl]thiophene-2-carboxamide insecticide (veterinary drug)

lotilaner 3-méthyl-N-{2-oxo-2-[(2,2,2-trifluoroéthyl)amino]éthyl}-5-[(5S)-5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydro-1,2-oxazol- 3-yl]thiophène-2-carboxamide antinéoplasique (usage vétérinaire)

lotilaner 3-metil-N-{2-oxo-2-[(2,2,2-trifluoroetil)amino]etil}-5-[(5S)-5-(3,4,5-triclorofenil)-5-(trifluorometil)-4,5-dihidro-1,2-oxazol-3-il]tiofeno- 2-carboxamida antineoplásico (uso veterinario)

C20H14Cl3F6N3O3S 1369852-71-0 F3C

Cl

Cl

Cl

NO

NH

HNS

CH3

O

O

CF3

luspaterceptum # luspatercept fusion protein for immune applications (FPIA) comprising the Homo

sapiens ACVR2B (activin receptor type 2B, activin A receptor type IIB, activin receptor type IIB, ACTR-IIB, ActR-IIB) extracellular domain, fused with Homo sapiens immunoglobulin G1 Fc fragment; Homo sapiens ACVR2B precursor fragment 25-131 L79>D (55) (1-107) -linker triglycyl (108-110) -gamma1 chain H-CH2-CH3 fragment [Homo sapiens IGHG1*03 (hinge 8-15 (111-118), CH2 (119-228), CH3 (229-333), CHS (334-335))] (111-335); dimer (114-114':117-117')-bisdisulfide antianaemic


423

luspatercept protéine de fusion pour applications immunitaires (FPIA) comprenant le domaine extracellulaire d'Homo sapiens ACVR2B (récepteur de type 2B de l'activine, récepteur de type IIB de l'activine A, récepteur de type IIB de l'activine, ACTR-IIB, ActR-IIB), fusionné au fragment Fc de l'Homo sapiens immunoglobuline G1; Homo sapiens ACVR2B fragment 25-131 du précurseur L79>D (55) (1-107) -linker triglycyl (108-110) -fragment H-CH2-CH3 de la chaîne gamma1 [Homo sapiens IGHG1*03 (charnière 8-15 (111-118), CH2 (119-228), CH3 (229-333), CHS (334-335))] (111-335); dimère (114-114':117-117')-bisdisulfure antianémique

luspatercept proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende el dominio extracelular d'Homo sapiens ACVR2B (receptor de tipo 2B de la activina, receptor de tipo IIB de la activina A, receptor de tipo IIB de la activina, ACTR-IIB, ActR-IIB), fusionada con el fragmento Fc de la inmunoglobulina G1 de Homo sapiens ; Homo sapiens ACVR2B fragmento 25-131 del precursor L79>D (55) (1-107) -linker triglicil (108-110) -fragmento H-CH2-CH3 de la cadena gamma1 [Homo sapiens IGHG1*03 (bisagra 8-15 (111-118), CH2 (119-228), CH3 (229-333), CHS (334-335))] (111-335); dímero (114-114':117-117')-bisdisulfuro antianémico

1373715-00-4 Fused chain / chaine fusionnée / cadena fusionada

ETRECIYYNA NWELERTNQS GLERCEGEQD KRLHCYASWR NSSGTIELVK 50KGCWDDDFNC YDRQECVATE ENPQVYFCCC EGNFCNERFT HLPEAGGPEV 100TYEPPPTGGG THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV 150VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD 200WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP PSREEMTKNQ 250VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV 300DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK 335 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntrachain ACVR2B 5-35 25-53 60-79 66-78 80-85 5'-35' 25'-53' 60'-79' 66'-78' 80'-85' IGHG1 (C23-C104) 149-209 255-313 149'-209' 255'-313' Interchain IGHG1 (h 11, h 14) 114-114' 117-117'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónACVR2B: 18, 41, 18', 41' IGHG1 CH2 N84.4: 185, 185'

mipsagarginum mipsagargin sarcoplasmic/endoplasmic reticulum Ca2+ dependent ATPase

(SERCA) inhibitor conjugated to a peptide targeting prostate-specific membrane antigen (PSMA): N4-(12-{[(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acetyloxy)- 3,3a-dihydroxy-3,6,9-trimethyl-8-{[(2Z)-2-methylbut-2-enoyl]oxy}- 7-(octanoyloxy)-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-decahydroazuleno[4,5-b]furan-4-yl]oxy}-12-oxododecyl)-L-asparaginyl-L-γ-glutamyl- L-γ-glutamyl-L-γ-glutamyl-L-glutamic acid antineoplastic

mipsagargine inhibiteur de l’ATPase dépendante du Ca2+ du réticulum sarcoplasmique/endoplasmique conjugué à un peptide ciblant l’antigène prostatique membranaire spécifique (APMS): acide N4-(12-{[(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acétyloxy)- 3,3a-dihydroxy-3,6,9-triméthyl-8-{[(2Z)-2-méthylbut-2-énoyl]oxy}- 7-(octanoyloxy)-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-décahydroazuléno[4,5-b]furan-4-yl]oxy}-12-oxododécyl)-L-asparaginyl-L-γ-glutamyl- L-γ-glutamyl-L-γ-glutamyl-L-glutamique antinéoplasique


424

mipsagargina inhibidor de la ATPasa dependiente de Ca2+ de retículo endoplásmico/sarcoplásmico (SERCA) conjugado con un péptido cuya diana es el antígeno de membrana especifico de la próstata (PSMA):

ácido N4-(12-{[(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acetiloxi)- 3,3a-dihidroxi-3,6,9-trimetil-8-{[(2Z)-2-metilbut-2-enoil]oxi}- 7-(octanoiloxi)-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-decahidroazuleno[4,5-b]furan-4-il]oxi}-12-oxododecil)-L-asparaginil-L-γ-glutamil- L-γ-glutamil-L-γ-glutamil-L-glutámico antineoplásico

C66H100N6O27

1245732-48-2

O

O

CH3

OH

OH

O

O

H

H

OCH3

OH

H

O

CH3

O CH3

OH3C

CH3

O

CH3

O NH2HNH

OH CO2H

OH

O

HN

4

H

osilodrostatum osilodrostat 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-

3-fluorobenzonitrile 11-β-hydroxylase inhibitor

osilodrostat 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]- 3-fluorobenzonitrile inhibiteur de la 11-β-hydroxylase

osilodrostat 4-[(5R)-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-5-il]- 3-fluorobenzonitrilo inhibidor de la 11-β-hidroxilasa

C13H10FN3

928134-65-0

CNF

HN

N


425

otlertuzumabum # otlertuzumab immunoglobulin G1-kappa heavy chain dimer, anti-[Homo sapiens

CD37 (tetraspanin-26, TSPAN26)], humanized monoclonal antibody; gamma1-kappa heavy chain ‘VH-linker-V-KAPPA-hinge-CH2-CH3' (1-483) [humanized VH (Homo sapiens IGHV5-51*01 (84.70%) -(IGHD)-IGHJ5*01) [8.8.9] (1-116) -linker pentakis(tetraglycyl-seryl) (117-141) -humanized V-KAPPA (Homo sapiens IGKV3-NL2 (89.90%) -IGKJ1*01) [6.3.9] (142-248) -linker glycyl-aspartyl-glutaminyl (249-251) -Homo sapiens IGHG1*01 (hinge C5>S (256), C11>S (262) (252-266), CH2 (267-376), CH3 (377-481), CHS (482-483)) (252-483)]; dimer (265-265')-disulfide immunomodulator, antineoplastic

otlertuzumab immunoglobuline G1-kappa chaîne lourde dimère, anti-[Homo sapiens CD37 (tétraspanine-26, TSPAN26)], anticorps monoclonal humanisé; gamma1-kappa chaîne lourde ‘VH-linker-V-KAPPA-charnière-CH2-CH3' (1-483) [VH humanisé (Homo sapiens IGHV5-51*01 (84.70%) -(IGHD)-IGHJ5*01) [8.8.9] (1-116) -linker pentakis(tétraglycyl-séryl) (117-141) -V-KAPPA humanisé (Homo sapiens IGKV3-NL2 (89.90%) -IGKJ1*01) [6.3.9] (142-248) -linker glycyl-aspartyl-glutaminyl (249-251) -Homo sapiens IGHG1*01 (charnière C5>S (256), C11>S (262) (252-266), CH2 (267-376), CH3 (377-481), CHS (482-483)) (252-483)]; dimère (265-265')-disulfure immunomodulateur, antinéoplasique

otlertuzumab inmunoglobulina G1-kappa cadena pesada dímero, anti-[Homo sapiens CD37 (tetraspanina-26, TSPAN26)], anticuerpo monoclonal humanizado; gamma1-kappa cadena pesada ‘VH-linker-V-KAPPA-bisagra-CH2-CH3' (1-483) [VH humanizado (Homo sapiens IGHV5-51*01 (84.70%) -(IGHD)-IGHJ5*01) [8.8.9] (1-116) -linker pentakis(tetraglicil-seril) (117-141) -V-KAPPA humanizado (Homo sapiens IGKV3-NL2 (89.90%) -IGKJ1*01) [6.3.9] (142-248) -linker glicil-aspartil-glutaminil (249-251) -Homo sapiens IGHG1*01 (bisagraC5>S (256), C11>S (262) (252-266), CH2 (267-376), CH3 (377-481), CHS (482-483)) (252-483)]; dímero (265-265')-disulfuro inmunomodulador, antineoplásico

1372645-37-8

Heavy chain / Chaîne lourde / Cadena pesadaEVQLVQSGAE VKKPGESLKI SCKGSGYSFT GYNMNWVRQM PGKGLEWMGN 50IDPYYGGTTY NRKFKGQVTI SADKSISTAY LQWSSLKASD TAMYYCARSV 100GPFDSWGQGT LVTVSSGGGG SGGGGSGGGG SGGGGSGGGG SEIVLTQSPA 150TLSLSPGERA TLSCRASENV YSYLAWYQQK PGQAPRLLIY FAKTLAEGIP 200ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ HHSDNPWTFG QGTKVEIKGD 250QEPKSSDKTH TSPPCPAPEL LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV 300DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL 350NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS RDELTKNQVS 400LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK 450SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 483

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 164-229 297-357 403-461 22''-96'' 164''-229'' 297''-357'' 403''-461''Inter-H-H (h 14) 265-265'



426

pexmetinibum pexmetinib N-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[(5-fluoro-

2-{[1-(2-hydroxyethyl)-1H-indazol-5-yl]oxy}phenyl)methyl]urea antineoplastic

pexmétinib N-[3-tert-butyl-1-(4-méthylphényl)-1H-pyrazol-5-yl]-N'-[(5-fluoro- 2-{[1-(2-hydroxyéthyl)-1H-indazol-5-yl]oxy}phényl)méthyl]urée antinéoplasique

pexmetinib N-[3-terc-butil-1-(4-metilfenil)-1H-pirazol-5-il]-N'-[(5-fluoro- 2-{[1-(2-hidroxietil)-1H-indazol-5-il]oxi}fenil)metil]urea antineoplásico

C31H33FN6O3 945614-12-0

HN

HN

OON

N

H3CCH3

CH3

CH3

NN

HO

F

pretomanidum pretomanid (6S)-2-nitro-6-{[4-(trifluoromethoxy)phenyl]methoxy}-6,7-dihydro-

5H-imidazo[2,1-b][1,3]oxazine antibacterial

prétomanid (6S)-2-nitro-6-{[4-(trifluorométhoxy)phényl]méthoxy}-6,7-dihydro- 5H-imidazo[2,1-b][1,3]oxazine antibactérien

pretomanid (6S)-2-nitro-6-{[4-(trifluorometoxi)fenil]metoxi}-6,7-dihidro- 5H-imidazo[2,1-b][1,3]oxazina antibacteriano

C14H12F3N3O5 187235-37-6

N

ONO2N

O

OCF3

H

ralpancizumabum # ralpancizumab immunoglobulin G2-kappa, anti-[Homo sapiens PCSK9 (proprotein

convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, NARC1, NARC-1, proprotein convertase 9, PC9)], humanized monoclonal antibody; gamma2 heavy chain (1-444) [humanized VH (Homo sapiens IGHV1-46*01 (91.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-118) -Homo sapiens IGHG2*01 (CH1 (119-216), hinge (217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-33*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimer (220-220":221-221":224-224":227-227")-tetrakisdisulfide antihyperlipidaemic


427

ralpancizumab immunoglobuline G2-kappa, anti-[Homo sapiens PCSK9 (proprotéine convertase subtilisine/kexine type 9, convertase 1 régulée par l'apoptose neuronale, NARC1, NARC-1, proprotéine convertase 9, PC9)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-444) [VH humanisé (Homo sapiens IGHV1-46*01 (91.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-118) -Homo sapiens IGHG2*01 (CH1 (119-216), charnière (217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-33*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (220-220":221-221":224-224":227-227")-tétrakisdisulfure antihyperlipidémiant

ralpancizumab inmunoglobulina G2-kappa, anti-[Homo sapiens PCSK9 (proproteína convertasa subtilisina/kexina tipo 9, convertasa 1 regulada por la apoptosis neuronal, NARC1, NARC-1, proproteína convertasa 9, PC9)], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-444) [VH humanizado (Homo sapiens IGHV1-46*01 (91.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-118) -Homo sapiens IGHG2*01 (CH1 (119-216), bisagra (217-228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV1-33*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (220-220":221-221":224-224":227-227")-tatrakisdisulfuro antihiperlipémico

1407495-04-8

Heavy chain / Chaîne lourde / Cadena pesadaQVQLVQSGAE VKKPGASVKV SCKASGYTFT SYYMHWVRQA PGQGLEWMGE 50IHPSGGRTNY NEKFKSRVTM TRDTSTSTVY MELSSLRSED TAVYYCARER 100PLYASDLWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF PPKPKDTLMI 250SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV 300SVLTVVHQDW LNGKEYKCKV SNKGLPSSIE KTISKTKGQP REPQVYTLPP 350SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS 400FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK 444

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDRVT ITCKASQDVH TAVAWYQQKP GKAPKLLIYH 50ASYRYTGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCQQ RYSLWRTFGQ 100GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 145-201 258-318 364-422 22''-96'' 145''-201'' 258''-318'' 364''-422''Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (CH1 10-CL 126) 132-214' 132''-214''' Inter-H-H (h 4, h 5, h 11, h 14) 220-220'' 221-221'' 224-224'' 227-227''



428

relamorelinum relamorelin [3-(1-benzothiophen-3-yl)-N-(piperidin-4-ylcarbonyl)-D-alanyl]-

D-tryptophyl-L-phenylalanyl-(4-aminopiperidine-4-carboxamide) growth hormone release-stimulating peptide

rélamoréline [3-(1-benzothiophén-3-yl)-N-(pipéridin-4-ylcarbonyl)-D-alanyl]- D-tryptophyl-L-phénylalanyl-(4-aminopipéridine-4-carboxamide) peptide stimulant la libération de l'hormone de croissance

relamorelina [3-(1-benzotiofen-3-il)-N-(piperidin-4-ilcarbonil)-D-alanil]-D-triptofil- L-fenilalanil-(4-aminopiperidina-4-carboxamida) péptido estimulante de la liberación de la hormona de crecimiento

C43H50N8O5S

661472-41-9

O

HN

NH

O

HN

NH

O

HN

NH2

OO

H

H

H

HN

NH

S

ribuvaptanum ribuvaptan (2R)-2-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-

2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}acetamido)- 2-[3-(trifluoromethyl)phenyl]ethyl carbamate vasopressin receptor antagonist

ribuvaptan carbamate de (2R)-2-({3-(4-chlorophényl)-5-oxo- 4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol- 1-yl}acétamido)-2-[3-(trifluorométhyl)phényl]éthyle antagoniste des récepteurs de la vasopressine

ribuvaptán carbamato de (2R)-2-({3-(4-clorofenil)-5-oxo-4-[(2S)-3,3,3-trifluoro- 2-hidroxipropil]-4,5-dihidro-1H-1,2,4-triazol-1-il}acetamido)- 2-[3-(trifluorometil)fenil]etilo antagonista de los receptores de la vasopresina

C23H20ClF6N5O5

1245620-47-6

NH

ON

N

NCl

O

F3C

HOH

O H

O

NH2

F3C


429

samatasvirum samatasvir methyl {(1R)-2-[(2S)-2-{4-[4-(6-{2-[(2S)-1-{(2S)-2-

[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]- 1H-benzimidazol-5-yl}thieno[3,2-b]thien-3-yl)phenyl]-1H-imidazol- 2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate antiviral

samatasvir {(1R)-2-[(2S)-2-{4-[4-(6-{2-[(2S)-1-{(2S)-2-[(méthoxycarbonyl)amino]-3-méthylbutanoyl}pyrrolidin-2-yl]-1H-benzimidazol-5-yl}thiéno[3,2-b]thién-3-yl)phényl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo- 1-phényléthyl}carbamate de méthyle antiviral

samatasvir {(1R)-2-[(2S)-2-{4-[4-(6-{2-[(2S)-1-{(2S)-2-[(metoxicarbonil)amino]- 3-metilbutanoil}pirrolidin-2-il]-1H-benzoimidazol-5-il}tieno[3,2-b]tien-3-il)fenil]-1H-imidazol-2-il}pirrolidin-1-il]-2-oxo-1-feniletil}carbamato de metilo antiviral

C47H48N8O6S2

1312547-19-5

N

HN

NH

O

O

N

O

CH3

H

S

SN

NH

N

O

HN O

OCH3

H

H3C

H3C H

H

selinexorum selinexor (2Z)-3-{3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}-

N'-(pyrazin-2-yl)prop-2-enehydrazide antineoplastic

sélinexor (2Z)-3-{3-[3,5-bis(trifluorométhyl)phényl]-1H-1,2,4-triazol-1-yl}- N'-(pyrazin-2-yl)prop-2-ènehydrazide antinéoplasique

selinexor (2Z)-3-{3-[3,5-bis(trifluorometil)fenil]-1H-1,2,4-triazol-1-il}-N'-(pirazin-2-il)prop-2-enohidrazida antineoplásico

C17H11F6N7O

1393477-72-9

F3C

CF3

N

N

HN

NH

O

N

N

N


430

sepetaprostum sepetaprost propan-2-yl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-

difluorophenoxy)-3-hydroxybut-1-en-1-yl]-7-hydroxyoctahydro- 2H-cyclopenta[b]oxepin-3-yl}butanoate antiglaucoma

sépétaprost 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophénoxy)- 3-hydroxybut-1-én-1-yl]-7-hydroxyoctahydro- 2H-cyclopenta[b]oxépin-3-yl}butanoate de propan-2-yle antiglaucomateux

sepetaprost 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorofenoxi)- 3-hidroxibut-1-en-1-il]-7-hidroxioctahidro-2H-ciclopenta[b]oxepin- 3-il}butanoato de propan-2-ilo antiglaucoma

C26H36F2O6

1262873-06-2

HOH

OH

OH

H

HO CH3

O CH3

H OH

F

F

sofituzumabum vedotinum # sofituzumab vedotin immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo

sapiens MUC16 (mucin 16, MUC-16, cancer antigen 125, CA125)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-446) [humanized VH (Homo sapiens IGHV3-48*03 (79.80%) -(IGHD)-IGHJ4*01) [9.8.9] (1-116) -Homo sapiens IGHG1*03 (CH1 R120>K (213) (117-214), hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-5*01 (87.90%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimer (225-225":228-228")-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker For the vedotin part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others"*. antineoplastic


431

sofituzumab védotine immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[Homo sapiens MUC16 (mucine 16, MUC-16, antigène de cancer 125, CA125)], anticorps monoclonal humanisé conjugué à l'auristatine E; chaîne lourde gamma1 (1-446) [VH humanisé (Homo sapiens IGHV3-48*03 (79.80%) -(IGHD)-IGHJ4*01) [9.8.9] (1-116) -Homo sapiens IGHG1*03 (CH1 R120>K (213) (117-214), charnière (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-5*01 (87.90%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (225-225":228-228")-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) Pour la partie védotine, veuillez-vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others"*. antinéoplasique

sofituzumab vedotina inmunoglobulina G1-kappa conjugada con la auristatina E, anti-[Homo sapiens MUC16 (mucina 16, MUC-16, antígeno de cáncer 125, CA125)], anticuerpo monoclonal humanizado conjugado con la auristatina E; cadena pesada gamma1 (1-446) [VH humanizado (Homo sapiens IGHV3-48*03 (79.80%) -(IGHD)-IGHJ4*01) [9.8.9] (1-116) -Homo sapiens IGHG1*03 (CH1 R120>K (213) (117-214), bisagra (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (Homo sapiens IGKV1-5*01 (87.90%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (225-225":228-228")-bisdisulfuro; conjugado, en una media de 3 a 4 restos cisteinil, con monometilauristatina E (MMAE), mediante un conector separable de tipo maleimidocaproil-valil-citrulinil- p-aminobencilloxicarbonilo (mc-val-cit-PABC) Para la fracción vedotina pueden referirse al documento "INN for pharmaceutical substances: Names for radicals, groups and others"*. antineoplásico


EVQLVESGGG LVQPGGSLRL SCAASGYSIT NDYAWNWVRQ APGKGLEWVG 50YISYSGYTTY NPSLKSRFTI SRDTSKNTLY LQMNSLRAED TAVYYCARWT 100SGLDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDRVT ITCKASDLIH NWLAWYQQKP GKAPKLLIYG 50ATSLETGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWTTPFTFGQ 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 143-199 260-320 366-424 22''-96'' 143''-199'' 260''-320'' 366''-424''Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (h 5-CL 126) * 219-214' 219''-214''' Inter-H-H (h 11, h 14) * 225-225'' 228-228'' *Two or three of the inter-chain disulfide bridges are not present, an average of 3 to 4 cysteinyl being conjugated each via a thioether bond to a drug linker.*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 à 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker.*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 a 4 cisteinil está conjugada a conectores de principio activo.



432

sotagliflozinum sotagliflozin methyl (5S)-5-C-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-1-thio-

β-L-xylopyranoside antidiabetic

sotagliflozine (5S)-5-C-{4-chloro-3-[(4-éthoxyphényl)méthyl]phényl}-1-thio- β-L-xylopyranoside de méthyle antidiabétique

sotagliflozina (5S)-5-C-{4-cloro-3-[(4-etoxifenil)metil]fenil}-1-tio-β-L-xilopiranósido de metilo hipoglucemiante

C21H25ClO5S

1018899-04-1

O

OH

OH

HO

SH3C

O

Cl

CH3

taladegibum taladegib 4-fluoro-N-methyl-N-{1-[4-(1-methyl-1H-pyrazol-5-yl)phthalazin-

1-yl]piperidin-4-yl}-2-(trifluoromethyl)benzamide antineoplastic

taladégib 4-fluoro-N-méthyl-N-{1-[4-(1-méthyl-1H-pyrazol-5-yl)phtalazin- 1-yl]pipéridin-4-yl}-2-(trifluorométhyl)benzamide antinéoplasique

taladegib 4-fluoro-N-metil-N-{1-[4-(1-metil-1H-pirazol-5-il)ftalazin- 1-il]piperidin-4-il}-2-(trifluorometil)benzamida antineoplásico

C26H24F4N6O

1258861-20-9

O

N

N

F

CF3

CH3

NN

NN

CH3


433

talazoparibum talazoparib (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-

5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one antineoplastic

talazoparib (8S,9R)-5-fluoro-8-(4-fluorophényl)-9-(1-méthyl-1H-1,2,4-triazol- 5-yl)-2,7,8,9-tétrahydro-3H-pyrido[4,3,2-de]phtalazin-3-one antinéoplasique

talazoparib (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-il)-2,7,8,9-tetrahidro-3H-pirido[4,3,2-de]ftalazin-3-ona antineoplásico

C19H14F2N6O

1207456-01-6

NH

HN

NO

F

F

H

NN

N

H3C H

tilapertinum tilapertin (4-{(R)-phenyl[3-(trifluoromethyl)phenyl]methyl}piperazin-1-yl)acetic

acid antipsychotic

tilapertine acide (4-{(R)-phényl[3-(trifluorométhyl)phényl]méthyl}pipérazin- 1-yl)acétique antipsychotique

tilapertina ácido (4-{(R)-fenil[3-(trifluorometil)fenil]metil}piperazin-1-il)acético antipsicótico

C20H21F3N2O2

1000690-85-6

N

N CO2H

H

F3C

ulocuplumabum # ulocuplumab immunoglobulin G4-kappa, anti-[Homo sapiens CXCR4 (chemokine

(C-X-C motif) receptor 4, fusin, stromal cell-derived factor 1 receptor, SDF-1 receptor, CXCL12 receptor, CD184)], human monoclonal antibody; gamma4 heavy chain (1-451) [Homo sapiens VH (IGHV3-48*02 (96.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-223), hinge S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (126-451)], (139-214')-disulfide with kappa light chain (1'-214') [Homo sapiens (V-KAPPA (IGKV1D-16*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (231-231":234-234")-bisdisulfide immunomodulator, antineoplastic


434

ulocuplumab immunoglobuline G4-kappa, anti-[Homo sapiens CXCR4 (récepteur

4 de chimiokine (C-X-C motif), fusine, récepteur du facteur 1 dérivé des cellules stromales, récepteur du SDF-1, récepteur du CXCL12, CD184)], anticorps monoclonal humain; chaîne lourde gamma4 (1-451) [Homo sapiens VH (IGHV3-48*02 (96.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-223), charnière S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (126-451)], (139-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens (V-KAPPA (IGKV1D-16*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (231-231":234-234")-bisdisulfure immunomodulateur, antinéoplasique

ulocuplumab inmunoglobulina G4-kappa, anti-[Homo sapiens CXCR4 (receptor 4

de quimiokina (C-X-C motif), fusina, receptor del factor 1 derivado de células estromales, receptor del SDF-1, receptor del CXCL12, CD184)], anticuerpo monoclonal humano; cadena pesada gamma4 (1-451) [Homo sapiens VH (IGHV3-48*02 (96.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-223), bisagra S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (126-451)], (139-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens (V-KAPPA (IGKV1D-16*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (231-231":234-234")-bisdisulfuro inmunomodulador, antineoplásico


EVQLVESGGG LVQPGGSLRL SCAAAGFTFS SYSMNWVRQA PGKGLEWVSY 50ISSRSRTIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRDED TAVYYCARDY 100GGQPPYYYYY GMDVWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL 150GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEFL GGPSVFLFPP 250KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ 300FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE 350PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL 450G 451

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDRVT ITCRASQGIS SWLAWYQQKP EKAPKSLIYA 50ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFVTYYCQQ YNSYPRTFGQ 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H (C23-C104) 22-96 152-208 266-326 372-430 22''-96'' 152''-208'' 266''-326'' 372''-430''Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (CH1 10-CL 126) 139-214' 139''-214''' Inter-H-H (h 8, h 11) 231-231'' 234-234''


veledimexum veledimex N'-(3,5-dimethylbenzoyl)-N'-[(3R)-2,2-dimethylhexan-3-yl]-2-ethyl-

3-methoxybenzohydrazide immunostimulant

vélédimex N'-(3,5-diméthylbenzoyl)-N'-[(3R)-2,2-diméthylhexan-3-yl]-2-éthyl- 3-méthoxybenzohydrazide immunostimulant


435

veledimex N'-(3,5-dimetilbenzoil)-N'-[(3R)-2,2-dimetilhexan-3-il]-2-etil- 3-metoxibenzohidrazida inmunoestimulante

C27H38N2O3

1093130-72-3

HN

N

O

H

H3C H3CCH3

CH3CH3

H3C

O

OCH3CH3

verdinexorum verdinexor (2Z)-3-{3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}-

N'-(pyridin-2-yl)prop-2-enehydrazide antineoplastic (veterinary drug)

verdinexor (2Z)-3-{3-[3,5-bis(trifluorométhyl)phényl]-1H-1,2,4-triazol-1-yl}- N'-(pyridin-2-yl)prop-2-ènehydrazide antinéoplasique (usage vétérinaire)

verdinexor (2Z)-3-{3-[3,5-bis(trifluorometil)fenil]-1H-1,2,4-triazol-1-il}-N'-(piridin-2-il)prop-2-enohidrazida antineoplásico (uso veterinario)

C18H12F6N6O

1392136-43-4

F3C

CF3

N

HN

NH

O

N

N

N

veruprevirum veruprevir (2R,6S,12Z,13aS,14aR,16aS)-N-(cyclopropylsulfonyl)-

6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin- 6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide antiviral

véruprévir (2R,6S,12Z,13aS,14aR,16aS)-N-(cyclopropylsulfonyl)- 6-(5-méthylpyrazin-2-carboxamido)-5,16-dioxo-2-(phénanthridin- 6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tétradécahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadécine-14a(5H)-carboxamide antiviral


436

veruprevir (2R,6S,12Z,13aS,14aR,16aS)-N-(ciclopropilsulfonil)- 6-(5-metilpirazin-2-carboxamido)-5,16-dioxo-2-(fenantridin-6-iloxi)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecina-14a(5H)-carboxamida antiviral

C40H43N7O7S 1216941-48-8

N

NHO O

H

H

H

HN

H

O

O

O NH

S

O

O

N

N N

CH3

zastumotidum # zastumotide 19,137,308,342,395-penta[S-(2-amino-2-oxoethyl)]-{[2-aspartic

acid(K2>D),3-proline(L3>P)]glycerophosphoryl diester phosphodiesterase (Haemophilus influenzae strain 86-028NP EC 3.1.4.46)-(1-127)-peptide fusion protein with [2-aspartic acid(P2>D)]human melanoma-associated antigen 3 (MAGE-3 antigen, antigen MZ2-D, cancer/testis antigen 1.3 or CT1.3) fusion protein with diglycylheptahistidine} immunological agent for active immunization, antineoplastic

zastumotide 19,137,308,342,395-penta[S-(2-amino-2-oxoéthyl)]-{[2-acide aspartique(K2>D),3-proline(L3>P)]phosphodiestérase du diester de glycérophosphoryle (Haemophilus influenzae souche 86-028NP EC 3.1.4.46)-(1-127)-peptide, protéine de fusion avec le [2-acide aspartique(P2>D)]antigène 3 humain associé au mélanome (antigène MAGE-3, antigène MZ2-D, antigen 1.3 associé au cancer des testicules ou CT1.3) protéine de fusion avec la diglycylheptahistidine} agent immunologique d'immunisation active, antinéoplasique

zastumotida 19,137,308,342,395-penta[S-(2-amino-2-oxoetil)]-{[2-ácido aspártico(K2>D),3-prolina(L3>P)]fosfodiestarasa del diéster de glicerofosforilo (Haemophilus influenzae cepa 86-028NP EC 3.1.4.46)-(1-127)-péptido, proteína de fusión con el [2-ácido aspártico(P2>D)]antígeno 3 humano asociado al melanoma (antígeno MAGE-3, antígeno MZ2-D, antígeno 1.3 asociado al cáncer de testículos o CT1.3) proteína de fusión con la diglicilheptahistidina} agente inmunológico para inmunización activa. antineoplásico


437

C2243H3465N597O686S16

949885-73-8

SCO2H

NH2H

H2N

OC

19-137-308-342-395S-(2-amino-2-oxoethyl)cysteine

Modified residues / Résidus modifiés / Restos modificados

MDPKTLALSL LAAGVLAGCS SHSSNMANTQ MKSDKIIIAH RGASGYLPEH 50TLESKALAFA QQADYLEQDL AMTKDGRLVV IHDHFLDGLT DVAKKFPHRH 100RKDGRYYVID FTLKEIQSLE MTENFETMDL EQRSQHCKPE EGLEARGEAL 150GLVGAQAPAT EEQEAASSSS TLVEVTLGEV PAAESPDPPQ SPQGASSLPT 200TMNYPLWSQS YEDSSNQEEE GPSTFPDLES EFQAALSRKV AELVHFLLLK 250YRAREPVTKA EMLGSVVGNW QYFFPVIFSK ASSSLQLVFG IELMEVDPIG 300HLYIFATCLG LSYDGLLGDN QIMPKAGLLI IVLAIIAREG DCAPEEKIWE 350ELSVLEVFEG REDSILGDPK KLLTQHFVQE NYLEYRQVPG SDPACYEFLW 400GPRALVETSY VKVLHHMVKI SGGPHISYPP LHEWVLREGE EGGHHHHHHH 450


438

AMENDMENTS TO PREVIOUS LISTS

MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES

Proposed International Nonproprietary Names (Prop. INN): List 1 Dénominations communes internationales proposées (DCI Prop.): Liste 1 (Chron. Wld Hlth Org., Vol. 7, No. 10, 1953)

p. 304 delete/supprimer insert/insérer cholinii gluconas cholini gluconas

cholinium gluconate choline gluconate

gluconate de cholinium gluconate de choline

p. 312 delete/supprimer insert/insérer methacholinii chloridum methacholini chloridum

methacholinium chloride methacholine chloride

chlorure de méthacholinium chlorure de méthacholine

Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 4 (Crón. Org. mund. Salud, Vol. 10, No. 1, 1956)

p. 28 suprimáse insertese cloruro de acetilcolinio cloruro de acetilcolina

p. 31 suprimáse insertese cloruro de colinio cloruro de colina

Proposed International Nonproprietary Names (Prop. INN): List 6(Chron. Wld Hlth Org., Vol. 12, No. 3, 1958)

p. 190 delete insert nitricholinii perchloras nitricholini perchloras

nitricholinium perchlorate nitricholine perchlorate

Dénominations communes internationales proposées (DCI Prop.): Liste 6 (Chron. Org. mond. Santé, Vol. 12, No. 3, 1958)

p. 115 supprimer insérer nitricholinii perchloras nitricholini perchloras

perchlorate de nitricholinium perchlorate de nitricholine

Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 6 (Crón. Org. mund. Salud, Vol. 12, No. 3, 1958)

p. 117 suprimáse insertese nitricholinii perchloras nitricholini perchloras

perclorato de nitricolinio perclorato de nitricolina


439

Proposed International Nonproprietary Names (Prop. INN): List 62 Dénominations communes internationales proposées (DCI Prop.): Liste 62 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 62 (WHO Drug Information, Vol. 3, No. 4, 1989) p. 212 dosmalfatum dosmalfate replace the structure by the following one

dosmalfate remplacer la structure par la suivante

dosmalfate sustitúyase la estructura por la siguiente

O

OOH

OR

OCH3

O

OR

OR

RO

O

OR

O

RO O

CH3

OR

R = SO3Al2(OH)5

Proposed International Nonproprietary Names (Prop. INN): List 100 Dénominations communes internationales proposées (DCI Prop.): Liste 100 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 100 (WHO Drug Information, Vol. 22, No. 4, 2008) p. 335 & ramucirumabum # 336 ramucirumab replace the description and the structure by the following ones ramucirumab remplacer la description et la structure par les suivants

ramucirumab sustitúyase la descripción y la estructura por los siguientes

immunoglobulin G1-kappa, anti-[Homo sapiens KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309) extracellular domain], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-446) [Homo sapiens VH (IGHV3-21*01(99.00%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) - IGHG1*03 (CH1 F5>L (125), hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01 E125>D (105)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (225-225'':228-228'')-bisdisulfide

immunoglobuline G1-kappa, anti-[Homo sapiens KDR (récepteur à domaine insert kinase, récepteur 2 du facteur de croissance endothélial vasculaire, VEGFR2, VEGF-R2, FLK1, CD309) domaine extracellulaire], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-446) [Homo sapiens VH (IGHV3-21*01 (99.00%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*03 (CH1 F5>L (125), charnière (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01 E125>D (105)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (225-225'':228-228'')-bisdisulfure


440

inmunoglobulina G1-kappa, anti-[Homo sapiens KDR (receptor con dominio insert-

kinasa, receptor 2 del factor de crecimiento endotelial vascular, VEGFR2, VEGF-R2, FLK1, CD309) dominio extracelular], Homo sapiens anticuerpo monoclonal; cadena pesada gamma1 (1-446) [Homo sapiens VH (IGHV3-21*01 (99.00%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*03 (CH1 F5>L (125), bisagra (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01 E125>D (105)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (225-225'':228-228'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesadaEVQLVQSGGG LVKPGGSLRL SCAASGFTFS SYSMNWVRQA PGKGLEWVSS 50ISSSSSYIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARVT 100DAFDIWGQGT MVTVSSASTK GPSVLPLAPS SKSTSGGTAA LGCLVKDYFP 150EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446

Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS VSASIGDRVT ITCRASQGID NWLGWYQQKP GKAPKLLIYD 50ASNLDTGVPS RFSGSGSGTY FTLTISSLQA EDFAVYFCQQ AKAFPPTFGG 100GTKVDIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-96 143-199 260-320 366-424 22''-96'' 143''-199'' 260''-320'' 366''-424''Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (h 5-CL 126) 219-214' 219''-214''' Inter-H-H (h 11, h 14) 225-225'' 228-228''


Proposed International Nonproprietary Names (Prop. INN): List 105 Dénominations communes internationales proposées (DCI Prop.): Liste 105 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 105 (WHO Drug Information, Vol. 25, No. 2, 2011)

p. 197 - upamostatum 198 upamostat replace the chemical name by the following one upamostat remplacer le nom chimique par le suivant upamostat sustitúyase el nombre químico por el siguiente

ethyl 4-{(2S)-3-{3-[(E)-N'-hydroxycarbamimidoyl]phenyl}- 2-[2,4,6-tri(propan-2-yl)benzenesulfonamido]propanoyl}piperazine- 1-carboxylate}

4-{(2S)-3-{3-[(E)-N'-hydroxycarbamimidoyl]phényl}- 2-[2,4,6-tri(propan-2-yl)benzènesulfonamido]propanoyl}pipérazine- 1-carboxylate d'éthyle

4-{(2S)-3-{3-[(E)-N’-hidroxicarbamimidoil]fenil}-2-[2,4,6-tri(propan- 2-il)bencenosulfonamido]propanoil}piperazina-1-carboxilato de etilo


441

Proposed International Nonproprietary Names (Prop. INN): List 107 Dénominations communes internationales proposées (DCI Prop.): Liste 107 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 107 (WHO Drug Information, Vol. 26, No. 2, 2012)

p. 172 delete/supprimer/suprimáse insert/insérer/insertese 173 duligotumabum # duligotuzumabum # duligotumab duligotuzumab

duligotumab duligotuzumab

duligotumab duligotuzumab

replace the description by the following one remplacer la description par la suivante sustitúyase la descripción por la siguiente

immunoglobulin G1-kappa, anti-[Homo sapiens ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3)], humanized monoclonal antibody; gamma1 heavy chain (1-451) [humanized VH (Homo sapiens IGHV3-74*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -IGHG1*03 CH1 R120>K (218) (122-451)], (224-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (87.40%) -IGKJ2*01 L124>V (104)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (230-230'':233-233'')-bisdisulfide

immunoglobuline G1-kappa, anti-[Homo sapiens ERBB3 (récepteur tyrosine-protéine kinase erbB3, HER3)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-451) [VH humanisé (Homo sapiens IGHV3-74*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -IGHG1*03 CH1 R120>K (218) (122-451)], (224-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (87.40%) -IGKJ2*01 L124>V (104)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (230-230'':233-233'')-bisdisulfure

inmunoglobulina G1-kappa, anti-[Homo sapiens ERBB3 (receptor tirosina-proteína kinasa erbB3, HER3)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-451) [VH humanizado (Homo sapiens IGHV3-74*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -IGHG1*03 CH1 R120>K (218) (122-451)], (224-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (87.40%) -IGKJ2*01 L124>V (104)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (230-230'':233-233'')-bisdisulfuro

p. 190 delete/supprimer/suprimáse insert/insérer/insertese neceprevirum deldeprevirum

neceprevir deldeprevir

nécéprévir deldéprévir

neceprevir deldeprevir

p. 206 tenapanorum tenapanor replace the chemical name by the following one ténapanor remplacer le nom chimique par le suivant tenapanor sustitúyase el nombre químico por el siguiente

N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane- 1,26-diyl)bis{3-[(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin- 4-yl]benzenesulfonamide}

N,N'-(10,17-dioxo-3,6,21,24-tétraoxa-9,11,16,18-tétraazahexacosane- 1,26-diyl)bis{3-[(4S)-6,8-dichloro-2-méthyl-1,2,3,4-tétrahydroisoquinoléin- 4-yl]benzènesulfonamide}

N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosano- 1,26-diyl)bis{3-[(4S)-6,8-dicloro-2-metil-1,2,3,4-tetrahidroisoquinolin- 4-il]bencenosulfonamida}


442

p. 213 delete/supprimer/suprimáse insert/insérer/insertese zatuximabum # modotuximabum #

zatuximab modotuximab



Proposed International Nonproprietary Names (Prop. INN): List 108Dénominations communes internationales proposées (DCI Prop.): Liste 108Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 108(WHO Drug Information, Vol. 26, No. 4, 2012) p. 403 delete/supprimer/suprimáse insert/insérer/insertese adelatinibum decernotinibum

adelatinib decernotinib

adélatinib décernotinib

adelatinib decernotinib

p. 406 bimagrumabum # bimagrumab replace the description by the following one bimagrumab remplacer la description par la suivante bimagrumab sustitúyase la descripción por la siguiente

immunoglobulin G1-lambda2, anti-[Homo sapiens ACVR2B (activin A receptor type IIB, ActR-IIB, ActRIIB) and ACVR2A (activin A receptor type IIA, ActR-II, ActRIIA)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-445) [Homo sapiens VH (IGHV1-2*02 (91.80%) -(IGHD)-IGHJ5*01 [8.8.8] (1-115) -IGHG1*03 (CH1 (116-213), hinge (214-228), CH2 L1.3>A (232), L1.2>A (233) (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-216')-disulfide with lambda light chain (1'-217') [Homo sapiens V-LAMBDA (IGLV2-23*02 (90.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimer (224-224'':227-227'')-bisdisulfide

immunoglobuline G1-lambda2, anti-[Homo sapiens ACVR2B (récepteur type IIB de l'activine A, ActR-IIB, ActRIIB) et ACVR2A (recepteur type IIA de l’activine A, ActR-II, ActRIIA)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-445) [Homo sapiens VH (IGHV1-2*02 (91.80%) -(IGHD)-IGHJ5*01 [8.8.8] (1-115) -IGHG1*03 (CH1 (116-213), charnière (214-228), CH2 L1.3>A (232), L1.2>A (233) (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-216')-disulfure avec la chaîne légère lambda (1'-217') [Homo sapiens V-LAMBDA (IGLV2-23*02 (90.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (224-224'':227-227'')-bisdisulfure

inmunoglobulina G1-lambda2, anti-[Homo sapiens ACVR2B (receptor tipo IIB de la activina A, ActR-IIB, ActRIIB) y ACVR2A (receptor tipo IIA de la activina A, ActR-II, ActRIIA)], anticuerpo monoclonal de Homo sapiens; cadena pesada gamma1 (1-445) [Homo sapiens VH (IGHV1-2*02 (91.80%) -(IGHD)-IGHJ5*01 [8.8.8] (1-115) -IGHG1*03 (CH1 (116-213), bisagra (214-228), CH2 L1.3>A (232), L1.2>A (233) (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-216')-disulfuro con la cadena ligera lambda (1'-217') [Homo sapiens V-LAMBDA (IGLV2-23*02 (90.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (224-224'':227-227'')-bisdisulfuro


443

p. 437 polatuzumabum vedotinum # & 438 polatuzumab vedotin replace the description by the following one polatuzumab védotine remplacer la description par la suivante polatuzumab vedotina sustitúyase la descripción por la siguiente

immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo sapiens CD79B (immunoglobulin-associated CD79 beta)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-447) [humanized VH (Homo sapiens IGHV3-23*04 (76.50%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo sapiens IGHG1*03 (CH1 R120>K (214) (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-218')-disulfide with kappa light chain (1’-218’) [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (85.90%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')]; dimer (226-226":229-229")-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker For the vedotin part, please refer to the document “INN for pharmaceutical substances: Names for radicals, groups and others”*.

immunoglobuline G1-kappa conjuguée à l’auristatine E, anti-[Homo sapiens CD79B (CD79 bêta associé à l’immunoglobuline)], anticorps monoclonal humanisé conjugué à l’auristatine E; chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens IGHV3-23*04 (76.50%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo sapiens IGHG1*03 (CH1 R120>K (214) (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-218')-disulfure avec la chaîne légère kappa (1’-218’) [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (85.90%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')]; dimère (226-226":229-229")-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) Pour la partie védotine, veuillez vous référer au document “INN for pharmaceutical substances: Names for radicals, groups and others”*.

inmunoglobulina G1-kappa conjugada con auristatina E, anti-[Homo sapiens CD79B (CD79 beta associado a la inmunoglobulina)], anticuerpo monoclonal humanizado conjugado con auristatina E; cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens IGHV3-23*04 (76.50%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo sapiens IGHG1*03 (CH1 R120>K (214) (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-218')-disulfuro con la cadena ligera kappa (1’-218’) [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (85.90%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')]; dímero (226-226":229-229")-bisdisulfuro; conjuguado, en 3 a 4 restos cisteinil por término medio, con monometilauristatina E (MMAE), mediante un vínculo escindible maleimidocaproil-valil-citrullinil- p-aminobenziloxicarbonil (mc-val-cit-PABC) Para la fracción vedotina se pueden referir al documento "INN for pharmaceutical substances: Names for radicals, groups and others"*.


444

Proposed International Nonproprietary Names (Prop. INN): List 109 Dénominations communes internationales proposées (DCI Prop.): Liste 109 Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 109 (WHO Drug Information, Vol. 27, No. 2, 2013) p. 161 delete/supprimer/suprimáse insert/insérer/insertese lambrolizumabum # pembrolizumabum #

lambrolizumab pembrolizumab



# Electronic structure available on Mednet: http://mednet.who.int/ # Structure électronique disponible sur Mednet: http://mednet.who.int/ # Estructura electrónica disponible en Mednet: http://mednet.who.int/ * http://www.who.int/entity/medicines/services/inn/Radical_Book_2012.pdf


445

ANNEX 1

PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1

The following procedure shall be followed by the World Health Organization (hereinafter also referred to as “WHO”)

in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with resolution WHA3.11 of the World Health Assembly, and in the substitution of such names. Article 1 - Proposals for recommended international nonproprietary names and proposals for substitution of such names shall be submitted to WHO on the form provided therefore. The consideration of such proposals shall be subject to the payment of an administrative fee designed only to cover the corresponding costs of the Secretariat of WHO (“the Secretariat”). The amount of this fee shall be determined by the Secretariat and may, from time to time, be adjusted. Article 2 - Such proposals shall be submitted by the Secretariat to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, such designated members hereinafter referred to as “the INN Expert Group”, for consideration in accordance with the “General principles for guidance in devising International Nonproprietary Names for Pharmaceutical Substances”, annexed to this procedure2. The name used by the person discovering or first developing and marketing a pharmaceutical substance shall be accepted, unless there are compelling reasons to the contrary. Article 3 - Subsequent to the examination provided for in article 2, the Secretariat shall give notice that a proposed international nonproprietary name is being considered. a) Such notice shall be given by publication in WHO Drug Information3

and by letter to Member States and to national and regional pharmacopoeia commissions or other bodies designated by Member States.

i) Notice shall also be sent to the person who submitted the proposal (“the original applicant”) and other persons known to be concerned with a name under consideration.

b) Such notice shall:

i) set forth the name under consideration; ii) identify the person who submitted the proposal for naming the substance, if so requested by such person; iii) identify the substance for which a name is being considered; iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed; v) state the authority under which WHO is acting and refer to these rules of procedure.

c) In forwarding the notice, the Secretariat shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by WHO. Article 4 - Comments on the proposed name may be forwarded by any person to WHO within four months of the date of publication, under article 3, of the name in WHO Drug Information.

1 See Annex 1 in WHO Technical Report Series, No. 581, 1975. The original text was adopted by the Executive Board in resolution EB15.R7 and amended in resolutions EB43.R9 and EB115.R4.

2 See Annex 2.

3 Before 1987, lists of international nonproprietary names were published in the Chronicle of the World Health Organization.


446

Article 5 - A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in WHO Drug Information.

Such objection shall:

i) identify the person objecting;

ii) state his or her interest in the name; iii) set forth the reasons for his or her objection to the name proposed. Article 6 - Where there is a formal objection under article 5, WHO may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by WHO of a substitute name or names, a name shall not be selected by WHO as a recommended international nonproprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn. Article 7 - Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Secretariat shall give notice in accordance with subsection (a) of article 3 that the name has been selected by WHO as a recommended international nonproprietary name. Article 8 - In forwarding a recommended international nonproprietary name to Member States under article 7, the Secretariat shall: a) request that it be recognized as the nonproprietary name for the substance; and b) request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name and to prohibit registration of the name as a trademark or trade name. Article 9 a) In the extraordinary circumstance that a previously recommended international nonproprietary name gives rise to errors in medication, prescription or distribution, or a demonstrable risk thereof, because of similarity with another name in pharmaceutical and/or prescription practices, and it appears that such errors or potential errors cannot readily be resolved through other interventions than a possible substitution of a previously recommended international nonproprietary name, or in the event that a previously recommended international nonproprietary name differs substantially from the nonproprietary name approved in a significant number of Member States, or in other such extraordinary circumstances that justify a substitution of a recommended international nonproprietary name, proposals to that effect may be filed by any interested person. Such proposals shall be submitted on the form provided therefore and shall: i) identify the person making the proposal;

ii) state his or her interest in the proposed substitution; and iii) set forth the reasons for the proposal; and

iv) describe, and provide documentary evidence regarding the other interventions undertaken in an effort to resolve the situation, and the reasons why these other interventions were inadequate.

Such proposals may include a proposal for a new substitute international nonproprietary name, devised in accordance with the General principles, which takes into account the pharmaceutical substance for which the new substitute international nonproprietary name is being proposed. The Secretariat shall forward a copy of the proposal, for consideration in accordance with the procedure described in subsection (b) below, to the INN Expert Group and the original applicant or its successor (if different from the person bringing the proposal for substitution and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations). In addition, the Secretariat shall request comments on the proposal from:

i) Member States and national and regional pharmacopoeia commissions or other bodies designated by Member States (by including a notice to that effect in the letter referred to in article 3(a), and


447

ii) any other persons known to be concerned by the proposed substitution. The request for comments shall:

i) state the recommended international nonproprietary name that is being proposed for substitution (and the proposed substitute name, if provided);

ii) identify the person who submitted the proposal for substitution (if so requested by such person);

iii) identify the substance to which the proposed substitution relates and reasons put forward for substitution; iv) set forth the time within which comments will be received and the person and place to whom they should be directed; and v) state the authority under which WHO is acting and refer to these rules of procedure.

Comments on the proposed substitution may be forwarded by any person to WHO within four months of the date of the request for comments. b) After the time period for comments referred to above has elapsed, the Secretariat shall forward any comments received to the INN Expert Group, the original applicant or its successor and the person bringing the proposal for substitution. If, after consideration of the proposal for substitution and the comments received, the INN Expert Group, the person bringing the proposal for substitution and the original applicant or its successor all agree that there is a need to substitute the previously recommended international nonproprietary name, the Secretariat shall submit the proposal for substitution to the INN Expert Group for further processing. Notwithstanding the foregoing, the original applicant or its successor shall not be entitled to withhold agreement to a proposal for substitution in the event the original applicant or its successor has no demonstrable continuing interest in the recommended international nonproprietary name proposed for substitution.

In the event that a proposal for substitution shall be submitted to the INN Expert Group for further processing, the INN Expert Group will select a new international nonproprietary name in accordance with the General principles referred to in article 2 and the procedure set forth in articles 3 to 8 inclusive. The notices to be given by the Secretariat under article 3 and article 7, respectively, including to the original applicant or its successor (if not the same as the person proposing the substitution, and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations), shall in such event indicate that the new name is a substitute for a previously recommended international nonproprietary name and that Member States may wish to make transitional arrangements in order to accommodate existing products that use the previously recommended international nonproprietary name on their label in accordance with national legislation.

If, after consideration of the proposal for substitution and the comments received in accordance with the procedure described above, the INN Expert Group, the original applicant or its successor and the person bringing the proposal for substitution do not agree that there are compelling reasons for substitution of a previously recommended international nonproprietary name, this name shall be retained (provided always that the original applicant or its successor shall not be entitled to withhold agreement to a proposal for substitution in the event that the original applicant or its successor has no demonstrable continuing interest in the recommended international nonproprietary name proposed to be substituted). In such an event, the Secretariat shall advise the person having proposed the substitution, as well as the original applicant or its successor (if not the same as the person proposing the substitution, and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations), Member States, national and regional pharmacopoeia commissions, other bodies designated by Member States, and any other persons known to be concerned by the proposed substitution that, despite a proposal for substitution, it has been decided to retain the previously recommended international nonproprietary name (with a description of the reason(s) why the proposal for substitution was not considered sufficiently compelling).


448

ANNEX 2

GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1

1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names in common use.

2. The INN for a substance belonging to a group of pharmacologically related substances should, where appropriate, show this relationship. Names that are likely to convey to a patient an anatomical, physiological, pathological or therapeutic suggestion should be avoided.

These primary principles are to be implemented by using the following secondary principles:

3. In devising the INN of the first substance in a new pharmacological group, consideration should be given to the possibility of devising suitable INN for related substances, belonging to the new group.

4. In devising INN for acids, one-word names are preferred; their salts should be named without modifying the acid name, e.g. “oxacillin” and “oxacillin sodium”, “ibufenac” and “ibufenac sodium”.

5. INN for substances which are used as salts should in general apply to the active base or the active acid. Names for different salts or esters of the same active substance should differ only in respect of the name of the inactive acid or the inactive base. For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style.

6. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.

7. To facilitate the translation and pronunciation of INN, “f” should be used instead of “ph”, “t” instead of “th”, “e” instead of “ae” or “oe”, and “i” instead of “y”; the use of the letters “h” and “k” should be avoided.

8. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration.

9. Group relationship in INN (see General principle 2) should if possible be shown by using a common stem. The following list contains examples of stems for groups of substances, particularly for new groups. There are many other stems in active use.2 Where a stem is shown without any hyphens it may be used anywhere in the name. Latin English -acum -ac anti-inflammatory agents, ibufenac derivatives -adolum -adol } analgesics -adol- -adol-} -astum -ast antiasthmatic, antiallergic substances not acting primarily as antihistaminics -astinum -astine antihistaminics -azepamum -azepam diazepam derivatives bol bol steroids, anabolic -cain- -cain- class I antiarrhythmics, procainamide and lidocaine derivatives -cainum -caine local anaesthetics 1

In its Twentieth report (WHO Technical Report Series, No. 581, 1975), the WHO Expert committee on Nonproprietary Names for Pharmaceutical Substances reviewed the general principles for devising, and the procedures for selecting, INN in the light of developments in pharmaceutical compounds in recent years. The most significant change has been the extension to the naming of synthetic chemical substances of the practice previously used for substances originating in or derived from natural products. This practice involves the use of a characteristic “stem” indicative of a common property of the members of a group. The reason for, and the implications of, the change are fully discussed. The guiding principles were updated during the 13th consultation on nonproprietary names for pharmaceutical substances (Geneva, 27-29 April 1983) (PHARM S/NOM 928 13 May 1983, revised 18 August 1983).

2 A more extensive listing of stems is contained in the working document WHO/EMP/RHT/TSN/2013.1 which is regularly updated and can be requested from the INN Programme, WHO, Geneva.


449

cef- cef- antibiotics, cefalosporanic acid derivatives -cillinum -cillin antibiotics, 6-aminopenicillanic acid derivatives -conazolum -conazole systemic antifungal agents, miconazole derivatives cort cort corticosteroids, except prednisolone derivatives -coxibum -coxib selective cyclo-oxygenase inhibitors -entanum -entan endothelin receptor antagonists gab gab gabamimetic agents gado- gado- diagnostic agents, gadolinium derivatives -gatranum -gatran thrombin inhibitors, antithrombotic agents gest gest steroids, progestogens gli gli antihyperglycaemics io- io- iodine-containing contrast media -metacinum -metacin anti-inflammatory, indometacin derivatives -mycinum -mycin antibiotics, produced by Streptomyces strains -nidazolum -nidazole antiprotozoal substances, metronidazole derivatives -ololum -olol β-adrenoreceptor antagonists -oxacinum -oxacin antibacterial agents, nalidixic acid derivatives -platinum -platin antineoplastic agents, platinum derivatives -poetinum -poetin erythropoietin type blood factors -pril(at)um -pril(at) angiotensin-converting enzyme inhibitors -profenum -profen anti-inflammatory substances, ibuprofen derivatives prost prost prostaglandins -relinum -relin pituitary hormone release-stimulating peptides -sartanum -sartan angiotensin II receptor antagonists, antihypertensive (non-peptidic) -vaptanum -vaptan vasopressin receptor antagonists vin- vin- } vinca-type alkaloids -vin- -vin-}

ANNEXE 1

PROCEDURE A SUIVRE EN VUE DU CHOIX DE DENOMINATIONS COMMUNES INTERNATIONALES RECOMMANDEES POUR LES SUBSTANCES

PHARMACEUTIQUES1

L’Organisation mondiale de la Santé (également désignée ci-après sous l’appellation « OMS ») observe la procédure exposée ci-dessous pour l’attribution de dénominations communes internationales recommandées pour les substances pharmaceutiques, conformément à la résolution WHA3.11 de l’Assemblée mondiale de la Santé, et pour le remplacement de telles dénominations. Article 1 - Les propositions de dénominations communes internationales recommandées et les propositions de remplacement de telles dénominations sont soumises à l’OMS sur la formule prévue à cet effet. L’examen de telles propositions est soumis au paiement d’une taxe administrative destinée uniquement à couvrir les coûts correspondants assumés par le Secrétariat de l’OMS (« le Secrétariat »). Le montant de cette taxe est déterminé par le Secrétariat et peut être modifié de temps à autre. Article 2 - Ces propositions sont soumises par le Secrétariat aux experts désignés à cette fin parmi les personnalités inscrites au Tableau d’experts de la Pharmacopée internationale et des Préparations pharmaceutiques, ci-après désignés sous l’appellation « le Groupe d’experts des DCI » ; elles sont examinées par les experts conformément aux « Directives générales pour la formation de dénominations communes internationales pour les substances pharmaceutiques » reproduites ci-après2.

La dénomination acceptée est la dénomination employée par la personne qui découvre ou qui, la première, fabrique et lance sur le marché une substance pharmaceutique, à moins que des raisons majeures n’obligent à s’écarter de cette règle.

1 Voir annexe 1 dans OMS, Série de Rapports techniques, N° 581, 1975. Le texte original a été adopté par le Conseil exécutif dans sa résolution EB15.R7 et amendé dans ses résolutions EB43.R9 et EB115.R4.

2 Voir annexe 2.


450

Article 3 - Après l’examen prévu à l’article 2, le Secrétariat notifie qu’un projet de dénomination commune internationale est à l’étude. a) Cette notification est faite par une insertion dans WHO Drug Information1 et par l’envoi d’une lettre aux Etats Membres et aux commissions nationales et régionales de pharmacopée ou autres organismes désignés par les Etats Membres.

i) Notification est également faite à la personne qui a soumis la proposition (« le demandeur initial ») et à d’autres personnes portant à la dénomination mise à l’étude un intérêt notoire.

b) Cette notification contient les indications suivantes :

i) dénomination mise à l’étude;

ii) nom de l’auteur de la proposition tendant à attribuer une dénomination à la substance, si cette personne le demande ;

iii) définition de la substance dont la dénomination est mise à l’étude ;

iv) délai pendant lequel seront reçues les observations et les objections à l’égard de cette dénomination ; nom et adresse de la personne habilitée à recevoir ces observations et objections ;

v) mention des pouvoirs en vertu desquels agit l’OMS et référence au présent règlement.

c) En envoyant cette notification, le Secrétariat demande aux Etats Membres de prendre les mesures nécessaires pour prévenir l’acquisition de droits de propriété sur la dénomination proposée pendant la période au cours de laquelle cette dénomination est mise à l’étude par l’OMS. Article 4 - Des observations sur la dénomination proposée peuvent être adressées à l’OMS par toute personne, dans les quatre mois qui suivent la date de publication de la dénomination dans WHO Drug Information (voir l’article 3). Article 5 - Toute personne intéressée peut formuler une objection formelle contre la dénomination proposée dans les quatre mois qui suivent la date de publication de la dénomination dans WHO Drug Information (voir l’article 3). Cette objection doit s’accompagner des indications suivantes :

i) nom de l’auteur de l’objection ; ii) intérêt qu’il ou elle porte à la dénomination en cause ; iii) raisons motivant l’objection contre la dénomination proposée. Article 6 - Lorsqu’une objection formelle est formulée en vertu de l’article 5, l’OMS peut soit soumettre la dénomination proposée à un nouvel examen, soit intervenir pour tenter d’obtenir le retrait de l’objection. Sans préjudice de l’examen par l’OMS d’une ou de plusieurs appellations de remplacement, l’OMS n’adopte pas d’appellation comme dénomination commune internationale recommandée tant qu’une objection formelle présentée conformément à l’article 5 n’est pas levée. Article 7 - Lorsqu’il n’est formulé aucune objection en vertu de l’article 5, ou que toutes les objections présentées ont été levées, le Secrétariat fait une notification conformément aux dispositions du paragraphe a) de l’article 3, en indiquant que la dénomination a été choisie par l’OMS en tant que dénomination commune internationale recommandée. Article 8 - En communiquant aux Etats Membres, conformément à l’article 7, une dénomination commune internationale recommandée, le Secrétariat : a) demande que cette dénomination soit reconnue comme dénomination commune de la substance considérée ; et b) demande aux Etats Membres de prendre les mesures nécessaires pour prévenir l’acquisition de droits de propriété sur cette dénomination et interdire le dépôt de cette dénomination comme marque ou appellation commerciale. 1

Avant 1987, les listes de dénominations communes internationales étaient publiées dans la Chronique de l’Organisation mondiale de la Santé.


451

Article 9 - a) Dans le cas exceptionnel où une dénomination commune internationale déjà recommandée donne lieu à des erreurs de médication, de prescription ou de distribution ou en comporte un risque démontrable, en raison d’une similitude avec une autre appellation dans la pratique pharmaceutique et/ou de prescription, et où il apparaît que ces erreurs ou ces risques d’erreur ne peuvent être facilement évités par d’autres interventions que le remplacement éventuel d’une dénomination commune internationale déjà recommandée, ou dans le cas où une dénomination commune internationale déjà recommandée diffère sensiblement de la dénomination commune approuvée dans un nombre important d’Etats Membres, ou dans d’autres circonstances exceptionnelles qui justifient le remplacement d’une dénomination commune internationale recommandée, toute personne intéressée peut formuler une proposition dans ce sens. Cette proposition est présentée sur la formule prévue à cet effet et doit s’accompagner des indications suivantes :

i) nom de l’auteur de la proposition ;

ii) intérêt qu’il ou elle porte au remplacement proposé ;

iii) raisons motivant la proposition ; et

iv) description, faits à l’appui, des autres interventions entreprises pour tenter de régler le problème et exposé des raisons pour lesquelles ces interventions ont échoué.

Les propositions peuvent comprendre une proposition de nouvelle dénomination commune internationale de remplacement, établie conformément aux Directives générales, compte tenu de la substance pharmaceutique pour laquelle la nouvelle dénomination commune internationale de remplacement est proposée. Le Secrétariat transmet une copie de la proposition pour examen, conformément à la procédure exposée plus loin au paragraphe b), au Groupe d’experts des DCI et au demandeur initial ou à son successeur (s’il s’agit d’une personne différente de celle qui a formulé la proposition de remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles). De plus, le Secrétariat demande aux entités et personnes ci-après de formuler des observations sur la proposition :

i) les Etats Membres et les commissions nationales et régionales de pharmacopée ou d’autres organismes désignés par les Etats Membres (en insérant une note à cet effet dans la lettre mentionnée à l’article 3.a), et

ii) toutes autres personnes portant au remplacement proposé un intérêt notoire. La demande d’observations contient les indications suivantes : i) dénomination commune internationale recommandée pour laquelle un remplacement est proposé (et la dénomination de remplacement proposée, si elle est fournie) ; ii) nom de l’auteur de la proposition de remplacement (si cette personne le demande) ; iii) définition de la substance faisant l’objet du remplacement proposé et raisons avancées pour le remplacement ; iv) délai pendant lequel seront reçus les commentaires et nom et adresse de la personne habilitée à recevoir ces commentaires ; et v) mention des pouvoirs en vertu desquels agit l’OMS et référence au présent règlement. Des observations sur la proposition de remplacement peuvent être communiquées par toute personne à l’OMS dans les quatre mois qui suivent la date de la demande d’observations. b) Une fois échu le délai prévu ci-dessus pour la communication d’observations, le Secrétariat transmet les observations reçues au Groupe d’experts des DCI, au demandeur initial ou à son successeur et à l’auteur de la proposition de remplacement. Si, après avoir examiné la proposition de remplacement et les observations reçues, le Groupe d’experts des DCI, l’auteur de la proposition de remplacement et le demandeur initial ou son successeur reconnaissent tous qu’il est nécessaire de remplacer la dénomination commune internationale déjà recommandée, le Secrétariat soumet la proposition de remplacement au Groupe d’experts des DCI pour qu’il y donne suite.


452

Nonobstant ce qui précède, le demandeur initial ou son successeur n’est pas habilité à refuser son accord à une proposition de remplacement au cas où il ne peut être démontré qu’il porte un intérêt durable à la dénomination commune internationale recommandée qu’il est proposé de remplacer.

Dans le cas où une proposition de remplacement est soumise au Groupe d’experts des DCI pour qu’il y donne

suite, le Groupe choisit une nouvelle dénomination commune internationale conformément aux Directives générales mentionnées à l’article 2 et selon la procédure décrite dans les articles 3 à 8 inclus. La notification faite par le Secrétariat en vertu de l’article 3 et de l’article 7, respectivement, y compris au demandeur initial ou à son successeur (si ce n’est pas la même personne que celle qui a proposé le remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles), doit dans un tel cas indiquer que la nouvelle dénomination remplace une dénomination commune internationale déjà recommandée et que les Etats Membres peuvent souhaiter prendre des mesures transitoires pour les produits existants qui utilisent la dénomination commune internationale déjà recommandée sur leur étiquette conformément à la législation nationale.

Si, après examen de la proposition de remplacement et des observations communiquées conformément à la

procédure exposée plus haut, le Groupe d’experts des DCI, le demandeur initial ou son successeur et l’auteur de la proposition de remplacement ne s’accordent pas sur le fait qu’il y a des raisons impératives de remplacer une dénomination commune internationale déjà recommandée, cette dernière est conservée (étant entendu toujours que le demandeur initial ou son successeur n’est pas habilité à refuser son accord à une proposition de remplacement au cas où il ne peut être démontré qu’il porte un intérêt durable à la dénomination commune internationale recommandée qu’il est proposé de remplacer). Dans un tel cas, le Secrétariat informe l’auteur de la proposition de remplacement, ainsi que le demandeur initial ou son successeur (s’il s’agit d’une personne différente de celle qui a formulé la proposition de remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles), les Etats Membres, les commissions nationales et régionales de pharmacopée, les autres organismes désignés par les Etats Membres et toutes autres personnes portant un intérêt notoire au remplacement proposé que, malgré une proposition de remplacement, il a été décidé de conserver la dénomination commune internationale déjà recommandée (avec une brève description de la ou des raisons pour lesquelles la proposition de remplacement n’a pas été jugée suffisamment impérative).

ANNEXE 2

DIRECTIVES GENERALES POUR LA FORMATION DE DENOMINATIONS

COMMUNES INTERNATIONALES APPLICABLES AUX SUBSTANCES PHARMACEUTIQUES1

1. Les dénominations communes internationales (DCI) devront se distinguer les unes des autres par leur consonance et leur orthographe. Elles ne devront pas être d’une longueur excessive, ni prêter à confusion avec des appellations déjà couramment employées. 2. La DCI de chaque substance devra, si possible, indiquer sa parenté pharmacologique. Les dénominations susceptibles d’évoquer pour les malades des considérations anatomiques, physiologiques, pathologiques ou thérapeutiques devront être évitées dans la mesure du possible. Outre ces deux principes fondamentaux, on respectera les principes secondaires suivants : 1. Lorsqu’on formera la DCI de la première substance d’un nouveau groupe pharmacologique, on tiendra compte de

la possibilité de former ultérieurement d’autres DCI appropriées pour les substances apparentées du même groupe.

1

Dans son vingtième rapport (OMS, Série de Rapports techniques, N° 581, 1975), le Comité OMS d’experts des Dénominations communes pour les Substances pharmaceutiques a examiné les directives générales pour la formation des dénominations communes internationales et la procédure à suivre en vue de leur choix, compte tenu de l’évolution du secteur pharmaceutique au cours des dernières années. La modification la plus importante a été l’extension aux substances de synthèse de la pratique normalement suivie pour désigner les substances tirées ou dérivées de produits naturels. Cette pratique consiste à employer des syllabes communes ou groupes de syllabes communes (segments-clés) qui sont caractéristiques et indiquent une propriété commune aux membres du groupe des substances pour lequel ces segments-clés ont été retenus. Les raisons et les conséquences de cette modification ont fait l’objet de discussions approfondies. Les directives ont été mises à jour lors de la treizième consultation sur les dénominations communes pour les substances pharmaceutiques (Genève, 27-29 avril 1983) (PHARM S/NOM 928, 13 mai 1983, révision en date du 18 août 1983).


453

4. Pour former des DCI des acides, on utilisera de préférence un seul mot. Leurs sels devront être désignés par un terme qui ne modifie pas le nom de l’acide d’origine : par exemple «oxacilline» et «oxacilline sodique», «ibufénac» et «ibufénac sodique».

5. Les DCI pour les substances utilisées sous forme de sels devront en général s’appliquer à la base active (ou à l’acide actif). Les dénominations pour différents sels ou esters d’une même substance active ne différeront que par le nom de l’acide inactif (ou de la base inactive). En ce qui concerne les substances à base d’ammonium quaternaire, la dénomination s’appliquera de façon appropriée au cation et à l’anion en tant qu’éléments distincts d’une substance quaternaire. On évitera de choisir une désignation évoquant un sel aminé.

6. On évitera d’ajouter une lettre ou un chiffre isolé ; en outre, on renoncera de préférence au trait d’union.

7. Pour simplifier la traduction et la prononciation des DCI, la lettre « f » sera utilisée à la place de « ph », « t » à la place de « th », « e » à la place de « ae » ou « oe », et « i » à la place de « y » ; l’usage des lettres « h » et « k » sera aussi évité.

8. On retiendra de préférence, pour autant qu’elles respectent les principes énoncés ici, les dénominations proposées par les personnes qui ont découvert ou qui, les premières, ont fabriqué et lancé sur le marché les préparations pharmaceutiques considérées, ou les dénominations déjà officiellement adoptées par un pays.

9. La parenté entre substances d’un même groupe (voir Directive générale 2) sera si possible indiquée dans les DCI par l’emploi de segments-clés communs. La liste ci-après contient des exemples de segments-clés pour des groupes de substances, surtout pour des groupes récents. Il y a beaucoup d’autres segments-clés en utilisation active. 1 Les segments-clés indiqués sans trait d’union pourront être insérés n’importe où dans une dénomination. Latin Français -acum -ac substances anti-inflammatoires du groupe de l’ibufénac -adolum -adol } analgésiques -adol- -adol- }

-astum -ast antiasthmatiques, antiallergiques n’agissant pas principalement en tant qu’antihistaminiques -astinum -astine antihistaminiques -azepamum -azépam substances du groupe du diazépam bol bol stéroïdes anabolisants -cain- -caïn- antiarythmiques de classe I, dérivés du procaïnamide et de la lidocaïne -cainum -caïne anesthésiques locaux cef- céf- antibiotiques, dérivés de l’acide céphalosporanique -cillinum -cilline antibiotiques, dérivés de l’acide 6-aminopénicillanique -conazolum -conazole agents antifongiques systémiques du groupe du miconazole cort cort corticostéroïdes, autres que les dérivés de la prednisolone -coxibum -coxib inhibiteurs sélectifs de la cyclo-oxygénase -entanum -entan antagonistes du récepteur de l’endothéline gab gab gabamimétiques gado- gado- agents diagnostiques, dérivés du gadolinium -gatranum -gatran antithrombines, antithrombotiques gest gest stéroïdes progestogènes gli gli antihyperglycémiants io- io- produits de contraste iodés -metacinum -métacine substances anti-inflammatoires du groupe de l’indométacine -mycinum -mycine antibiotiques produits par des souches de Streptomyces -nidazolum -nidazole substances antiprotozoaires du groupe du métronidazole -ololum -olol antagonistes des récepteurs β-adrénergiques -oxacinum -oxacine substances antibactériennes du groupe de l’acide nalidixique -platinum -platine antinéoplasiques, dérivés du platine -poetinum -poétine facteurs sanguins de type érythropoïétine -pril(at)um -pril(ate) inhibiteurs de l’enzyme de conversion de l’angiotensine -profenum -profène substances anti-inflammatoires du groupe de l’ibuprofène prost prost prostaglandines

1

Une liste plus complète de segments-clés est contenue dans le document de travail WHO/EMP/RHT/TSN/2013.1 qui est régulièrement mis à jour et qui peut être demandé auprès du programme des DCI, OMS, Genève.


454

-relinum -réline peptides stimulant la libération d’hormones hypophysaires -sartanum -sartan antagonistes d’un récepteur de l’angiotensine II, antihypertenseurs (non peptidiques) -vaptanum -vaptan antagonistes du récepteur de la vasopressine vin- vin- } alcaloïdes du type vinca -vin- -vin- }

ANEXO 1

PROCEDIMIENTO DE SELECCIÓN DE DENOMINACIONES COMUNES INTERNACIONALES RECOMENDADAS PARA SUSTANCIAS FARMACÉUTICAS1

La Organización Mundial de la Salud (OMS) seguirá el procedimiento que se expone a continuación tanto para seleccionar denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas, de conformidad con lo dispuesto en la resolución WHA3.11, como para sustituir esas denominaciones. Artículo 1 - Las propuestas de denominaciones comunes internacionales recomendadas y las propuestas de sustitución de esas denominaciones se presentarán a la OMS en los formularios que se proporcionen a estos efectos. El estudio de estas propuestas estará sujeto al pago de una tasa destinada a sufragar los costos de administración que ello suponga para la Secretaría de la OMS («la Secretaría»). La Secretaría establecerá la cuantía de esa tasa y podrá ajustarla periódicamente. Artículo 2 - Estas propuestas serán sometidas por la Secretaría a los miembros del Cuadro de Expertos en Farmacopea Internacional y Preparaciones Farmacéuticas encargados de su estudio, en adelante designados como «el Grupo de Expertos en DCI», para que las examinen de conformidad con los «Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas», anexos a este procedimiento.2 A menos que haya poderosas razones en contra, la denominación aceptada será la empleada por la persona que haya descubierto o fabricado y comercializado por primera vez esa sustancia farmacéutica. Artículo 3 - Tras el examen al que se refiere el artículo 2, la Secretaría notificará que está en estudio un proyecto de denominación internacional. a) Esa notificación se hará mediante una publicación en Información Farmacéutica OMS3

y el envío de una carta a los Estados Miembros y a las comisiones nacionales y regionales de las farmacopeas u otros organismos designados por los Estados Miembros.

i) La notificación será enviada también a la persona que haya presentado la propuesta («el solicitante inicial») y a otras personas que tengan un interés especial en una denominación objeto de estudio.

b) En esa notificación se incluirán los siguientes datos: i) la denominación sometida a estudio; ii) la identidad de la persona que ha presentado la propuesta de denominación de la sustancia, si lo pide esa persona; iii) la identidad de la sustancia cuya denominación está en estudio; iv) el plazo fijado para recibir observaciones y objeciones, así como el nombre y la dirección de la persona a quien deban dirigirse; y v) los poderes conferidos para el caso a la OMS y una referencia al presente procedimiento.

1 Véase el anexo 1 en OMS, Serie de Informes Técnicos, Nº 581, 1975. El texto vigente fue adoptado por el Consejo Ejecutivo en su resolución EB15.R7 y modificado en las resoluciónes EB43.R9 y EB115.R4..

2 Véase el anexo 2.

3 Hasta 1987 las listas de DCI se publicaban en la Crónica de la Organización Mundial de la Salud.


455

c) Al enviar esa notificación, la Secretaría solicitará de los Estados Miembros la adopción de todas las medidas necesarias para impedir la adquisición de derechos de patente sobre la denominación propuesta, durante el periodo en que la OMS la tenga en estudio. Artículo 4 - Toda persona puede formular a la OMS observaciones sobre la denominación propuesta dentro de los cuatro meses siguientes a su publicación en Información Farmacéutica OMS, conforme a lo dispuesto en el artículo 3. Artículo 5 - Toda persona interesada puede presentar una objeción formal a una denominación propuesta dentro de los cuatro meses siguientes a su publicación en Información Farmacéutica OMS, conforme a lo dispuesto en el artículo 3. Esa objeción deberá acompañarse de los siguientes datos:

i) la identidad de la persona que formula la objeción; ii) las causas que motivan su interés por la denominación; y iii) las causas que motivan su objeción a la denominación propuesta.

Artículo 6 - Cuando se haya presentado una objeción formal en la forma prevista en el artículo 5, la OMS podrá reconsiderar el nombre propuesto o utilizar sus buenos oficios para intentar lograr que se retire la objeción. La OMS no seleccionará como denominación común internacional una denominación a la que se haya hecho una objeción formal, presentada según lo previsto en el artículo 5, que no haya sido retirada, todo ello sin perjuicio de que la Organización examine otra denominación o denominaciones sustitutivas. Artículo 7 - Cuando no se haya formulado ninguna objeción en la forma prevista en el artículo 5, o cuando todas las objeciones presentadas hayan sido retiradas, la Secretaría notificará, conforme a lo dispuesto en el párrafo a) del artículo 3, que la denominación ha sido seleccionada por la OMS como denominación común internacional recomendada. Artículo 8 - Al comunicar a los Estados Miembros una denominación común internacional, conforme a lo previsto en el artículo 7, la Secretaría: a) solicitará que esta denominación sea reconocida como denominación común para la sustancia de que se trate; y b) solicitará a los Estados Miembros que adopten todas las medidas necesarias para impedir la adquisición de derechos de patente sobre la denominación, y prohíban que sea registrada como marca de fábrica o como nombre comercial. Artículo 9 a) En el caso excepcional de que, debido a su semejanza con otra denominación utilizada en las prácticas farmacéuticas y/o de prescripción, una denominación común internacional recomendada anteriormente ocasione errores de medicación, prescripción o distribución, o suponga un riesgo manifiesto de que esto ocurra, y parezca que tales errores o potenciales errores no sean fácilmente subsanables con otras medidas que no sean la posible sustitución de esa denominación común internacional recomendada anteriormente; en el caso de que una denominación común internacional recomendada anteriormente difiera considerablemente de la denominación común aprobada en un número importante de Estados Miembros, o en otras circunstancias excepcionales que justifiquen el cambio de una denominación común internacional recomendada, cualquier persona interesada puede presentar propuestas en este sentido. Esas propuestas se presentarán en los formularios que se proporcionen a estos efectos e incluirán los siguientes datos:

i) la identidad de la persona que presenta la propuesta;

ii) las causas que motivan su interés en la sustitución propuesta;

iii) las causas que motivan la propuesta; y

iv) una descripción, acompañada de pruebas documentales, de las otras medidas que se hayan adoptado con el fin de resolver la situación y de los motivos por los cuales dichas medidas no han sido suficientes.

Entre esas propuestas podrá figurar una relativa a una nueva denominación común internacional sustitutiva,

formulada con arreglo a los Principios generales y que tenga en cuenta la sustancia farmacéutica para la que se proponga la nueva denominación común internacional sustitutiva.

La Secretaría enviará al Grupo de Expertos en DCI y al solicitante inicial o a su sucesor (en el caso de que sea una persona diferente de la que ha presentado la propuesta de sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones


456

industriales) una copia de la propuesta, para que sea examinada de conformidad con el procedimiento descrito en el párrafo b) infra. Además, la Secretaría solicitará observaciones sobre la propuesta:

i) a los Estados Miembros y a las comisiones nacionales y regionales de las farmacopeas u otros organismos designados por los Estados Miembros (ello se hará incluyendo una notificación a tal efecto en la carta a la que se refiere el párrafo a) del artículo 3), y

ii) a cualquier persona que tenga un interés especial en la sustitución propuesta.

Al solicitar que se formulen estas observaciones se facilitarán los siguientes datos: i) la denominación común internacional recomendada que se propone sustituir (y la denominación sustitutiva propuesta, si se ha facilitado);

ii) la identidad de la persona que ha presentado la propuesta de sustitución (si lo pide esa persona); iii) la identidad de la sustancia a la que se refiere la sustitución propuesta y las razones para presentar la propuesta de sustitución; iv) el plazo fijado para recibir observaciones, así como el nombre y la dirección de la persona a quien deban dirigirse; y

v) los poderes conferidos para el caso a la OMS y una referencia al presente procedimiento.

Toda persona puede formular a la OMS observaciones sobre la sustitución propuesta dentro de los cuatro meses siguientes a la fecha en que se realizó la solicitud de observaciones. b) Una vez agotado el mencionado plazo para la formulación de observaciones, la Secretaría enviará todos los comentarios recibidos al Grupo de Expertos en DCI, al solicitante inicial o a su sucesor, y a la persona que haya presentado la propuesta de sustitución. Si después de examinar la propuesta de sustitución y las observaciones recibidas, el Grupo de Expertos en DCI, la persona que haya presentado la propuesta de sustitución y el solicitante inicial, o su sucesor, están de acuerdo en la necesidad de sustituir la denominación común internacional recomendada anteriormente, la Secretaría remitirá la propuesta de sustitución al Grupo de Expertos en DCI para que la tramite. No obstante lo anterior, el solicitante inicial o su sucesor no tendrán derecho a impedir el acuerdo sobre una propuesta de sustitución en el caso de que hayan dejado de tener un interés demostrable en la denominación común internacional cuya sustitución se propone.

En caso de que la propuesta de sustitución sea presentada al Grupo de Expertos en DCI para que la tramite, este grupo seleccionará una nueva denominación común internacional de conformidad con los Principios generales a los que se refiere el artículo 2 y al procedimiento establecido en los artículos 3 a 8 inclusive. En ese caso, en las notificaciones que la Secretaría ha de enviar con arreglo a los artículos 3 y 7, respectivamente, incluida la notificación al solicitante inicial o a su sucesor (en el caso de que no sea la misma persona que propuso la sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales), se indicará que la nueva denominación sustituye a una denominación común internacional recomendada anteriormente y que los Estados Miembros podrán, si lo estiman oportuno, adoptar disposiciones transitorias aplicables a los productos existentes en cuya etiqueta se utilice, con arreglo a la legislación nacional, la denominación común internacional recomendada anteriormente que se haya sustituido.

En caso de que, después de haber estudiado la propuesta de sustitución y los comentarios recibidos de conformidad con el procedimiento descrito anteriormente, el Grupo de Expertos en DCI, el solicitante inicial o su sucesor y la persona que haya presentado la propuesta de sustitución no lleguen a un acuerdo sobre la existencia de razones poderosas para sustituir una denominación común internacional recomendada anteriormente, esta denominación se mantendrá (siempre en el entendimiento de que el solicitante inicial o su sucesor no tendrán derecho a impedir el acuerdo sobre una propuesta de sustitución en el caso de que hayan dejado de tener un interés demostrable en la denominación común internacional cuya sustitución se propone). En ese caso, la Secretaría comunicará a la persona que haya propuesto la sustitución, así como al solicitante inicial o a su sucesor (en el caso de que no sea la misma persona que propuso la sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales), a los Estados Miembros, a las comisiones nacionales y regionales de las farmacopeas o a otros organismos designados por los Estados Miembros y a cualquier otra persona que tenga interés en la sustitución


457

propuesta, que, pese a la presentación de una propuesta de sustitución, se ha decidido mantener la denominación común internacional recomendada anteriormente (con una descripción de la o las razones por las que se ha considerado que la propuesta de sustitución no estaba respaldada por razones suficientemente poderosas).

ANEXO 2

PRINCIPIOS GENERALES DE ORIENTACIÓN PARA FORMAR DENOMINACIONES

COMUNES INTERNACIONALES PARA SUSTANCIAS FARMACÉUTICAS1

1. Las denominaciones comunes internacionales (DCI) deberán diferenciarse tanto fonética como ortográficamente. No deberán ser incómodamente largas, ni dar lugar a confusión con denominaciones de uso común.

2. La DCI de una sustancia que pertenezca a un grupo de sustancias farmacológicamente emparentadas deberá mostrar apropiadamente este parentesco. Deberán evitarse las denominaciones que puedan tener connotaciones anatómicas, fisiológicas, patológicas o terapéuticas para el paciente.

Estos principios primarios se pondrán en práctica utilizando los siguientes principios secundarios:

3. Al idear la DCI de la primera sustancia de un nuevo grupo farmacológico, deberá tenerse en cuenta la posibilidad de poder formar DCI convenientes para las sustancias emparentadas que se agreguen al nuevo grupo.

4. Al idear DCI para ácidos, se preferirán las de una sola palabra; sus sales deberán denominarse sin modificar el nombre del ácido: p. ej. «oxacilina» y «oxacilina sódica», «ibufenaco» y «ibufenaco sódico».

5. Las DCI para las sustancias que se usan en forma de sal deberán en general aplicarse a la base activa o al ácido activo. Las denominaciones para diferentes sales o esteres de la misma sustancia activa solamente deberán diferir en el nombre del ácido o de la base inactivos. En los compuestos de amonio cuaternario, el catión y el anión deberán denominarse adecuadamente por separado, como componentes independientes de una sustancia cuaternaria y no como sales de una amina.

6. Deberá evitarse el empleo de letras o números aislados; también es indeseable el empleo de guiones.

7. Para facilitar la traducción y la pronunciación, se emplearán de preferencia las letras «f» en lugar de «ph», «t» en lugar de «th», «e» en lugar de «ae» u «oe», e «i» en lugar de «y»; se deberá evitar el empleo de las letras «h» y «k».

8. Siempre que las denominaciones propuestas estén de acuerdo con estos principios, recibirán una consideración preferente las denominaciones propuestas por la persona que haya descubierto las sustancias, o que fabrique y comercialice por primera vez una sustancia farmacéutica, así como las denominaciones ya adoptadas oficialmente en cualquier país.

9. El parentesco entre sustancias del mismo grupo se pondrá de manifiesto en las DCI (véase el Principio 2) utilizando una partícula común. En la lista que figura a continuación se indican ejemplos de partículas para grupos de sustancias, en particular para grupos nuevos. Existen muchas otras partículas que se usan habitualmente.2 Cuando una partícula aparece sin guión alguno, puede utilizarse en cualquier lugar de la palabra.

1 En su 20º informe (OMS, Serie de Informes Técnicos, Nº 581, 1975), el Comité de Expertos de la OMS en Denominaciones Comunes para las Sustancias Farmacéuticas revisó los Principios generales para formar denominaciones comunes internacionales (DCI), y su procedimiento de selección, a la luz de las novedades registradas en los últimos años en materia de compuestos farmacéuticos. El cambio más importante había consistido en hacer extensivo a la denominación de sustancias químicas sintéticas el método utilizado hasta entonces para las sustancias originadas en productos naturales o derivadas de éstos. Dicho método conlleva la utilización de una «partícula» característica que indica una propiedad común a los miembros de un grupo. En el citado informe se examinan en detalle las razones y consecuencias de este cambio. Los Principios generales de orientación se actualizaron durante la 13ª consulta sobre denominaciones comunes para sustancias farmacéuticas (Ginebra, 27 a 29 de abril de 1983) (PHARM S/NOM 928, 13 de mayo de 1983, revisado el 18 de agosto de 1983). 2 En el documento de trabajo WHO/EMP/RHT/TSN/2013.1, que se actualiza periódicamente y puede solicitarse al Programa sobre Denominaciones Comunes Internacionales, OMS, Ginebra, figura una lista más amplia de partículas.


458

Latin Español -acum -aco antiinflamatorios derivados del ibufenaco -adolum -adol ) analgésicos -adol- -adol- ) -astum -ast antiasmáticos, sustancias antialérgicas cuya acción principal no es la antihistamínica -astinum -astina antihistamínicos -azepamum -azepam derivados del diazepam bol bol esteroides anabolizantes -cain- -caína- antiarrítmicos de clase I, derivados de procainamida y lidocaína -cainum -caína- anestésicos locales cef- cef- antibióticos, derivados del ácido cefalosporánico -cillinum - cilina antibióticos derivados del ácido 6-aminopenicilánico -conazolum -conazol antifúngicos sistémicos derivados del miconazol cort cort corticosteroides, excepto derivados de prednisolona -coxibum -coxib inhibidores selectivos de ciclooxigenasa -entanum -entán antagonistas del receptor de endotelina gab gab gabamiméticos gado- gado- agentes para diagnóstico derivados de gadolinio -gartranum -gatrán inhibidores de la trombina antitrombóticos gest gest esteroides progestágenos gli gli hipoglucemiantes, antihiperglucémicos io- io- medios de contraste iodados -metacinum -metacina antiinflamatorios derivados de indometacina -mycinum -micina antibióticos producidos por cepas de Streptomyces -nidazolum -nidazol antiprotozoarios derivados de metronidazol -ololum -olol antagonistas de receptores -adrenérgicos -oxacinum -oxacino antibacterianos derivados del ácido nalidíxico -platinum -platino antineoplásicos derivados del platino -poetinum -poetina factores sanguíneos similares a la eritropoyetina -pril(at)um -pril(at) inhibidores de la enzima conversora de la angiotensina -profenum -profeno antiinflamatorios derivados del ibuprofeno prost prost prostaglandinas -relinum -relina péptidos estimulantes de la liberación de hormonas hipofisarias -sartanum -sartán antihipertensivos (no peptídicos) antagonistas del receptorde angiotensina II -vaptanum -vaptán antagonistas del receptor de vasopresina vin- vin- ) alcaloides de la vinca -vin- -vin- )